A global Core Outcome Set to optimise the evidence base for burn care (COSB-i). by Young, Amber
                          
This electronic thesis or dissertation has been





A global Core Outcome Set to optimise the evidence base for burn care (COSB-i).
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint






A global Core Outcome Set to 
optimise the evidence base for burn 
care (COSB-i). 
 
Amber Elizabeth Russel Young 
 
 
A dissertation submitted to the University of Bristol in accordance with 
the requirements for award of the degree of Doctor of Philosophy in the 
Bristol Medical School,  
 
Population Health Sciences 
April 2020 
 




I dedicate this thesis to my amazing and wonderful husband Norman, who has supported me 
in health and scientific matters throughout.  
I also dedicate this to my brilliant and kind oncologist, Dr Jeremy Braybrooke, who kept me 
alive, happy and able to work on this thesis. 
I have undertaken this PhD to leave a collection of work behind after my death, that will 
hopefully improve healthcare for patients with burns.  





Please see, in addition, a lay summary and pictorial abstract below. 
 
Gold-standard medical care requires collated evidence from systematic reviews, to support 
clinicians in identifying the treatment that results in optimal patient outcomes. In burn care, 
this evidence is required to improve survival, optimise function and cosmesis, and minimise 
the pain and psychological impact of the injury. Although burns are common (11 million 
annual global incidence), management and outcomes vary within and between countries. This 
is likely to be due to a lack of guidelines based on synthesised evidence. One reason that data 
from trials cannot be synthesised, is because of a variation in outcome reporting across trials. 
Establishing how to improve this is challenging. The development of a Core Outcome Set 
(COS), a scientifically agreed minimum set of the most important outcomes to be reported in 
all studies of a medical condition, is likely to provide the answer. 
The aim of this thesis is to explore variation in outcome reporting in burn care research and to 
develop a COS as a novel solution to this problem. 
Four systematic reviews and a mixed-methods study, including Delphi surveys and a 
consensus meeting were undertaken. The reviews highlighted the extent of outcome 
heterogeneity across burn trials, problems with outcome definition and timing of assessment 
and a focus on short-term clinical, not patient-important, outcomes.  
Development of the COS has used shared decision-making, with 668 health professionals 
from 77 countries of varying income, and 126 UK patients, ensuring relevance to both 
stakeholder groups. Seven core outcomes have been agreed: death, specified complications, 
ability to do daily tasks, wound healing, neuropathic pain and itch, patient psychology and 
time to return to school or previous occupation.  
It is hoped that this COS will improve data synthesis, to support evidence-based clinical 
decision-making. This will ultimately resolve uncertainty over clinical decisions to ensure 






Lay Summary and Pictorial Abstract 
In healthcare, treatments need to be based on scientific research, so that patients receive the 
highest quality care, with the best possible information. Each year, almost 11 million people 
around the world require medical treatment for burns. Deciding how to treat these patients is 
difficult and varies considerably. Recovery outcomes, which include infection, pain, and 
scarring also vary. One reason for this, is that not all researchers use the same outcomes to 
measure recovery. This makes it very difficult to bring together and make sense of global 
research evidence in order to agree the best treatments.  
The aim of my thesis is to understand why researchers find it difficult to use the evidence that 
is published, to find the best treatment for patients. 
My findings have shown that researchers have difficulty in agreeing which outcomes are most 
important. There are also challenges in knowing which outcomes are the same and which are 
different (is burn pain the same as the need for pain relief after a burn?). Researchers measure 
outcomes at different times and most often shortly after the burn rather than years later. The 
latter are likely to be more important to patients. It is now possible to understand why the 
evidence in burn care is difficult to compare.  
I have developed a practical solution to this problem through the work in this thesis, a Core 
Outcome Set. This is a scientifically agreed set of the most important outcomes which can be 
used by all researchers. This will allow researchers to compare like-with-like, when summing 
up evidence in burn research. 
In creating the Core Outcome Set, I included the views of 668 health professionals in 77 
countries and 126 patients and carers in the UK. Seven core outcomes were agreed. These 
were: death, serious complications, ability to do daily tasks, time to wound healing, long-term 
nerve pain and itch, patient psychology and time to return to school or previous occupation.  
It is hoped that the COS will be widely used in research studies in burn care. It will improve 
patient care by making research comparable, and therefore improving the amount of evidence 
available to patients and professionals. This evidence will ultimately inform decision making, 
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Chapter 1 Evidence to support decision-
making in burn care; what is quality?  
1.1 Introduction 
Clinical decision-making for patients with burn injuries impacts more than 11 million people 
globally each year, according to the most recent published data (1). Clinical choice of 
management strategy for these patients requires evidence synthesised from high quality, well 
designed and conducted studies. These studies include randomised and non-randomised 
studies. Non-randomised studies are defined by the Cochrane Collaboration as “any 
quantitative study estimating the effectiveness of an intervention (harm or benefit) that does 
not use randomization to allocate units to comparison groups”(2). These include cohort 
studies, case-control studies, controlled before-and-after studies, interrupted-time-series 
studies and controlled trials that use ineffective randomization strategies. However, the 
highest quality evidence is gained from randomised controlled trials (RCTs) and from 
systematic reviews (SRs) that analyse data from RCTs(3). RCTs are the preferred trial design 
for investigating harms and benefits of healthcare interventions because they are the least 
likely to be biased. In burn care, numbers of RCTs are increasing(4). However, SRs of these 
RCTs have not provided conclusive data to support many commonly used treatment 
strategies. This is most likely to be associated with poor methodological quality and 
inconsistency in outcome reporting (5-10). The failure to synthesise outcome data results in a 
lack of reliable evidence, research waste and variation in clinical practice and patient 
outcomes(11-13).  
This thesis will explore the reasons that limit researchers’ ability to synthesis data that answers 
clinical questions in burn care and assess any potential solutions. It will focus on challenges in 
aggregating data from RCTs relating to outcome choice and reporting. 
 
2 
1.2 Thesis aim and research questions 
Thesis research question:  
Is it possible to increase the provision of data from burn care RCTs that can be synthesised into 
evidence that answers clinical questions, through the development of a Core Outcome Set?  
Objectives and chapters: 
The following objectives will be used to answer the research question: 
1. An exploration of the variation in clinical outcome reporting across burn care RCTs. 
(Chapter Two). 
2. The development of an understanding of what makes an outcome unique. (Chapter 
Three). 
3. An analysis of how variation in the definition of a specific outcome (burn wound infection) 
across burn care trials, impacts evidence synthesis (Chapter Four). 
4. An analysis of how variation in the timing of the assessment of unique outcomes across 
trials, impacts relevance to patients (Chapter Five). 
5. A consensus on which burn care outcomes are most important to patients, carers, 
researchers and international multi-disciplinary burn care professionals (Chapter Six). 
In this introductory chapter, the need and requirements for developing research data of high 
enough quality, to be collated into reliable and truthful evidence to answer clinical questions 
in burn care, will be explored. This will be placed within the context of a large, global, burn-
injured population, with many diverse treatments and little synthesised evidence to prevent 
variation in clinical decision-making.  
In the Discussion chapter, the thesis research question will be answered. The methodological 
challenges impacting evidence synthesis in burn care research (Figure 1) will be explored. 
Their relative importance, will be justified, through a comprehensive assessment of the work 
described in Chapters Two to Five. The utility of a burn care Core Outcome Set to solve some, 
or all of these issues, will be debated. Future work, originating from the work undertaken for 








1.3 Burns: aetiology, epidemiology and principles of care  
Ten percent of all deaths worldwide are from injury(1). In terms of global injury type, the 
incidence of burns is fourth. Burns are injuries caused by heat, freezing, electricity, chemicals, 
radiation or friction. Thermal burns from dry sources (fire or flame) and wet sources (scalds) 
account for approximately 80% of all reported burns(14). This thesis will focus on research 
relating to patients with cutaneous burns caused by thermal sources(15-17).  
Burn injuries are common, with numbers particularly high in lower income countries (1, 18, 
19). Globally, burn injuries increase as economic wealth decreases(20). In India, with a 
population of over 1 billion, there are 700,000 to 800,000 burn admissions annually(21). In 
Bangladesh, in 2003, a survey of 350,000 children and 470,000 adults reported an overall 
incidence of 166 burns per 100,000 people (22). In higher income countries, such as the USA, 
410,149 non-fatal burns were reported in 2008. In England and Wales, approximately 130,000 
patients attend emergency departments with burns annually (http://www.ibidb.org/ accessed 
December 2019). From 1st January 2003 to 31st December 2011, 81,181 patients were referred to 
NHS specialist burn services, of which 57,801 required hospital admission(23). Children 
account for almost half of the population with severe burn injuries in Europe, and children 
younger than five years, account for 50% to 80% of all childhood burns (24).  
Of deaths from burns, more than 95% of fatal fire-related burns occur in low- and middle-
income countries (25). When burn rates are compared between countries of varying economic 
wealth at global level, there is a negative correlation between Gross Domestic Product (r = − 
0.69, p < 0.01) and burn mortality rates, and a positive correlation with income inequality (r = 
0.44, p < 0.001)(20). Worldwide, the incidence of deaths from burns in children is 2.5 per 
100,000 people and is highest in Sub-Saharan Africa (4.5 per 100,000 people)(20). It has not 
been possible to identify published evidence on current numbers of deaths in adults from 
burn injuries worldwide. The World Health Organisation (WHO) report “an estimated 
265,000 deaths occur each year from fires alone, with more deaths from scalds, electrical 
burns, and other forms of burns, for which global data are not available” 
(https://www.who.int/en/news-room/fact-sheets/detail/burns). The majority of burns, 
however, are non-fatal and mortality is continuing to decrease in higher income countries (1). 
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In the USA, the age-adjusted death rate from fire and burns has dropped from 2.99 per 
100,000 in 1981, to 1.2 per 100,000 in 2006(1). Similar trends in mortality are seen in Europe 
and the UK(24). If death occurs, it is most commonly due to sepsis and/or multi-organ 
failure(26, 27).  
Burn wounds range from small area burns (usually due to hot drinks or contact with hot 
surfaces), to a severe flame or bath water injury (23, 28). Wounds vary in severity, in terms of 
the tissues affected (depth) and surface area (size)(29).The severity of the injury can be 
quantified, which allows some ability to provide a prognosis, in terms of mortality and 
morbidity(30). Independent of severity, all injuries have the potential to affect patients from a 
cosmetic, functional or psychological viewpoint, for many years after the primary injury (31-
33).  
The primary aim of burn care is to achieve survival and then to restore function and cosmesis, 
while minimising pain and psychological impact. Management is primarily surgical, with 
supportive systemic care. Surgical care depends upon early excision of damaged tissue, while 
leaving as much undamaged dermis as possible, early wound coverage, and prevention and 
early treatment of infection(15, 34). Improved patient outcomes result from advances in fluid 
resuscitation, improved coverage of wounds, early treatment of infections, better management 
of the burn-induced hypermetabolic response and early functional and psychological 
rehabilitation (15, 35). New surgical techniques continue to be introduced, and advances are 
regularly made in understanding the wound environment, critical care and dressing 
technology(14). The frequent surgical episodes, dressing costs, short- and long-term wound 
and scar treatment, long lengths of stay in hospital and a need for rehabilitation, result in burn 
care being costly (36-38).  
For clinicians to make choices regarding the management strategy that will deliver the most 
clinical- and cost-effective care for patients with burns, requires SRs and meta-analyses that 
collate evidence from high quality trials(39). This chapter will explore what is meant by high 
quality research. It will debate why RCTs, and SRs of RCTs, are maximally influential. Issues 
with RCT methodology that challenge evidence synthesis, including risks of bias and outcome 
choice, definition and timing of reporting will also be discussed. The chapter will propose a 
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possible solution to issues that limit collation of trial results in burn care, and prevent the use 
of evidence in clinical treatment choice globally.  
1.4 What quality of evidence is required to support clinical 
decision-making in burn care? 
In 1996, Sackett stated that the most effective way to ensure that clinical decision-making will 
result in improved patient outcomes is “the conscientious and judicious use of current best 
evidence in conjunction with clinical expertise and patient values …..” (40). The principles of 
using current best evidence to support clinical management choices, known as evidence-based 
medicine (EBM), are that evidence varies in quality, and that clinical decisions should be based 
on the highest quality evidence available (3, 41-44). SRs of well-designed and conducted RCTs 
provide the most reliable evidence regarding the effects of healthcare interventions(45, 46). If 
there is a lack of evidence, or evidence that cannot be synthesised, it is likely that clinical 
practice will remain based on historical strategies and will vary between healthcare 
services(47-49). Accumulated data suggests that this is true in burn care, with treatment 
strategies and patient outcomes inconsistent between services, within and between 
countries(11-13, 50, 51). 
Recognition of the importance of using evidence to standardise care, has resulted in the 
development of the Cochrane Collaboration. Cochrane has developed standards for research 
methodology including RCT design and conduct, SR techniques and trial reporting through 
the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network 
(http://www.equator-network.org/ ). It has also developed processes to translate new 
knowledge into evidence-based clinical guidelines (knowledge translation) (52-55). Despite 
advances in EBM, it has drawn recent criticism(56). The practice has been described as 
relatively inflexible, not sufficiently patient-centred, and that it is difficult to draw clinical 
inference from studies with statistical significance alone. There are also concerns that RCT 
designs, and other studies, lack the sophistication to account for and provide evidence to treat 
patients with multiple co-morbidities(57). Despite this, there is agreement in the literature, 
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that EBM (perhaps with some modifications) should continue in order to provide the basis for 
safer, more consistent, and more cost- and clinically-effective care(41).  
1.5 What makes evidence high quality? 
A principle of EBM described by Sackett as current best evidence, requires an understanding of 
methodological quality. Guyatt defines quality in this context as: “reflecting the extent to 
which confidence in an estimate of the effect is adequate to support a particular 
recommendation”(58). The hierarchy classification of evidence quality ranks trial design for 
reliability of evidence of causal effects of interventions(59, 60). This prescribes the superiority 
of well-conducted RCTs for determining the trustworthiness or quality of evidence for the 
clinical benefit of an intervention(41, 61-63). An RCT can be defined as a methodological 
design, that includes random assignment of subjects to two or more subject groups, in which 
one or more clinical interventions are applied to one of the groups and not to the other(64). In 
burn care, RCTs are increasing in number, as new surgical techniques and care pathways are 
introduced. However, trial quality is uncertain(4, 65-67). Understanding quality in research, 
requires an understanding that any flaws in design, conduct, analysis and reporting, can bias 
results of RCTs and prevent the reported conclusions from reflecting the truth (68-70). This 
thesis will focus on one aspect of methodological quality, that can challenge the utility of RCT 
conclusions and make collating the data from the RCTS challenging. This relates to outcome 
reporting, in terms of choice, definition and timepoint of assessment(71). These issues will be 
explored in Chapters Two to Five, with Chapter Six suggesting a possible solution. However, 
understanding and resolving issues with outcome reporting still requires that reporting a 
truthful effect of an intervention, needs an RCT to be internally and externally valid(72, 73). 
To assess the quality of RCTs, the truthfulness of the results (internal validity), the relevance of 
the study (external validity), the extent to which study results are free from random error 
(precision) and adherence of the study to standards of reporting, are all requirements for 
confidence in using the evidence as current best evidence (74-77). External validity can be 
defined, as whether research findings can be generalised to different persons, settings, and 
times, and is important if the research is to be clinically relevant. External validity determines 
the relevance of trial results(74, 78). The internal validity of a study is the extent to which it is 
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free from bias. Bias is a systematic error that leads to a deviation of the results from the 
truth(62, 79, 80). It determines if a fair comparison of intervention and comparator has been 
made. Bias is distinguished from random error, the latter being error due to chance, and is 
accommodated and quantified by statistical methods (e.g. confidence intervals)(81, 82). 
Precision depends upon the number of participants and events in a study (sample size) and 
the degree of variation in the outcome measure (83, 84).  
This thesis is focused on the ability to synthesise evidence from burn care RCTs that are at low 
risk of bias and are internally and externally valid (of high quality).  
1.5.1 Risk of Bias 
For a clinical question to be answered truthfully and reliably, evidence synthesised from data 
included in SRs, must be derived from RCTs at low risk of bias(85). Bias in RCTs may lead to 
an over or underestimation of the true effectiveness of an intervention. The risk of bias can be 
assessed, and the possible effect on study results explored, through sensitivity analyses for 
example. It can be assessed to see how it can influence the conclusions drawn from the 
trial(76, 86). In burn care, few studies have assessed the risk of bias across trials, and these 
studies have been limited by their lack of comprehensiveness and methods of quality 
assessment (65, 66, 87, 88). The issues with poor quality have been noted by authors of 
Cochrane SRs of burn care interventions. Conclusions can commonly not be drawn, due to the 
high risk of bias in included studies(8, 9, 89).  
Common types of bias include those listed below.  
• For trials: 
• Selection bias: is defined as “systematic differences between baseline characteristics of 
the groups that are compared” (2). The aim of randomisation, is to ensure that factors 
that might influence outcome, whether known or unknown, are equally distributed in 
the trial groups (90-94).  
• Measurement bias: is the biased assessment of outcomes, and refers to systematic 
differences between groups in how outcomes are determined (95).  
 
9 
• Attrition bias: occurs if there are systematic differences in the characteristics of 
participants dropping out of the trial between study groups(96).  
• Outcome reporting bias (ORB): refers to the selective reporting of some results but not 
others depending on the nature of the results (97).  
 
• For systematic reviews: 
Bias is related to the systematic review process, and is also inherent within the included 
trials as discussed above(98). Systematic reviews need an accessible and registered 
protocol. Reviews also need to access literature from as many sources as possible and to 
clarify the extent of publication bias.  
• Publication bias: exists when trials with statistically significant results are more 
likely to be published than those with non-significant results (99). 
 
Several other types of bias exist, which will not be covered in detail here, as they lie outside of 
the scope of this work. 
1.5.1.1 Assessment of type and magnitude of bias in RCTs 
Since the introduction of the EBM-defined hierarchy of evidence, more sophisticated 
judgements on assessment of bias and reporting quality have been developed(58, 100, 101). In 
2005, the Cochrane Collaboration developed a strategy for assessing the quality of research, 
currently the most commonly used tool for assessing the risk of bias in RCTs(45). A revised 
version of the tool (Risk of Bias (RoB 2)) has now been developed(102).  
Assessment of bias in RCTs is required to understand if the study findings represent the truth 
and can, therefore, be synthesised to provide more precise and truthful findings. The second 
group of challenges that affect RCT quality and which are further potential blocks to the 
ability to synthesis evidence across trials, include issues of outcome choice and reporting (71). 
This forms the main topic for the work covered in this thesis. 
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1.6 Outcome selection and reporting; what is quality? 
1.6.1 Outcome selection in RCTs 
The rest of this chapter will describe what is meant by an outcome and describe the different 
types of outcome assessed in RCTs. Methodological challenges with outcome reporting will be 
explored. 
Clinical trials aim to assess whether a healthcare intervention is effective, by comparing 
outcomes chosen to reflect benefit or harm(103). A 2014 on-line Delphi survey of 48 UK 
Clinical Research Collaboration registered Clinical Trials Unit directors, found that “choosing 
appropriate outcomes to measure” was one of the top three priorities for research into study 
methodology(104). The World Health Organisation (WHO) stated that: “choosing the most 
important outcome is critical to producing a useful healthcare guideline”, reflecting the 
impact of outcome choice on the provision of evidence for clinical decision-making(105). 
Outcomes selected for use in RCTs must be clearly defined and reported(106). This ensures 
trial relevance and ability to answer the research question. Factors affecting outcome selection 
relate to trial logistics(107). The choice of outcome(s) will determine the study sample size 
and length of follow-up (study duration)(108). Outcomes also need to be important to 
patients if the trial results are to be relevant(71, 106, 109, 110). This is particularly important in 
effectiveness trials, as discussed in Chapter Five. Disagreement by researchers on which 
outcomes are the most important to measure and report in any healthcare area, results in 
inconsistent reporting across trials and limits the ability to compare and collate evidence(111).  
1.6.2 What is an outcome? 
Before discussing types of outcome and issues with outcome choice and reporting, it is 
important to consider what is meant by a healthcare outcome and the context in which the 
definitions are used. The New South Wales Health Department defines an outcome as a 
“change in the health of an individual, group of people or population, which is attributable to 
an intervention or series of interventions” (112) (113). Within the context of clinical trials, with 
which this thesis is concerned, Ferreira states: “outcomes (also called events or endpoints) are 
 
11 
variables that are monitored during a study to document the impact that a given intervention 
or exposure has on the health of a given population”(114). The term trial outcome has been 
defined by Williamson et al in the Core Outcome Measures in Effectiveness Trials (COMET) 
handbook, as “a measurement or observation used to capture and assess the effect of 
treatment such as assessment of side effects (risk) or effectiveness (benefits)”(115). Chan takes 
the definition further by adding a temporal element. He describes a research outcome as “a 
variable measured at a specific time point to assess the efficacy or harm of an intervention” 
(116). For the purposes of this thesis, a healthcare outcome will be initially defined using 
Chan’s definition, as the timing of outcome assessment in burn care research is important. For 
example, the impact of scarring is likely to be different for patients at six months in 
comparison to five years after injury(117). The definition of a unique (single) outcome and the 
impact of a variation in outcome definition and timing of assessment will be discussed in 
Chapters Three, Four and Five. 
The above discussion relates to generic definitions of healthcare outcomes in different 
contexts. It is also important to consider the definition and importance of the different types 
of outcomes chosen, measured and reported in RCTs. 
 
1.6.3 Types of outcomes 
1.6.3.1 Primary and secondary outcomes 
The USA Food and Drug Administration (FDA https://www.fda.gov/home) discusses the 
hierarchy of families of endpoints(118). These include primary, secondary and exploratory 
endpoint families.  
The FDA defines the primary outcome as “the endpoint(s) that will be the basis for concluding 
that the study met its objective”. Calvert describes the primary outcome as “the most 
important outcome in a trial, providing the most clinically relevant and convincing evidence 
directly related to the primary objective of the trial”(119, 120). The choice of primary outcome 
will determine study sample size, (121). Sample size is the number of observations to be 
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included in a sample that will achieve sufficient statistical power to determine differences 
between groups(122). The most appropriate primary outcome, is the one for which there is the 
most reliable evidence associated with the intervention of interest(123). However, relevance to 
patients must also be considered and which will be discussed further in Chapter Five(124).  
Secondary outcomes can be defined as “outcomes pre-specified in the protocol that assess 
additional effects of the intervention”(119). The FDA describe secondary endpoints as “not 
sufficient to establish efficacy in the absence of an effect on the primary endpoints; not 
required for establishing efficacy”. Secondary outcomes are most useful if they add supporting 
evidence to the primary outcome(114). They are outcomes of interest which the study is not 
specifically powered to assess. Calculations can be made for secondary outcomes. However, 
this may increase the sample size required(114).  
Exploratory outcomes are those used to evaluate and/or form hypotheses about the 
intervention outcome(s) (NCI Thesaurus: https://ncithesaurus.nci.nih.gov/ncitbrowser/). The 
FDA discuss exploratory endpoints as hypothesis-generating endpoints (clinical utility 
unknown) or variations on primary or secondary endpoints. There is still a lack of clarity 
about pre-specified secondary and exploratory outcomes(125).  
1.6.3.2 Composite primary outcomes  
A primary outcome may be a combination of outcomes instead of a single outcome. A 
composite outcome may be chosen because:  
• no single outcome fully describes the overall outcome of interest. 
• individual outcomes are rare and therefore statistical power would require an 
impractically large sample size to demonstrate a significant effect. 
• when it makes biological or clinical sense to group outcomes together (126).  
It is important to understand that a positive result for a composite outcome, applies only to 
the outcome group and not the individual components. Whilst they are valuable in 
overcoming the issues listed above, they also have drawbacks; for example, a composite of 
several event outcomes will often be dominated by the more frequently occurring early and 
less serious event types. Composite outcomes can also overstate the results of the individual 
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outcomes(109, 127). Composite outcomes are most commonly used in cardiovascular research, 
with this and other issues reported(127-130) In burn care research, composite outcomes are 
uncommon, except within trials assessing outcomes relating to critical illness and when 
longer-term scoring systems are used to assess scarring and function(131-133) 
There are many ways to define the different types of outcome assessed in RCTs. The 









1.6.3.3 Clinical outcomes  
Clinical outcomes are the most widely chosen and reported outcomes in RCTs in healthcare. 
They can be defined as: “variables that reflect how a patient functions, or how long a patient 
survives”(134). Examples include measurable changes in clinical condition, survival status, 
functional or physical status, and health-related quality of life, when assessed by a clinician. In 
burn care, short-term clinical outcomes commonly relate to the healing process or 
complications related to it, such as wound infection, time to complete wound healing and 
survival. Longer-term clinical outcomes include scarring and physical function. Most clinical 
outcomes involve an assessment made by a clinician. Examples include blood pressure, core 
temperature, assessment of symptoms etc. Some of these are objective (e.g. blood pressure). 
These are not subject to individual interpretation and likely to be reliable measures(108). 
Others (e.g. clinician assessment of patients’ symptoms; pain assessments) are subjective. In 
burn care, clinical outcomes include length of stay in hospital, incidence of sepsis or 
quantitatively or qualitatively measured scarring.  
A sub-set of clinical outcomes, surrogate outcomes, are defined as “laboratory measurements 
or physical signs used as a substitute for a clinically meaningful outcome” and are usually 
assessed in the short-term (124, 135, 136). The number of surrogate outcomes are, therefore, 
likely to be more in number than longer-term outcomes and easier (cheaper) to measure(137). 
Surrogate outcomes can be used as proxies for longer-term patient-important clinical 
outcomes, but only with knowledge that the surrogate will serve as a direct substitute for the 
longer-term outcome (134, 137). Such validation is likely to require RCTs assessing the 
surrogate and clinical outcome, to demonstrate that both are changed by the intervention in a 
comparable manner(138). Surrogate outcomes that have not been validated as proxies for 
longer-term outcomes, should be described as exploratory outcomes (as described above), 
until validation has been proven and agreed. The relationship between surrogate and longer-
term outcomes will be explored further in Chapter Five.  
Another group of short-term outcomes relate to intervention complications or adverse 
events(139-142). Adverse events can be defined as “injuries or complications which occur as a 
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result of health care management and not as a result of the patient's pathology, and which 
cause prolonged hospital stay, morbidity, or mortality”(143, 144). A specific group of adverse 
events relate to surgery and known as post-operative complications(140). The definition of a 
surgical complication is “any deviation from the expected steady recovery after a surgical 
operation”(145). Postoperative complications, such as blood loss, wound infection, skin graft 
loss in burn patients, will necessarily impact, but cannot be substituted for other more 
patient-important, longer-term clinical outcomes(146). 
1.6.3.4 Patient-important outcomes 
A patient-important outcome has been defined as: “a characteristic or variable that reflect how 
a patient feels, functions or survives”(147). Patient-important outcomes are directly relevant to 
clinical practice(148). They may be assessed short-term (e.g. acute pain) but are more 
commonly assessed at a longer-term timepoint. Examples in  burn care include scar quality, 
physical function or quality of life(149-152). Gandhi and colleagues showed that trials that are 
of longer duration, are more likely to report patient-important primary outcomes(124). In 
2010, the US Congress set up the Patient-Centred Outcome Research Institute, a research 
funding body for comparative effectiveness research(153). It recommends “measuring 
outcomes that people in the population of interest notice and care about”(154). This issue will 
be discussed in more detail in Chapter Five. 
1.6.3.5 Patient-reported outcomes. 
It is important, as discussed above, that outcomes selected for use in RCTs should be relevant, 
and as a result of engagement with stakeholders including patients (155, 156). Researchers and 
research funders are increasingly assessing patient-reported outcomes (PROs), using 
standardised health-related questionnaires. These are outcomes assessed directly from the 
patient’s perspective(157, 158). Not all PROs are patient-important; patients are asked, but 
may not have chosen the questions(159). PROs are often used to assess symptoms, such as 
pain or fatigue, interference with activities of daily living, treatment satisfaction or quality of 
life(160, 161). They may also assess emotional, psychological and physical function. Many 
generic, disease- and domain-specific instruments for assessing PROs have now been 
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developed and validated, each containing multiple scales and items(162). Condition-specific 
PROs are likely to have greater relevance and sensitivity to change(163, 164). PROs in burn 
care include scar quality, quality of life and anxiety(162).Recent work by Griffiths and team on 
burn care-specific PROs has produced the CARe (https://www.careburnscales.org.uk/) burn 
scales (159, 161, 162, 165, 166). For PRO data from RCTs to provide value, the PROs need to be 
reported consistently across trials, to allow comparison of data between trials(167). This is 
limited by the multiplicity and heterogeneity of tools available(168). In burn care, a 2010 
literature review described a number of clinical and patient reported tools to quantify scars, of 
which five are different patient-reported versions(169).  
1.6.4 Outcome classification 
Classifying outcomes allows an increased ability to search for, and compare trials assessing the 
effect of an intervention on the same outcome. There is currently no agreement on how 
clinical outcomes should be classified. Wilson and Cleary suggested a taxonomy dividing 
clinical outcomes into biological and physiological, symptoms, functioning, general health 
perceptions, and overall quality of life(170). Other authors proposed the ECHO (Economic, 
Clinical, Humanistic Outcomes) Model, which also includes costs and the inter-relationships 
with clinical and quality of life outcomes (171). The International Classification of Functioning, 
Disability and Health is the World Health Organisation's (WHO) framework for measuring 
health and disability at individual and population levels(172).  
A further way to understand trial outcomes relates to their use in different types of trial. 
Randomized trials can provide evidence related to the efficacy or effectiveness of an 
intervention (173, 174). RCTs using an efficacy (explanatory) design, aim to provide evidence of 
whether the treatment will work in optimal settings(175). These trials generally compare the 
effects of a treatment to a placebo, or usual treatment, and commonly use short-term clinical 
outcomes such as symptom scores or biomarkers(141). An efficacy trial can overestimate an 
intervention’s potential effect in clinical practice (176). Effectiveness (pragmatic) trials assess 
the intervention effect under real-world clinical conditions(177). Effectiveness is a measure of 
the extent to which a specific intervention, when used in routine care, does what it is intended 
to do for a specific population. The term pragmatic was first introduced by Schwartz for trials 
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that combine the real-world nature of an observational study with the scientific methodology 
of an RCT. These trials are designed to give better answers to questions of relevance in day-to-
day clinical practice (132). Pragmatic studies examine more heterogeneous patient 
populations, have less-standardised treatment protocols, are delivered in routine clinical 
settings, compare the intervention to another intervention or standard care and use longer-
term outcomes such as physical function or quality of life(178). They are likely to have 
increased external validity (generalisability)(179). As a result, there may therefore be an 
increased risk of bias, which must be balanced against an understanding of the relative 
benefits and risks of treatments in the true clinical scenario (66, 81, 131).  
1.6.5 Reporting of RCTs 
1.6.5.1 Outcome reporting standards:  
The Consolidated Standards of Reporting Trials (CONSORT) statement have been developed to 
standardise the reporting of RCTs (70, 77, 180). In the section below, I will focus specifically 
on outcome reporting. 
1.6.5.2 Outcome reporting bias within RCTs 
If completeness of outcome reporting, as per the CONSORT statement, is not achieved, trials 
are at risk of outcome reporting bias (ORB); defined as the publication of a subset of the 
original outcomes, on the basis of the results, for inclusion in publication (181). It can include:  
• The omission of all data for an outcome. 
• The reporting of data for a subset of time points. 
• Partially reporting outcomes (sub-group analyses).  
Statistically significant results have higher odds of being reported compared to non-significant 
results, for both benefit and harm outcomes(97, 116, 182). ORB can therefore lead to the over- 
or underestimation of treatment effects, with overestimation most likely (125, 183-185). ORB 
occurs, because researchers either do not pre-specify outcomes, or do not report all the pre-
specified outcomes(186). In 2005, the International Committee of Medical Journal Editors 
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(ICMJE) introduced mandatory trial registration guidelines. Member journals require trial 
registration prior to patient enrolment, as a condition of publication (122). Registering trials 
requires researchers to pre-specify both primary and secondary outcomes. Despite this, the 




Table 1: Selection of studies providing evidence for existence of ORB in RCTs. 
Note: text extracted verbatim from cited studies. 
Author Year Methodology Main findings Reference 
Chan et al 2004 Analysis of protocols for RCTs approved by the Canadian 
Institutes of Health Research with journal publications.  
Of 48 trials with 1,402 outcomes, a median of 31% assessing the efficacy and 59% 
assessing the harm of the intervention per trial were incompletely reported.  
(116) 
Chan at al 2004 Analysis of 122 protocols and published reports of RCTs 
approved by Danish Scientific-Ethical Committees 1994-
1995. 
3,736 outcomes reported: 50% efficacy and 65% harm outcomes per trial 
incompletely reported. Statistically significant outcomes had more than a two-
fold greater odds ratio of being fully reported versus non-significant results. 
(187) 
Chan et al 2005 Assessment of all published RCTs in PubMed whose primary 
publication appeared in December 2000.  
519 trials, 553 publications and 10,557 outcomes identified. The median 
proportion of incompletely reported efficacy outcomes per trial was 42% (n=505). 
For harm outcomes, the median proportion per trial was 50% (n=308). Within 
any trial, incompletely reported outcomes had a higher odds ratio of being 
statistically non-significant versus fully reported outcomes.  
(97) 
Dwan et al 2008 Assessment of study publication bias and ORB in RCTs. Three of 16 studies found that statistically significant outcomes had a higher odds 




2009 Comparison of primary outcomes specified 
in RCTs with those reported in articles in 2008 in 10 
journals with the highest impact factors to determine 
whether primary ORB favoured significant outcomes.  
Among articles with trials adequately registered, 31% (46 of 147) showed some 
evidence of discrepancies between the outcomes registered and the outcomes 
published. The influence of these discrepancies could be assessed in only half and 
in these statistically significant results were favoured in 82.6%. 
(188) 
Dwan et al 2010 Assessment of RCTs for ORB in a SR of intravenous and 
nebulised magnesium for treatment of asthma. 
Of 24 studies, two were excluded for not reporting either of the two outcomes of 




2011 Trial protocols were compared with subsequent 
publication(s) to identify any discrepancies in the outcomes 
reported. Telephone interviews were conducted with the 
respective trialists to investigate more extensively the 
reporting of the research and the issue of unreported 
outcomes. 
268 trials were identified. Interviews were conducted with 59 (37%) of the 161 
trialists. Sixteen trial investigators failed to report analysed outcomes at the time 
of the primary publication, 17 trialists collected outcome data that were 
subsequently not analysed, and five trialists did not measure a pre-specified 
outcome over the course of the trial. In almost all trials in which pre-specified 
outcomes had been analysed but not reported (15/16, 94%) of this under-
reporting resulted in bias. Of trials in which pre-specified outcomes had been 
measured but not analysed, in (4/17, 24%) the direction of the main findings 




2010 Assessment of the prevalence of ORB and its impact on 
Cochrane reviews. Examination of unselected cohort of new 
reviews from 50 of the 51 Cochrane collaboration review 
groups published in three issues of the Cochrane Library 
2006-2007. 
In 31% of 2,562 trials from 309 new Cochrane reviews in 2006/7, the review 
primary outcome was either partially reported or not reported. ORB was 
suspected in at least one RCT in 35% of the reviews. For 6% of the trials, the 




data could not be included in a meta-analysis. The median amount of review 
primary outcome data missing from trials for any reason was 10%.  
Page et al 2015 A Cochrane review to summarise the characteristics of 
studies that have investigated the prevalence of selective 
inclusion or reporting in SRs of RCTs. 
Meta-analysis of 4 studies (including 485 Cochrane Reviews); 38 reviews added, 
omitted, upgraded or downgraded at least one outcome between the protocol and 




2017 Centre for Evidence Based Medicine Outcome Monitoring 
Project: checked articles published in 2015/16 in the top five 
general medicine journals based on impact factor, against 
protocols and registries pre-dating trial recruitment. 
13% of clinical trials reported all primary and secondary outcomes the same in the 




2017 Search of PubMed between 2010 and 2015 for RCTs 
published in the top three impact factor neurology journals. 
From 180 trials, 6% of primary outcomes were demoted, 21% primary outcomes 
were omitted from the publication, and 34% of unregistered primary outcomes 
were added to the published report. There were 10% of secondary outcomes 






1.6.5.3 Variation in outcome reporting across trials 
ORB is an issue that occurs within a single RCT. Inconsistency of outcome reporting is an issue 
that occurs across RCTs within one healthcare area. It occurs because of the reporting of many 
outcomes assessing the same health issue, or the use of many definitions of one outcome, in 
terms of meaning or timing of assessment. The impact of this variation of outcome reporting, 
is an inability to synthesise evidence effectively(71, 168, 191, 195). This topic will be explored 
further in Chapters Three, Four and Five.  
In burn care research, there are many outcomes used to test the effect of interventions(31). 
Reasons for this include a variation in patient age, mechanism of burn injury, depth, site and 
size of burn and a high level of different co-morbidities in adults with burns(1). Short-term 
outcomes, specific to burn care, include healing time, skin-graft loss, infection rates and NHS 
costs. Longer-term outcomes include functional, cosmetic and psychological issues, and are 
likely to be more important to patients (176). This issue will be explored further in Chapter 
Five. It is not known how extensive outcome reporting inconsistency is in published trials 
relating to burn care interventions and what impact this has on evidence synthesis. This will 
be explored in Chapter Two. 
The last section of this chapter looks at the impact that the issues with outcome choice, 
reporting and assessment have on evidence synthesis and knowledge translation, along with a 
possible solution. 
1.7 Synthesising evidence from RCTs 
Outcome reporting variation across trials will make the synthesis of evidence from RCTs 
difficult and the findings unreliable. This is important because evidence from single RCTs will 
not usually provide an answer that is trustworthy enough to support clinical decision-
making(196, 197). Synthesising evidence from multiple RCTs, into a SR is the new apex of the 
evidence quality hierarchy, and provides more reliable evidence to support clinical decision-
making(85, 198, 199). SRs can allow the synthesis of large amounts of information and provide 
estimated effect sizes that have greater generalisability and reliability than individual studies 
(2, 200).  
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Systematic reviews can use a narrative or a quantitative analysis to synthesise individual study 
results(201). A quantitative synthesis, or meta-analysis can be defined as the use of statistical 
techniques to combine and summarise the results of multiple studies to provide new, more 
reliable and more precise, estimates of the effects of health care than those derived from the 
individual studies(202, 203). Meta-analysis can therefore be used to provide a more accurate 
estimate of intervention effects and analysis of whether effects are consistent across sub-
groups(204). Formally assessing variability or heterogeneity between studies is important 
when undertaking meta-analyses. Unless the consistency of the included studies is 
understood, the validity of the meta-analysis findings will not be clear(205). The presence of 
significant and substantial heterogeneity may make a meta-analysis inappropriate 
altogether(206). This will be discussed further in Chapter Three. 
1.7.1 Using systematic reviews to inform healthcare policy 
Translating the synthesis of evidence from multiple, high quality RCTs into clinical care is 
necessary to improve outcomes for patients. Commonly, however, there is a gap between 
evidence-based practice and clinical knowledge. This has been illustrated by researchers in the 
USA, who assessed medical records of adults living in 12 metropolitan areas and evaluated 
performance on 439 indicators of quality of care for 30 acute and chronic conditions (207). 
Participants were found to have received 55% of evidence-based recommended care. Quality 
varied according to the medical condition, ranging from 79% of recommended care for senile 
cataract to 11% of recommended care for alcohol dependence. This is also fund to be the case 
in burn care, with a lack of standardisation of care across services and a resultant variation in 
patient outcomes(11-13, 208). 
Knowledge translation describes any activity or process that enables the transfer of high-
quality evidence into effective changes in health policy or clinical practice(209). Woolf 
defined knowledge translation as “the translation of results from clinical studies into everyday 
clinical practice and health decision making”(210). The Canadian Institutes of Health Research 
defines knowledge translation as “the exchange, synthesis and ethically sound application of 
knowledge to accelerate the capture of the benefits of research for patients through improved 
health, more effective services and products, and a strengthened health care system”(209). 
Knowledge translation has improved certain aspects of burn care, including fluid 
resuscitation, first aid, wound depth and management of the hypermetabolic response(211-
214). Many other clinical strategies remain uninformed by evidence(213). 
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To achieve the full cycle of translating evidence from RCTs though well-conducted SRs into 
improvements into clinical care, improved patient outcomes and reduced research waste, it is 
necessary to remove any blocks, or challenges, to this cycle (Figure 1). The potential 
methodological blocks are:  
• The risk of bias within RCTs. 
• Reporting completeness within RCTs. 
• The heterogeneity of outcome choice, definition and reporting across RCTs. 
This thesis is focused on the latter two methodological issues. 
1.7.2 Core Outcome Sets 
A potential solution to the multiplicity of outcomes reported within and between trials, is to 
achieve consistency and completeness of pre-specified RCT outcome choice. This can be 
achieved by standardising outcome choice, definition and reporting. Standardised outcome 
reporting can be achieved through the development of a Core Outcome Set (COS). This is a 
minimum set of the most important outcomes that are relevant to stakeholders, as well as 
being scientifically agreed, defined, measured and reported in all studies of any particular 
condition(71). Importantly this would not prevent researchers from reporting other outcomes, 
but provides a subset that are standardised, and which can then be compared and collated. 
The effect of this, in terms of impact on aggregating data to support clinical decision-making 
internationally, will be discussed in more detail in Chapter Six. 
1.8 Conclusion 
In this chapter, the need and requirements for developing an evidence base for burn care that 
is of high enough quality to reduce research waste and translate into clinical knowledge, has 
been discussed. This need has been placed within the context of a large, global burn-injured 
population with diverse treatments and little evidence synthesised from high quality RCTs. 
The lack of evidence to support clinical decisions, results in a variation in care and patient 
outcomes. The term quality of research has been explored. Synthesised data from high quality 
RCTs are the building blocks of knowledge that inform clinical decision-making. The two 
aspects of quality that impact this, are the risk of bias of individual RCTs and the ability to 
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collate outcome data across trials (215). If outcome data cannot be effectively compared across 
trials, evidence synthesised will be unreliable and clinical questions will remain unanswered.  
The aim of this thesis is to explore outcome reporting across burn care RCTs. Consistency in 
outcome reporting is one of the determinants of research quality and is necessary for effective 
evidence synthesis. The thesis also aims to propose and develop a possible solution to this 
methodological challenge.  
Through the work undertaken in the following six chapters, the thesis research question will 
be answered:  
Is it possible to increase the provision of data from burn care RCTs such that it can be 
synthesised into evidence to answer clinical questions?  
In Chapter Two, I will explore whether there is variation in the reporting of clinical outcomes 
across trials of burn care. I will discuss the different forms this variation can take in terms of 
choice, definition and timing of assessment. These aspects of outcome reporting will be 
further explored in Chapters Three, Four and Five. Chapter Six will suggest a potential 




Chapter 2 Is there variation in clinical 
outcome reporting across burn care RCTs? 
This chapter is based upon the published paper:  
Young AE, Davies A, Bland S, Brookes S, Blazeby JM. Systematic review of clinical outcome 
reporting in randomised controlled trials of burn care. BMJ Open. 2019 Feb 1;9(2):e025135.  
I conceived the study and wrote the paper as detailed in the Disclosure on page vii. Excerpts 
from the paper are incorporated into this chapter. 
2.1 Introduction 
The previous chapter set the scene for understanding the need for quality of methodology and 
consistency in outcome reporting across trials in burn care research.  
This chapter will answer:  
Thesis Objective 1: An exploration of the variation in clinical outcome reporting across 
burn care RCTs.  
This will be achieved by undertaking a systematic review (SR), extracting clinical outcomes 
reported over a five year period across RCTs in burn care. The extraction of patient-reported 
outcomes are part of a separate study which is reported in Chapter Six. 
2.2 Background 
Systematic reviews (SR) of randomised controlled trials (RCT) are regarded as the highest 
quality in terms of evidence, as discussed in Chapter One (85, 216, 217). An SR identifies, 
appraises and synthesises all the empirical evidence that meets pre-specified eligibility criteria 
to answer a given research question(218). In burn care, systematic reviews of RCTs have not 
provided evidence to support many commonly used interventions or management strategies, 
despite increasing numbers of published trials (219-221). As discussed in the last chapter, a 
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potential reason for the lack of synthesised outputs from burn care SRs, is that trial outcomes 
are reported inconsistently across trials (222). The term trial outcome has been defined by 
Williamson et al. in the Core Outcome Measures in Effectiveness Trials (COMET) handbook, 
as “a measurement or observation used to capture and assess the effect of treatment such as 
assessment of side effects (risk) or effectiveness (benefits)” (115). This definition will be 
explored further in Chapter Three. If there are differences in outcome choice, definition or 
timepoint of assessment across RCTs, evidence synthesis will be challenging. SRs may fail to 
produce reliable results, as systematic reviewers will not be able to compare and collate like-
with-like. Evidence for the presence and impact of variation in outcome reporting across trials 
exists, is illustrated in Table 2. 
The aim of this study is to undertake a SR, to determine if there is variation in clinical 




Table 2: Examples of variation in outcome reporting across RCTs in systematic reviews. Note: Text extracted verbatim from reviews. 
Author Year Method Findings Reference 
Bruce et al 2001 Systematic review of prospective studies of 
surgical wound infection published 1993–1999. 
90 studies reported 41 different definitions of surgical wound infection.  (223) 
Bruce et al  2001 Systematic review of five databases 1993 and 
1999. 
Of 97 studies, 56 separate definitions of anastomotic leak after gastrointestinal 
surgery were reported. 
(224) 
Tendal et al 2011 All Cochrane systematic reviews published from 
2006 to 2007 were examined to assess if 
protocols described the outcomes reviewed. 
19 eligible meta-analyses (including 83 trials). 29% trials reported data for 
multiple intervention groups, 36% reported data for multiple time points, and 
35% reported the primary outcome measured on multiple scales.  
(150) 
Blencowe et al 2012 SRs published 2005 and 2009 reporting 
morbidity and mortality after esophagectomy. 
Data analysed for frequency of complication 
reporting and whether outcomes were defined. 
122 studies (17 RCTs, 105 observational studies), reporting outcomes of 57,299 
oesophagectomies. No single complication was reported in all papers. 61% did 
not define any measured complications. Anastomotic leak was assessed in 80% 
of articles, defined in 28% with 22 different descriptions used. 115 papers 
reported postoperative mortality rates, 25 used 10 different definitions. In-
hospital mortality was the most common term, with 6 different 
interpretations. 
(140) 
Ma et al 2018 MEDLINE, EMBASE, and the Cochrane Library 
searched from inception to March 2017, for 
placebo-controlled RCTs of adult patients with 
ulcerative colitis. 
Data from 83 RCTs. Substantial variation in definitions of clinical or 
composite-clinical outcomes, with more than 50 definitions of response or 
remission. Greater proportion of trials published after 2007 had no 
standardised definitions of histologic or biomarker outcomes.  
(225) 
Ma et al 2018 MEDLINE, EMBASE, and the Cochrane Library 
searched to March 2017 for placebo-controlled 
RCTs of adult patients with Crohn’s disease. 
116 RCTs enrolling 27,263 patients. 38 unique definitions of clinical response 
or remission and 32 definitions of loss of response. 
(226) 
Whitehead et al 2014 RCTs enrolling patients with cardiac arrest 
(2002–2012) were identified by applying a search 
strategy to four databases. 
61 studies. Wide variation in focus, method and timing of assessment. Over 
160 individual outcomes reported across the trials. 39 different survival 
measures reported. 20 different assessments of activity limitation reported. 
Many assessments poorly defined or non-reproducible. No single outcome 
measure was assessed across all trials. 
(155) 
Deckert et al 2015 Three databases searched for studies reporting on 
chronic pain for at least three months. 
70 studies. Most studies (45/70) assessed a combination of three health areas. 
Variation in domains to address these. No domain measured in all studies.  
(154) 
Allin et al 2016 SR conducted. Studies eligible if they compared 
surgical treatment of Hirschsprung’s disease. 
35 studies. 74 unique outcomes investigated. None of the assessed studies met 
all criteria for transparent outcome reporting. 
(227) 
Fish et al 2018 Systematic literature searches for studies 
evaluating radiotherapy or chemoradiotherapy. 
Outcomes and accompanying definitions were 
extracted verbatim and categorized into domains. 
95 eligible studies, reporting 1,192 outcomes and 533 unique terms. No 
outcome was reported in every publication. Over half (43/ 86) of the 
standardized outcome terms reported in fewer than five studies, and 21 (25%) 
reported in a single study. Wide variation in definitions of disease-free 





The systematic review adhered to a pre-specified protocol and is reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement(229). It was registered with the PROSPERO international prospective register of 
systematic reviews (ID CRD42017060908). 
 
2.3.1 Study Eligibility 
Studies were included if they met the following: 
Types of studies: Full text RCTs, RCT protocols and RCT pilot studies were included. Protocols 
and pilot studies were excluded if the full RCT had been published within the selected time 
period. Conference proceedings and abstracts, non-English language publications and studies 
not involving human subjects were also excluded.  
Types of participants: We included studies recording outcomes from patients of any age with a 
cutaneous burn of any type or size, determined by either clinician evaluation or objective 
assessment, which required treatment in any health care facility. Studies where the population 
consisted of patients with combined thermal and mechanical injuries, were only included if it 
was possible to separate out the burn care outcomes. Trials studying patients with pure carbon 
monoxide poisoning, chemical ocular or caustic oesophageal burns were excluded, as the former 
does not involve a burn and the latter have different aetiology and management to cutaneous 
burns.  
Type of interventions: Any surgical or non-surgical burn care intervention with any appropriate 
comparator were included. The variety of outcomes reported across RCTs was studied, rather 
than the choice or effectiveness of an intervention.  
Types of outcomes: These were defined as the exact terms used in a published trial abstract, 
methods or result sections, including tables and figures, for any observer-reported clinical 
endpoint. These included physiological, metabolic or adverse or mortality events, measured by 
researchers and relevant to patients’ recovery and long-term well-being after burn care (230). 
Trials assessing quality of life were only included if the data were observer-reported.  
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2.3.2 Identification of studies 
Electronic searches of Ovid MEDLINE, Ovid EMBASE, Web of Science and The Cochrane 
Library were searched from 1st January 2012 to 31st December 2016, for RCTs related to burn 
care. Medical subject heading (MESH) and free text terms including the terms burn, scald, 
thermal injury and RCT were used. This time period was chosen, so that the outcomes 
extracted, reflected use in trials relating to recent burn care. Limiting the review to five years 
allowed us to balance workload against the likelihood of selecting enough trials fulfilling 
inclusion criteria, to demonstrate whether heterogeneity of outcome reporting was present in 
burn care research. The thesaurus vocabulary of each database was used to adapt the search 







Table 3: Search strategy using Ovid MEDLINE. 
 Search term 
1 exp Burns/ 
2 burn*.tw. 
3 scald*.tw. 
4 (thermal* adj injur*).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms] 
5 (smoke adj inhalation).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms] 
6 1 or 2 or 3 or 4 or 5 
7 heartburn.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
8 burnout.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
9 (burn* adj out).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
10 burning.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
11 burnish*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
12 burnet*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
13 7 or 8 or 9 or 10 or 11 or 12 
14 6 not 14 
15 (randomi?ed adj control* adj trial*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
16 RCT.tw. 
17 trial.tw. 
18 16 or 17 or 18 
19 15 and 19 
20 limit 20 to (english language and humans and year="2012 - 2016") 









2.3.3 Study selection process 
The reference management software EndNote (version 8, Clarivate Analytics) was used to 
compile all titles derived from the initial searches, with duplicates removed to allow screening 
of titles and abstracts against the eligibility criteria. Screening of titles and abstracts was 
completed independently, then in duplicate by the thesis author and another researcher (AD). 
All screening disagreements were discussed, with any outstanding disagreements resolved by a 
senior reviewer (JMB). Any studies appearing to meet the inclusion criteria based on the 
abstract were retrieved as full-text articles. The two reviewers then read the full-text articles in 
their entirety to assess for eligibility, with decisions on exclusion recorded. Reasons for 
exclusion were ordered hierarchically (Table 4) and applied to each full text. The highest 
reason for exclusion met by a paper was recorded as its reason for exclusion. Any 




 Table 4: Hierarchy of exclusion of trials for systematic review.
Reasons for exclusion. 
Duplicate. 
Not published between Jan 1st 2012 and Dec 31st 2016. 
Not written in English. 
Not relating to burn care alone. 
Population is non-human. 
Abstract with no full text available. 
Study not an RCT testing an intervention on burn care. 
Laboratory based and not carried out in clinical setting.  
Reports only patient-reported outcomes. 
Volunteer study. 
Study relating to caustic oesophageal burns only. 
Study relating to chemical ocular burns only. 
Anaesthetic / sedation technique only. 






2.3.4 Quality assessment 
The aim of this study was to comprehensively document any variation in clinical outcomes 
selected, defined, measured and reported in burn care RCTs and not to synthesise data about 
the effect of interventions. Inclusion of all trials, regardless of quality of methodology of the 
trial, was necessary to demonstrate if a variation in outcome reporting was present across trials. 
A quality assessment of studies was therefore not undertaken.  
 
2.3.5 Data Extraction 
Data were extracted into a standardised data extraction sheet (Microsoft Excel). This included 
study author, country or countries recruiting (categorised into the United Nations six regions 
(231)), publication year, number of sites and number of participants recruited per trial, design 
(full RCT, pilot, protocol) and intervention tested. For protocols, the planned participant 
inclusion criteria and sample size were extracted.  
No distinction was made between primary or secondary outcomes. All outcomes were 
extracted verbatim, with 20% of the extracted data verified by a second reviewer (AD). True 
duplicates, spelled and worded the same, were included once. As a second process, two 
reviewers discussed all verbatim outcomes to assess duplicates in meaning but worded in a 
slightly different manner. Examples are: length of time in hospital and number of days in 
hospital, platelet level and levels, and serum IL-10 and IL-10 in blood. Outcomes with the 
same meaning were named as one outcome with the chosen wording, and the others deleted 
as duplicates. The remaining outcomes were therefore all different in meaning. Any 
discrepancies were discussed with a senior researcher (JMB). The number of outcomes per 
trial and the variation in outcomes reported across trials was recorded. 
The timepoints after injury that outcomes were measured were noted separately, in order to 
assess the heterogeneity in outcome measurement timing and to understand at what stage 
after injury the effects of the intervention were being assessed. If a single outcome was 
assessed at different timepoints, all assessment timings were recorded. Data extraction for the 
timing of outcome reporting from 10% of trials was undertaken independently by another 
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researcher (AD). Timings of outcome assessment were categorised into time periods after 
injury: 
• Less than or equal to 1 month. 
• More than 1 month and less than or equal to three months. 
• More than 3 months and less than or equal to six months. 
• More than six months and less than or equal to one year. 
• More than one year and less than or equal to three years. 
• More than three years.  
We reported two other outcome time periods; those assessed during acute hospitalisation and 
during burn wound healing, as these were commonly reported in the literature with no 
associated timepoint. It was clear, however, from the reported length of stay and healing data, 
that all these outcomes were assessed within six months of injury. The frequency of outcomes 
reported within each time period was recorded. 
The data were tabulated so that each study was listed with study and population details along 
with outcomes measured. Outcomes were extracted from this spreadsheet into another, with 
duplicates removed, as described above. Outcomes measuring the same healthcare issue but 
at different timepoints were noted as one outcome for the final set. These final unique 
outcomes were then grouped into domains. 
2.3.6 Classification of outcomes into outcome domains 
In this thesis, outcome domains will be defined as groups of similar outcomes, in terms of the 
health issue. This is described in more detail in work undertaken by the 
Nephrology−Hemodialysis (SONG-HD) Core Outcome Set group and will be discussed further 
in Chapters Three and Six(232). Organisation of outcomes into domains is necessary, as 
maintaining a large set of outcomes when a significant number are similar, would make any 
future classification of the outcomes in terms of importance, extremely challenging.  
In this study, outcomes were classified into domains in a three-stage iterative approach.  
• Stage One: four researchers (the thesis author, AD and two senior research nurses 
experienced in burn care) independently reviewed the list of outcomes and attributed a 
potential domain to each one, using their own terms.  
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• Stage Two: the researchers met to review the domains and agreed: 
o Appropriate groupings of outcomes into domains.  
o An appropriate name for each domain.  
Rules for attribution of outcomes to domains were recorded in a coding log to ensure 
consistency.  
• Stage Three: a patient representative reviewed the outcomes and their attributed domains 
to check: 
o The clarity of the domain name. 
o That the outcomes under each domain were appropriately attributed.  
A final meeting with an experienced outcome researcher (JMB) was held to finalise outcomes 
and domains. The use of a published classification system was not undertaken, as none appeared 
to allow the flexibility or fit to the types of outcomes reported in burn care trials(233, 234). This 
will be discussed further in Chapter Six, within the context of international outcome research. 
The results described below indicate the characteristics of the reported studies and provide 
detail on variation of outcome reporting between studies, outcome definitions, timepoints of 
assessment and outcome domains.  
2.4 Results 
2.4.1 Included studies 
The initial search strategy identified 3,110 studies. Following de-duplication, a total of 2,070 
studies remained. Independent scrutiny of the titles and abstracts identified 306 potentially 
relevant articles for full text review. Of these, 158 studies did not meet the inclusion criteria and 
were excluded. Therefore, a total of 147 studies formed the basis of this study (Appendix B). Of 
the 147 studies (Table 5), 127 (86.4%) were reports of full RCTs, 13 (8.8%) were pilot studies and 
7 (4.8%) were study protocols. The number of studies published increased between 2012 and 
















Table 5: Details of included studies. 
 Studies n=147 (%) 
Number of RCTs 
Number of Pilot studies 
Number of RCT protocols 
127 (86%) 
13  (9%) 
7  (5%) 
World region for recruitment (n=147): 
- Asia 
- North America 
- Europe 
- Africa 






15  (9%) 
1    (1%) 
15  (9%) 
















- > 5 
 
132 (90%) 
9    (6%) 
2    (1%) 
4    (3%) 
Number of participants in full RCTs (n=127): 






4   (3%) 
62 (49%) 
39  (31%) 
11   (9%) 
11   (9%) 
Participants (to be) recruited (n=147): 
- < 18 years 
- > 18 years 
- Mixed age range 
- Not stated 






5   (3%) 
Type of intervention (n=147): 
- Dressings and wound care 
- Surgical technique 
- Treatment of pain or itcha 
- Impact of exercise and rehabilitation 
- Intensive care management 
- Treatment of hypermetabolism 
- Nutrition  
- Scar management 
- Treatment of inhalational injury 
- Use of topical rHGM 
- Use of rHGH 
- Sugar management 
- Treatment of infection 
- Treatment of DVT 
- Blood management 
- Extracorporeal shock wave therapy 






















aIncluding: distraction for dressing changes. 




Details of the studies are shown in Table 5. Across the 140 studies (protocols not included 
n=7), 9,022 participants were recruited. The number of patients recruited per trial ranged 
from 3 to 612 (median 50; IQR 30-88) for full RCTs, and from 10 to 52 (median 21; IQR 16-28) 
for pilot studies. Of the full RCTs, 50% recruited fewer than 50 participants. The large 
majority (90%) of studies recruited (or planned to recruit) participants on one site alone. Of 
the 15 (10%) studies that were multi-centre, nine (60%) undertook research at two or three 
sites only. Thirty-two countries, from six global regions, recruited patients into the 147 RCTs. 
The number of studies per continent are listed in Table 5. In terms of individual countries, the 
USA undertook most trials (33 (22%)), followed by Iran (19 (13%)) and China (16 (11%)). Of the 
32 countries, 19 (59%) published only one trial in this time period. The most common trial 
interventions related to dressings and wound care 43 (29%), followed by surgical technique 17 
(12%) and management of pain and itch 11%. 
 
2.4.2 Outcome reporting 
From all studies, 1,494 differently defined clinical outcomes were reported. After grouping 
those with the same meaning, 955 unique outcomes remained. The number of the original 
1,494 outcomes reported per trial varied from one to 37 (median 9; IQR 8) (Table 6).  
The data that is of interest to this thesis, however, is how many times the outcome with the 
same definition or meaning (unique) is reported across trials. Key outcomes should be 
reported in all trials. This study shows that 810 unique outcomes were each reported in only 
one trial (Table 7). No single outcome was reported across all 147 studies. This identified 
problem indicates the clear need for consistent reporting of a minimum set of outcomes 
across trials.  







Table 6: Number of reported outcomes per study. 
Number of outcomes per study: Number of studies n=147 (%) 
1 4  (27%) 
2-5 34 (23%) 
6-10 53 (36%) 
11-20 41 (28%) 
>20 15 ( 10%) 
 
Table 7: Number of studies in which each outcome is reported. 
Number of studies reported in. Number (%) of unique outcomes 
(n=955) 
1 810 (84.8) 
2 - 5  108 (11.3) 
6 - 10 25 (2.6) 
11 - 15 5 (0.5) 













2.4.2.1 Outcome definition variation 
Outcomes assessing the same healthcare issue were commonly defined differently. An 
example is burn wound healing, which was defined in 166 different ways (Table 8). Examples 
include, healing percentage at specified timepoints, incidence of complete wound healing and 
length of time until 50% epithelialisation of the burn wound. There was a similar variation in 
the definition of burn wound infection and scarring. For wound infection, 79 unique outcome 
definitions were reported, including: bacterial colonisation of burn wound, days of antibiotics, 
incidence of local infection, incidence of positive wound cultures, peri-wound redness, rate of 
bacterial clearance from wound and number of inflammatory cells in the wound. This issue 


















Table 8: Variation in definitions of wound healing across trials. 
Verbatim definitions of wound healing (n=166) across RCTs (n=147) listed alphabetically (with % and < listed first). 
 
% burn wound healed at each 
assessment 
Duration of treatment for complete 
wound healing in relation to wound 
depth 
Skin necrosis 
% burn wound reepithelialisation at 4 
to 6 days 
Duration of treatment for complete 
wound healing in relation to wound 
size 
Start of epithelialisation 
% burn wound size reduction at 
3,7,10,14,21,28,35,42 days 
Epithelialisation time status of burn wound 
% burn wounds fully healed at 4 weeks Expression levels of vascular endothelial 
growth factor in local wound tissue 
Time for formation of granulation 
tissue 
% epithelialisation at day 10 Failure to heal burn with a need for skin 
grafting 
Time of formation of basement 
membrane. 
% epithelialisation at specified time 
points until day 21 
Healing % at 14 days Time of healing 
% epithelialisation of wound at 5-7 days 
after grafting 
Healing % at 7 days Time to > 90% eschar removed 
% improvement in burn wound at 4 
weeks 
Healing rate Time to > 90% reepithelialisation 
% initial wound area healed at each 
dressing change 
Healing rate on 10th day Time to > 95% burn wound 
epithelialisation 
% of burn wound epithelialisation at 
dressing changes 
Healing rate on day 14 Time to > 95% epithelialisation 
% of burn wounds that are 50% healed 
at 4 weeks 
Healing rates Time to > 95% wound epithelialisation 
% of type I and type III collagen in 
dermis 
Healing time Time to >95% reepithelialisation 
% of wounds healed at 1 week Healing time in relation to burn depth Time to 100% reepithelialisation 
% of wounds healed at 2 weeks Incidence of 30% wound healing Time to 90% confluent re-epithelisation 
of the donor site 
% of wounds healed at 3 weeks Incidence of 70% wound healing Time to 95% burn wound 
epithelialisation 
% of wounds healed at 4 weeks Incidence of burn wound depth 
conversion 
Time to complete epithelialisation 
% of wounds healed by day 21 Incidence of complete wound healing Time to complete epithelialisation after 
burn 
% of wounds re-epithelialised after 14 
days 
Incidence of complete wound recovery 
at 2 months 
Time to complete epithelialisation or 
granulation 
% reepithelialisation Incidence of healed burn wound > 95% 
at day 10 
Time to complete healing 
% reepithelialisation at each dressing 
change 
Incidence of incomplete wound 
recovery at 2 months 
Time to complete wound closure 
% wound epithelialisation Incidence of wound deepening from 
partial to full thickness 
Time to complete wound healing of 
burn wound 
% wound healing Incomplete wound closure Time to complete wound 
reepithelialisation 
% wound progression Length of time for 50% re-
epithelialisation of burn wound 
Time to healing 
% wounds healed by day 10 Length of time for 70% 
reepithelialisation of burn wound 
Time to healing in relation to age 
> 90% wound Reepithelialisation Length of time to > 95% wound healing Time to healing in relation to burn 
depth 
> 95% Burn reepithelialisation time Length of time until complete healing Time to healing in relation to burn size 
Amount of granulation tissue present 
inside the ulcer/wound; 
Mean time to wound closure Time to healing of grafted wounds to > 
90% 
Amount of necrotic tissue present 
inside the ulcer/wound 
Median wound healing time Time to healing of un-grafted wounds 
Amount of wound healing by means of 
epithelization of the ulcer/wound 
Need for wound debridement Time to wound healing 
Basement membrane structure Number of apoptotic cells in dermis at 
48 hours after burn 
Time until epithelialisation 
Blinded assessment of time to complete 
reepithelialisation 
Number of blood vessels in wound Total time of wound healing 
44 
 
Burn wound area every 4 days Number of burn wounds epithelialised 
within 10 days 
Type of granulation tissue present 
inside the ulcer/wound; 
Burn wound condition Number of burn wounds epithelialised 
within 20 days 
Vascular density in wound bed at 
specified time points up to 21 days 
Burn wound healing time Number of burn wounds epithelialised 
within 30 days 
Wound closure > 95% 
Cellular and molecular regenerative 
effects in burn wounds 
Number of burn wounds epithelialised 
within 40 days 
Wound epithelialisation 
Change in burn depth after treatment Number of burn wounds requiring a 
skin graft 
Wound healing 
Complete wound closure Number of burn wounds requiring 
debridement in relation to burn size 
Wound healing duration 
Complete wound healing time Number of cases completely healed at 4 
weeks 
Wound healing rate 
Condition of edge of wound Number of days to 95% epithelialisation 
for donor site 
Wound healing rate at 14 days 
Condition of surrounding skin Number of days until > 95% 
reepithelialisation of burn wound 
Wound healing rate at 20 days 
Condition of surrounding unburned 
tissues 
Number of debridement surgeries Wound healing rate at 28 days 
Days to re-epithelialisation adjusted for 
deepest part of wound 
Number of fibroblasts in wound Wound healing rate at 3 days 
Days to re-epithelialisation adjusted for 
wound depth 
Number of keratinocyte cell layers in 
wound bed at specified time points 
during healing 
Wound healing rate at 5 days 
Days until 95% epithelialisation of burn 
wound 
Number of wounds healed by day 24 Wound healing rate in relation to burn 
depth 
Days until wound closure Numbers achieving complete healing 
before 18 weeks 
Wound healing time 
Density of angiogenesis in wound bed 
at specified time points during healing 
Numbers of wounds not re-
epithelialising > 95% before discharge 
Wound reepithelialisation to > 95% 
Density of arterioles, meta-arterioles 
and venules in wound bed at specified 
time points during healing 
Numbers of wounds reepithelialised in 
14 days or more 
Wound secretion 
Density of endothelial cells in wound 
bed at specified time points during 
healing 
Optical density of the fibroblast growth 
factor in burn wound 
Wound size at 10 days 
Density of fibroblasts at specified time 
points during healing 
Optical density of the vascular 
endothelial factor in burn wound 
Wound size at 2 days 
Density of inflammatory cells in wound 
bed at specified time points during 
healing 
Progression of burn to full thickness Wound size at 21 days 
Density of keratinocytes at specified 
time points during healing 
Proportion of wounds healed at day 21 Wound surface area at 14 days 
Density of myofibroblasts in wound bed 
at specified time points during healing 
Rate of re-epithelialisation Wound surface area at 7 
Difference in healing time based on 
anatomical location 
Reepithelialisation rate after skin 
grafting on day 21 
Wound surface area at 7 and 14 days 
Difference in healing time related to 
cause of burn 
Reepithelialisation rates Wound surface healing time 
Duration of healing Size of remaining wound at specific 
time points until day 21 
 






2.4.2.2  Outcome timing variation  
There were 2,743 outcomes reported, if the same outcome, measured at different timepoints 
across all the 147 RCTs, are included. For example, the size of burn wound measured at one 
week and again at two weeks, were recorded as two different outcomes for this exercise.  
In terms of timing after injury (Figure 4):  
• 77% (2,109) were assessed before, or at, six months after injury. 
• 17% (456) were measured after six months and before, or at, three years after injury.  
• 5% (140) were measured at more than three years after injury. 
The timing of outcome measurement was not reported for 38 outcomes. This issue will be 

















Figure 4: Timing of outcome assessment. 
Note: This is the percentage of all outcomes reported across all included trials with their 
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2.4.3 Outcome domains  
The 955 different clinical outcomes were initially organised into 54 domains (groups of similar 
outcomes). Table 9 groups the domains into over-arching categories and gives examples and 




Table 9: Outcome category, domains with outcome examples and numbers of outcomes per domain. 
Outcome Category Outcome Domain Outcome Examples Nos. of unique outcomes per 
domain 
Patient-reported Ability to carry out daily tasks Functional level of independence 3 
 Anxiety about medical procedures and 
appointments 
Pain anxiety 
Anxiety before dressing changes 
4 
 Generalised anxiety General anxiety 1 
 Appearance Facial symmetry 
Overall scar appearance 
3 
 Blister fluid Amount of exudate 3 
 Burden of care Frequency of dressing changes 
Time taken for daily wound cleaning 
8 
 Comfort of dressings Dressing comfort 2 
 Psychological wellbeing Improvement in well-being 1 
 Mental ability Cognitive performance 2 
 Sleep Quantity of sleep 
Incidence of sleep disturbance 
16 
 Effect of scar on movement (contractures) Ability to walk 3 
 Return to work/school or previous function Return to work or previous function 1 
 Burn wound pain Wound pain intensity at baseline 
Pain tolerance 
48 
 Donor site pain Donor site pain at rest 
Donor site pain while walking 
10 
 Pain during procedures Wound pain at dressing changes 
Pain during hydrotherapy 
7 
 Scar pain Functional scar pain 
Incidence of neuropathic pain 
4 
 Itch Baseline pruritus 
Itch severity reduction 
22 
Pathophysiological Ability to fight infection Change in IgA 
IL-1beta in blood 
Serum interferon gamma levels 
40 
 Body weight maintenance Incidence of weight loss 




 Bone strength Bone mineral density 
Incidence of osteoporosis 
21 
 Breathing and lungs Forced expiratory volume in 1 second 
Functional residual capacity 
36 
 Donor site problems after healing Donor site pigmentation 
Sensation of donor site 
23 
 Effect of burn on genes Gene expression patterns 5 
 Effect of burn on how the body uses energy Change in percentage of predicted resting energy expenditure 1 
 Effect on heart and blood circulation Incidence of cardiomegaly 
Number of patients requiring noradrenaline 
36 
 Fitness Max. aerobic capacity 
Exercise max. minute ventilation 
5 
 Growth in children Duration of growth arrest 
Percentage change in height 
12 
 How well muscles work Facial mimic function 
Change in muscle function 
19 
 Mobility Stride length 
Knee range of motion 
11 
 Kidney function Incidence of acute kidney injury 
Requirement for renal replacement therapy 
18 
 Liver function Hepatic function 
Ammonia levels 
15 
 Medical tests to indicate how unwell a patient 
is 
Albumin level 
Change in Ph 
40 
 More than one organ failing (multi-organ 
failure) 
Incidence of multi organ failure 
Percentage of patients with organ dysfunction 
6 
 Muscle strength Knee extensor strength 
Hamstring strength adjusted for body weight 
41 
 Stomach and bowel function Days of diarrhoea 
Incidence of abdominal distension 
14 
 Burn wound healing Burn wound area at timepoints 
Days until wound closure 
160 
 Donor site healing Donor site healing to 90% 
Time to donor site re-epithelialisation 
17 
Complications Complications of drug treatment Adverse drug reactions 
Allergic dermatitis 
36 
 Blood product transfusion Blood transfused per kg during hospitalisation 





 Burn wound infection Wound bacterial colonisation 
Wound contamination post-operatively 
86 
 Death from burn injury Mortality related to burn size 1 
 Death from any cause Overall mortality 
In-hospital mortality 
13 
 Effects of fluid from a drip Incidence of fluid creep 
Net fluid balance at specified times 
 22 
 Infections other than burn wound infection Incidence of central catheter related infections 
Pulmonary infection 
11 
 Sepsis Days of sepsis 
Incidence of positive blood cultures 
 10 
Scar-related Scar colour Erythema index 
Scar melanin levels 
16 
 Scar texture Scar height 
Change in scar distensibility 
40 
 Scar size Scar surface area  2 
 Treatment for scars Numbers of patients assessed for scar management 
Numbers of patients needing scar management 
2 
Healthcare-related Costs of treatment for NHS/Hospital Costs of analgesics for dressing changes 
Pressure garment costs 
14 
 Length of hospital stay Length of stay adjusted for burn size 
Days in hospital 
6 
 Length of stay in intensive care unit  Length of ICU stay 3 
 Length of time on life support machine  Duration of mechanical ventilation 3 
 Use of medicines to treat symptoms Pain relief required during dressing changes 
Opioid consumption 
4 





2.5.1 Outcome reporting variation across trials 
In this chapter, I have reported an SR showing variation in clinical outcome choice and 
reporting across burn care RCTs. This is one type of outcome reporting variation across 
studies and is illustrated in Figure 5. Of the 147 studies included in the SR, 1,494 outcomes 
were identified. Only 15% of the outcomes reported were included in more than one study. 
Outcomes that were more commonly reported, included: length of hospital stay (n=30 studies, 
20% of 147 studies), incidence of wound infection (n=28, 19%), scar pliability (n=21, 14%), scar 
vascularity (n=20, 14%), adverse events (n=18, 12%) and mortality (n=18, 12%). There was no 
single outcome reported across all 147 trials and 810 outcomes were reported in only one 
study.  
Commonly reported outcomes were defined differently between trials. Burn wound healing 
was defined in 166 different ways across the 147 studies. These variations in definition, 
included a variation in timing of outcome assessment. Such heterogeneity of outcome 
reporting across trials will limit evidence synthesis and result in research wastage. Variation in 
outcome definition will be explored in more detail in Chapters Four and Five. Chapter Three 
will explore how to define a unique outcome. Chapter Four will concentrate on the variation 
in definition of one specific outcome; burn wound infection. Chapter Five will explore 




Figure 5: Versions of outcome reporting variation across trials. 








2.5.2 Outcome grouping into domains 
In this systematic review, I identified and agreed the grouping of the 955 unique outcomes 
into 54 outcome domains. There is no agreement on how to best classify outcomes with 
similar meaning, into groups, known as domains. Dodd and colleagues published a taxonomy 
of categorised outcome domains (235). Other authors have suggested various additional 
categorisation methods, all addressing different needs(111, 233, 234)). In the Williamson 
taxonomy, the authors state that of 99 systematic reviews grouping outcomes into domains, 
only 21 applied their own approach to outcome classification and only six used an existing 
system. It is unclear how the remaining authors classified the extracted outcomes. As many 
different clinical burn outcomes have been identified in this review, and as the outcomes 
extracted did not clearly fall within the Dodd taxonomy, a classification system determined by 
the author of this thesis was used instead. There is a plan for a re-look at the use of the Dodd 
taxonomy with burn outcomes in the future. This was achieved with input from five multi-
disciplinary colleagues and a patient, as described in section 2.2.6. The team worked 
independently, and subsequently together, to bring different views and as little bias as 
possible to the process. This process was challenging and involved much learning from each 
other, with the final domain names and associated outcomes agreed by all. Classification of 
outcomes into domains will be discussed in more detail in Chapter Six. 
2.5.3 A potential solution 
The findings in this review, in terms of the variation in outcome reporting, have been 
observed elsewhere in the burns-specific literature. A Cochrane review of 30 RCTs concluded 
that it was impossible to draw conclusions about burn dressing effectiveness, as the trials 
evaluated a variety of clinical outcomes(8, 236). Since 2000, 12 Cochrane reviews have had 
direct relevance to the management of patients with cutaneous burns(8, 10, 89, 237-245). 
None could draw firm conclusions, due to methodological issues including heterogeneity of 




One way to resolve variation in outcome reporting across trials is to pre-specify a minimum 
set of outcomes through the development of a Core Outcome Set (COS) (246). The 
development of a COS for burn care research will be presented in Chapter Six.  
In burn care research, there is no agreed set of clearly defined outcomes, despite problems 
with outcome reporting being increasingly reported(8, 33, 150). Pre-specifying outcomes 
requires research to determine and agree the most important outcomes for a clinical 
condition. If this is not undertaken, the outcomes reported may not reflect patients’, carers’ or 
other stakeholders’ needs, and outcomes will vary between studies (71, 186). Choosing the 
most important outcomes to measure in burn care is complex, as patients are a heterogeneous 
population, with variations in age, mechanism of injury, depth, site and size of burn (247, 
248). The time frame at which outcomes are measured, may also determine the types of 
outcomes assessed. Outcomes reported in clinical trials during the acute treatment phase 
include healing time, skin-graft loss, infection rates and NHS costs (38, 249-251). Longer-term 
reported outcomes relate to functional, cosmetic and psychological issues (152).  
2.5.4 Strengths and limitations  
The strengths of this review are that the protocol and data extraction proforma were pre-
specified and the literature search was systematic and comprehensive, including four major 
healthcare trial databases. This review was undertaken to a pre-specified protocol which has 
been published(252). To account for multi-disciplinary perspectives, two researchers, two 
clinicians and a patient were involved in the process of defining the outcome domains. All 
screening of abstracts and full texts and all data extraction was double-checked in 
completeness or partially, to assess agreement. The review is novel, as it is the first to 
demonstrate, in detail and using systematic methodology, the scale of the heterogeneity of 
outcome reporting in burn care research. Limitations include the exclusion of publications in 
languages other than English. However, international publications were included to reduce 
the risk of selection bias. The search was also time-limited, which may have excluded 
outcomes from older studies. The time limitation was applied, to identify research relevant to 
recent burn care. The search was also limited to trials reporting clinical outcomes. Other work 




reported in Chapter Six. A formal quality assessment of studies was not undertaken, as we 
were researching the reporting of outcomes and not attempting to analyse the effects of 
interventions. 
2.6 Conclusion 
This study has demonstrated that multiple, different, apparently individual, outcomes are 
reported across RCTs of burn care interventions. Various definitions are used to report the 
same outcome and outcomes are measured at different time points after injury. This 
inconsistency in outcome reporting prevents effective evidence collation, as researchers 
cannot compare like-with-like. Until there is greater consistency of outcome reporting, it is 
unlikely that clinicians will be able to synthesise data across studies. This will limit 
understanding of the effectiveness of surgical and non-surgical treatments for burn injury. 
One potential solution to this, is a COS for burn care research (Figure 5). 
In the following chapter, I will explore in more detail the methodological challenges 
demonstrated by this systematic review. This will relate to an exploration of the definition of 
an individual (unique) outcome in research reporting. The work will explore how difficulties 
in determining what makes one outcome different to another, affects the magnitude of the 





Chapter 3 What is the definition of a unique 
trial outcome? 
This chapter is based upon the published paper:  
Young AE, Brookes ST, Avery KN, Davies A, Metcalfe C, Blazeby JM. A systematic review of 
core outcome set development studies demonstrates difficulties in defining unique outcomes. 
Journal of Clinical Epidemiology 2019 Nov 1;115:14-24.  
I conceived the study alone and wrote the paper, with input, in terms of editing and 
readability, by the senior authors. The Bristol Centre for Surgical Research assisted with the 
development of a proposal for a unique outcome. All collaboration is presented in the 
Disclosure section. The paper was peer-reviewed. Excerpts from the paper are incorporated 
into this chapter. 
3.1 Introduction 
This chapter will answer:  
Thesis Objective 2: The development of an understanding of what makes an outcome 
unique.  
The chapter will focus on the methodological challenges relating to the definition of an 
individual (defined here as unique) outcome in research reporting and in COS development. 
The chapter will also explore the requirement to provide transparent methodology for the 
basis of any quoted magnitude of variation in outcome reporting in COS literature reviews. 
This concept will be defined as outcome reporting heterogeneity (ORH). The implications of 
ORH in COS development, and on the need for a COS in any healthcare area, will be 
discussed. The impact of a lack of definition of a unique outcome on the development of a 




The chapter will report a systematic review using the Core Outcome Measures in Effectiveness 
Trials (COMET) database, which will identify how individual outcomes are extracted and 
grouped into unique outcomes by researchers undertaking COS systematic reviews. The 
chapter will conclude with a suggested definition of a unique outcome, and a proposed 
strategy for refining verbatim outcomes into unique outcomes, to allow quantitative reporting 
of ORH. The work will link ORH, to variation in definition of the same outcome, as discussed 
in Chapter Four and variation in outcome measurement timing, as discussed in Chapter Five. 
3.2 Background 
Well designed and conducted randomised controlled trials (RCTs) determine effectiveness, 
through an un-biased comparison of outcomes (events or endpoints) by intervention group 
(103). The choice and selection of outcomes is critical in RCT design and trials may be 
regarded to be “only as credible as their outcomes”(253, 254). Trial outcomes, however, may 
be defined in various ways(112, 113, 115, 195, 255-257). These include: “as variables that are 
monitored during a study to document the impact that a given intervention or exposure has 
on the health of a given population”(114) and as “a variable measured at a specific time point 
to assess the efficacy or harm of an intervention”(116). Whilst these definitions explain the role 
of an outcome in a trial, they do not define what an outcome is per se. Other authors have 
defined outcome reporting using four or five levels. These include outcome, measurement, 
metric, aggregation of outcomes and timing of measurement (258, 259). None of these 
publications describe how to determine what makes an outcome unique (116, 192). Without a 
definition for an individual or unique outcome, difficulties arise in differentiating one outcome 
from another. As illustrated in the previous chapter, the lack of a definition for a unique 
outcome, results in the reporting of multiple, apparently different, outcomes across studies 
and impacts negatively on evidence synthesis. This contributes to research waste. The lack of 
definition of a unique outcome, may also complicate the development of Core Outcome Sets 
(COS). 
A COS is a minimum set of outcomes that are selected, measured and reported in trials of a 
specific healthcare condition(71). COSs will be discussed in more detail in Chapter Six. They 
are typically developed by identifying all outcomes in the literature and discussion with 
stakeholders, and combining these into groups or domains for stakeholders to prioritise using 




literature and extract outcomes verbatim, for reasons of transparency(115). Outcomes are then 
de-duplicated and grouped into unique outcomes for the prioritisation process. The process 
may identify between 20 to more than 1,000 outcomes(260-263). This wide variation is likely 
to reflect the lack of application of a uniform definition of a unique outcome, in addition to 
real differences in numbers of different outcomes. Guidance as to when the use of different 
wording defines the same outcome, and when it does not is lacking; for example, 30 day 
mortality and in-hospital mortality(264, 265). There is no advice as to how to group similar 
outcome terms into a single unique outcome. Some researchers may choose to include all the 
definitions of a specific outcome under one term, with others seeking more granularity and 
reporting several different definitions as unique (227, 261). There is no clarity as to which 
process is correct for demonstrating variation in outcome reporting in a quantitative manner, 
and for outcome long-list generation for COS development. It is also unclear whether the 
timing of outcome measurement affects the singularity of an outcome. For example, the 
incidence of wound healing at two specified timepoints. Some researchers will count these as 
two outcomes and others as one(266, 267).  
The reporting of methods for extracting and grouping outcomes in COS development studies 
is often poor. The impact of identifying unique outcomes is that that different researchers may 
extract a different number of outcomes from the same dataset, and the scale or presence of 
true variation in outcome reporting, will therefore be difficult to establish. Inconsistency in 
methods for extracting outcomes, means that the scale of ORH is difficult to establish. ORH is 
a quantitative measure of the variation in outcomes reported across trials in one healthcare 
area and has been defined through the work in this thesis. It is commonly reported in COS 
development as a number: n=x different outcomes were reported across n=x trials in a specific 
healthcare area. ORH will impact on the validity of the long-list of outcomes used to inform 
the consensus processes in the development of COSs. 
In this chapter, I will suggest a first working definition for a unique outcome, through work 
undertaken for this thesis and on discussion with the senior co-authors of this paper and other 
senior members of the Bristol Centre for Surgical Research 
(https://www.bristol.ac.uk/population-health-sciences/centres/surgical-research/). A final 
agreed definition will ensure that COS researchers can accurately and consistently identify a 
quantitative assessment of the inconsistency of outcome reporting (defined here as ORH). 
This work is a starting point for a debate between international COS researchers, with further 




The aim of this chapter is to examine methods used to extract and combine outcomes with 
the same meaning, from published research papers. Standardisation of this process would 
inform how to establish a reproducible and quantifiable long-list of unique outcomes.  
3.3 Methods 
This study consisted of two phases:  
• Phase 1: an in-depth literature review was undertaken to analyse and summarise methods 
for outcome extraction, grouping, defining and counting, from SRs used to inform COS 
development.  
• Phase 2: combined the findings from Phase 1, with the input of multidisciplinary expert 
opinions. This informed the development of a first working definition of a unique 
outcome, and methodology for the conversion of outcomes extracted verbatim from trials 
into unique outcomes. A first definition of ORH was developed, based on the definition of 
a unique outcome. 
3.3.1 Phase One Literature Review 
3.3.1.1     Data source and search strategy 
A structured search of the COMET database (a repository of COS studies http://www.comet-
initiative.org/Studies) was undertaken. As optimal COS development methodology is still 
evolving, it was hypothesised that the most current advances in methodology are likely to be 
found in recent studies registered with the COMET database. This database allows the use of 
filters to identify the nature of the COS work (e.g. protocol, full paper, population studies 
etc.).  
3.3.1.2 Study selection criteria and identification 
Searches of the COMET database were used to identify COS development papers. The filters 
applied in this study are described in Table 10. Hand-searching the reference lists of these 
papers, and the use of two other search engines (Ovid MEDLINE and PubMed), were used to 
identify related articles using key words from the COMET database articles (268). Papers were 




outcome extraction, grouping and counting from literature reviews, to inform the presence of 
ORH, as well as reporting the development of a COS outcome long-list. The study flow chart is 
illustrated in Figure 6. 
Inclusion criteria: 
• A primary COS development study published between January 1st 2015 and August 20th 
2018. 
• A COS protocol (without an associated final COS published within the above time period). 
• A previously published literature review that was referenced in, informed or directly 
related to a primary COS study published within the above time period.  
There was no restriction on the type of studies in terms of patient characteristics or disease 
area.  
3.3.1.3 Identification of studies 
Full-text articles were retrieved and reviewed to determine eligibility, independently and in 
duplicate by myself and another researcher (AD). Reasons for exclusion were ordered 
hierarchically in order of importance (Figure 6) and applied to each full text. Discrepancies 
were resolved by discussion and consulting with co-authors. Reference lists of full texts were 













Table 10: Filters for the COMET database. 
COMET Filters 
• COS for clinical trials or clinical research 
• COS for practice 
• COS for registry 
• Defining clinical improvement using the core outcome set  
• Overview of literature 
• Recommendations made for systematic reviews  
• Recommended outcome measures (measurement)  
• Systematic review of core outcome sets 
• Systematic review of outcome measures/measurement instruments  











Data extraction and synthesis: 
Two authors extracted data using a form developed and piloted by the author of this thesis. 
Data extracted were: 
1. Type of study: primary COS study, COS protocol, literature review to support a COS. 
2. Methodology for extraction and grouping: whether outcomes were extracted verbatim. 
Methodology for grouping similar outcomes into unique outcomes. 
3. Outcome details: total number of unique outcomes reported (quantitative measure of 
ORH), presence of different wording for the same outcome and impact of timing of 
outcome measurement on numbers of unique outcomes. 
Results were compared between researchers, with any disagreements resolved by a senior COS 
researcher (JMB). Primary COS development studies and their respective literature review(s) 
that directly informed the development of that COS were paired for data extraction, so that 
data was not duplicated. 
Data analysis: 
Numerical data are presented as summary statistics. A narrative synthesis was applied to 
methods for extracting and grouping outcomes from trials and for managing the timing of 
outcome assessment(269-271). Heterogeneity and/or similarity of outcome extraction 
methodology was noted, exploring relationships between studies. 
 
3.3.2 Phase 2: Development of a definition of a unique outcome and 
methodology for grouping verbatim outcomes into unique 
outcomes. 
A summary of the findings from Phase 1 of the study were presented to, and discussed by, a 
single-centre multidisciplinary group of senior researchers experienced in COS research 
(Bristol Centre for Surgical Research https://www.bristol.ac.uk/population-health-
sciences/centres/surgical-research/). A first working definition of a unique trial outcome, and 
methods for conversion of outcomes extracted verbatim into unique outcomes, were 
developed. These were iteratively refined through further discussion and a detailed review of 




ability to define a unique outcome. These definitions are a first attempt to describe a unique 
outcome and to use this to understand ORH. The definitions will be finalised after formal 
collaboration with COS developers and COMET, prior to validation. 
3.4 Results 
3.4.1 Phase 1: Literature review 
The COMET database search yielded 121 titles (seven duplicates removed) for COS studies. 
These 121 articles were identified in OVID Medline and PubMed and full texts were extracted. 
Hand-searching identified a further 111 related literature reviews. This led to a total of 232 
studies (Figure 7). Of these, 100 articles did not reach the inclusion criteria, leaving 132 studies 












Type of study: Of the 132 included studies (listed in Appendix C), 43 (33%) were a final COS, 
80 (61%) were a literature review undertaken to support a COS, and nine (7%) were COS 
protocols with details of a literature review, where the final COS was not yet published. Of the 
final COSs, 30 (70%) paired directly with a previously published literature review, leaving 13 
COS studies that were analysed alone. The results described below are therefore taken from 
102 (132-30) different COS studies. Final numbers of unique outcomes are taken from 93 
studies. The 9 protocols were excluded as they did not report extracted outcome numbers, as 
detailed in Figure 7. 
Outcome Details (Table 11): Thirty-two studies (31%) discussed the issue of the timing of 
outcome assessment. In 17 (53%) these were counted as unique outcomes (e.g. wound 
infection at 30-days was reported as a different outcome to wound infection at 90-days) based 
on time alone, whereas the remainder of studies counted these as just one outcome. Of the 
102 studies (with the nine protocol studies excluded i.e. n=93), 82 (88%) reported a 
quantitative assessment of the number of outcomes reported across the included trials (a 
quantitative assessment of ORH). The total number of unique outcomes reported, varied from 
12 to 5,776 per review (median: 82 IQR: 261). Varying definitions for the same outcome across 
included trials were reported in 53 studies (52%). 
Methodology for extraction and grouping: 18 studies (18%) reported that extraction of 
outcomes was verbatim. Of these 18, 44% (8% of all 102 studies) included some text 












Table 11: Outcome details. 
Note: paired study data were collated. 
Numbers of studies reporting: Number of studies (%) 
Final numbers of unique outcomes reported across trials within 
systematic review (excluding protocols n=9)  
82/93 (88) 
Researchers state that outcomes were extracted verbatim from trials 
within systematic review 
18/102 (18) 
Researchers report different definitions for the same outcome across 
trials within systematic review 
53/102 (52) 
Researchers report the timing of outcome assessment  32/102 (31) 
Researchers report that the timing of assessment impacts on number 
of outcomes reported 
17/32 (53) 
Methodology reported for grouping outcomes into unique outcomes  8/18 (44) 
 
Table 12: Methodology for identifying outcomes as unique. 
COS review title Conversion of verbatim outcomes into unique outcomes (text extracted) 
A systematic review of 
outcomes in 
postoperative pain 
studies in paediatric 
and adolescent patients: 
towards development of 
a core outcome 
set(272).  
“Outcomes were abstracted based on group consensus. We defined an outcome as the exact 
word-for-word terms ….. for any clinical end-point, or physiological, metabolic or mortality 
event measured by clinicians or researchers.” “Final outcomes were then standardised to 
improve the consistency of naming. For example, ‘objective pain score’ was changed to 
‘pain measurement’. After the outcomes had been standardised, we placed them in broader 
domains.” 
Evaluating physical 
activity in dementia: a 
systematic review of 
outcomes to inform the 
development of a core 
outcome set(273).  
“From verbatim outcomes to outcome domains: One author, ….., grouped verbatim 
outcomes with the same semantic meaning, into outcome domains. For instance, the 
verbatim outcomes ‘Functional independence’, ‘Ability to develop basic activities of daily 
living’ and ‘Functional performance’ were grouped into the outcome domain ‘Functional 
abilities and independence’.” 
Outcomes mapping 
study for childhood 
vaccination 
communication: too few 
concepts were 
measured in too many 
ways(274). 
“For each outcome mentioned in an included trial, we extracted into a spreadsheet all 
information defining the outcome, such as type…, outcome variables …, age of the subjects, 
and any other related details. We used the exact words of the trial authors. We did not 
extract data related to the timing and scale or tool used to measure the outcomes, as 
examination of how specific outcome variables were measured was not the subject of the 
research.” “Two researchers reviewed the extracted data. One author coded the individual 
outcomes according to what these measured, using the language of the trialists. These 
codes were discussed and confirmed.” “This first round of codes became the most specific 
level of the taxonomy. We retained a relatively large number of different groups, rather 
than aggregating the information and potentially losing important details.” 






“In the 35 included studies, 95 outcomes were investigated a total of 337 times.” “35 
outcomes were considered to be too similar to at least one other outcome to be 
meaningfully differentiated, and these outcomes were therefore mapped to one common 
term (e.g. continence/ incontinence, or frequency of stool/bowel movement frequency). 
Following this exercise, 74 unique outcomes were identified as having been reported.” 
“Within the included studies, 102 outcomes were investigated a total of 247 times. Within 
these 102 outcomes there were 63 that were felt to be too similar to at least one other 
outcome to be meaningfully differentiated, and these were therefore mapped to one 
common term. Following this mapping process, there remained 62 unique outcomes.” 
No common 
denominator: a review 
“We also did not record outcomes multiple times where these corresponded to repeated 
measurements at several time points.” “For each reported outcome, we extracted the 




of outcome measures in 
IVF RCTs(275). 
the corresponding definition used by the study authors.” “Data were extracted into two 
databases, one containing study-level information and another containing reported-
outcome-level information. Due to the large number of outcomes identified, we reported 
only those appearing in more than one study. We simplified the results by combining 
similar numerators and denominators. For example, we combined live birth with take 
home baby rate, and combined the denominators ‘per patient with sufficient embryos’ and 
‘per patient with sufficient blastocysts’, where ‘sufficiency’ could be defined on the basis of 
quantity or quality of embryos (or both).” “For this primary analysis, we did not distinguish 
between subtly different definitions of outcomes (e.g. clinical pregnancy may have been 
defined as foetal heartbeat on ultrasound at different time points in different studies). 
However, at the suggestion of an anonymous peer reviewer, we also present the definitions 
used by trial authors for pregnancy and live birth outcomes.” 




the treatment of anal 
cancer 
(CORMAC)(228). 
“Verbatim outcomes were initially reviewed by a single researcher and assigned a 
standardized name (‘standardized outcome term’) to overcome variations in wording used 
for the same outcome. The standardized outcome term and domain assigned to each 
verbatim outcome were reviewed and agreed at a meeting of the CORMAC Study Advisory 
Group (SAG). There were 533 unique terms collapsed into 86 ‘standardized outcome 
terms’, representing outcomes with the same meaning but with differing wording, and 
assigned to the appropriate outcome domain.” 
Outcome reporting in 
randomized controlled 
trials and systematic 
reviews of gastroschisis 
treatment: a systematic 
review(276). 
“We anticipated some diversity in terminology used to report outcomes 
and therefore grouped similar outcomes. We identified outcomes that seemed similar or of 
a similar theme despite differing definitions used across studies and assigned an 
appropriate term to them. For instance, the outcomes ‘proven catheter-related sepsis (line 
positive blood cultures necessitating antibiotic treatment or catheter removal)’ and ‘central 
line infections’ were included in the term ‘central venous catheter sepsis’.” 
Developing a core 
outcome set for 
fistulising perianal 
Crohn’s disease(277). 







3.4.2 Phase 2: Agreement on methodology for grouping verbatim 
outcomes into unique outcomes 








Detailed discussions undertaken with a single centre, multidisciplinary, expert panel of senior 
COS researchers explored how a unique outcome should be defined and how this would 
impact the quantitative measure of ORH. After iterative refinement, the following definition 
of a unique outcome was suggested:  
“A unique trial outcome is one that has original meaning and context”.  
Outcomes with different words, phrasing or spelling, addressing the same concept and context 
should be categorised as a single outcome. In other words, researchers should group together 
outcome synonyms into one unique outcome term. By the term original meaning, individual 
clinicians and patients would need to clearly understand what a particular outcome meant 
and how it was different to any other outcome. For example, number of days in hospital has 
the same meaning as hospital length of stay. The term original context should be taken to 
mean that researchers must be clear when defining the context of the outcome. For example, 
post-operative pain and neuropathic pain would be two different outcomes as they are 
different in context.  
The timing of outcome measurement should be clearly stated, but an outcome differing only in 
this aspect is not considered to be unique. Supporting evidence for this is in the fact that 
outcomes measured at different time-points can be pooled in a meta-analysis(278).  
The definition of ORH, relates to the quantitative variation in outcome choice and reporting 
across trials in one healthcare area and is dependent on the ability to define a unique 
outcome. The definition of ORH is proposed as:  
“the reporting of multiple unique outcomes across trials within one healthcare condition”. 
The definitions suggested here are proposals for further discussion and validation. Other types 
of ORH will be explored in Chapters Four and Five. 
3.5 Discussion 
The work in this chapter has explored, through examination of COS literature reviews, what 
makes one outcome different to any other outcome. Of all 102 COS studies included in this 
review, only eight reported any methodological detail about how verbatim outcomes were 




different outcomes were determined, authors of 88% of studies, still reported the final unique 
outcomes as a number i.e. they reported variation in outcome reporting across studies of one 
healthcare area quantitatively.  
3.5.1 Quantitative measure of ORH across trials 
The number of reported outcomes across studies in this review varied from 12 to 5,776 (median: 
82 IQR: 261). It is unclear why there was such a wide variation in the numbers of different 
outcomes extracted between reviews. The answer is likely to lie in the authors’ decisions 
regarding the granularity of outcomes extracted and the use of timing of measurement to 
define unique outcomes. Chong et al. in a systematic review on pediatric chronic kidney 
disease, reported 5,776 different outcomes from 213 studies(279). In one group of outcomes, 
19 relate to glomerular filtration rate and were measured at several time points. Each of these 
was counted as a unique outcome. This resulted in 148, apparently unique, outcomes in this 
one group. Another review used in the development of a COS, on the variability in the 
reporting of renal function endpoints in immunosuppression trials in renal transplantation, 
reported only 345 outcomes in total (compared to 5,776 in the previously quoted review) from 
213 studies(280). This review did not include outcomes measured at different times as unique. 
It is otherwise not possible to clarify this disparity, as neither paper reports how the number of 
unique outcomes were calculated. 
The timing of outcome assessment was reported in just under one third of studies. Of these, 
more than half reported outcomes with different times of assessment as unique. Definitions of 
outcomes with similar meanings varied across 52% of included reviews. For example, different 
definitions of wound healing (as also illustrated in the review in Chapter Two) such as length 
of time to heal to 50% or to 70% healed and time to 90% re-epithelialisation, suggests that 
further grouping of outcomes was necessary and that these outcomes were not unique.  
The lack of methodological detail and significant variation in numbers of outcomes reported 
across studies suggests a non-systematic approach to outcome extraction and counting. This 
approach, therefore, will not allow any true variation in numbers of outcomes reported across 
studies to be accurately assessed (quantitative measure of ORH). The following chapter will 




3.5.2 Defining ORH 
Other authors have previously described, but not defined, the variation in outcome reporting 
or ORH (226, 227, 281). They have, however, demonstrated that it leads to problems in 
evidence synthesis (227, 282, 283). One reason for the existence of ORH, is a lack of clarity 
regarding what constitutes a unique outcome; what makes one outcome different to another. 
Although COSs have been developed to resolve ORH, they require the extraction of outcomes 
verbatim from trials, and the subsequent grouping of the same or similar outcomes into 
individual, unique outcomes. This process requires an understanding of what constitutes a 
unique outcome and which outcomes are so similar they can be combined into one term. It is 
important to agree the level of granularity required in outcome reporting and this may be 
partially responsible for the wide variation in the numbers of unique outcomes reported across 
trials.  
The presence of variability in aspects of COS development, has been noted by the COMET 
Initiative (284-287). Their analyses have identified variations in the scope, stakeholder 
involvement and consensus process (284, 285, 288, 289). COMET has undertaken work to 
provide methodological guidance regarding these aspects of COS development (115, 286-291). 
This is useful, although there is little focus on the early part of COS development. These early 
stages include extraction of comprehensive lists of outcomes and identifying the magnitude of 
ORH. They are undertaken, not only to justify the need for a COS, but to directly feed into the 


















3.5.3 Strengths and limitations 
The strengths of this review are that 132 COS development studies, including 90 systematic 
reviews used to inform COSs, have been critically and systematically analysed. A limitation of 
the study is that a full systematic review was not undertaken, but attention was focussed on 
studies identified through the COMET database, with related articles identified through two 
other search engines, as per the published advice on methodological systematic reviews(289, 
292). To support this approach, Gargon et al. noted the comprehensive nature of the COMET 
database, in that 720 studies relevant to the development of COS had been included in the 
database by the end of December 2015 (286). Moreover, COSs registered on the COMET 
database are likely to be of high quality due to the publication of the COMET standards for 
COS development and reporting (115, 286). The search was extended by including directly 
related studies identified though two search engines and hand searching references. It is 
unlikely that COS development studies reported before 2015 will have described methodology 
for the extraction of unique outcomes, if later studies do not. The work for this chapter, is not 
aimed to be comprehensive in exploring all COS development papers. The focus of the study is 
to demonstrate, that in a recent group of high-quality COS research collected in a pre-
specified manner, no-one has determined objectively and with repeatability, how to extract 
and count unique outcomes to determine a quantitative measure of ORH across papers in one 
healthcare area. 
3.6 Conclusion 
This review has shown that the process of extracting outcomes from trials included in COS 
literature reviews and grouping the verbatim outcomes into a list of outcomes that are 
individual and different (unique) from each other, is complex and poorly reported. Verbatim 
outcome extraction is recommended by COMET, for reasons of transparency(71, 115). “The first 
step is to group these different definitions together (extracting the wording description 
verbatim) under the same outcome name”(115). Issues with this, include determining when 
outcomes are the same, even when they are differently worded; for example, serum albumin 
and albumin levels in plasma. Another issue is how to incorporate the timing of outcome 




percentage wound healed at six weeks. If authors could agree and transparently report how 
they extracted, grouped and counted the outcomes reported, a true quantitative assessment of 
ORH would be possible. A lack of understanding of what constitutes a unique outcome will 
impact on the validity of the reported presence and magnitude of ORH, as demonstrated by 
the widely varying numbers of unique outcomes reported in the COS literature reviews 
included in this study. Furthermore, when outcomes presented in the later stages of COS 
development are not unique, it makes prioritisation difficult and can hinder the consensus 
process. 
 A final agreed definition for a unique outcome, and methods for objectively grouping 
outcomes extracted verbatim into unique outcomes, will provide a methodological basis for 
COS researchers to develop a reproducible long-list and to determine an quantitative measure 
of ORH. The aim of this work is to start formal discussions between international COS 
researchers and COMET for the purpose of raising awareness of this methodological issue and 
to undertake collaborative work to refine and validate a definition for a unique outcome.  
The next two chapters will describe two other versions of ORH. Chapter Four will explore how 
agreeing unique outcomes is further complicated by variations in the definition of any specific 
unique outcome. The chapter will use burn wound infection (BWI) as the unique outcome 
example. A systematic review will explore the variation in the definition of BWI across studies 
assessing burn care interventions and reporting BWI. Chapter Five will explore, through 
another SR, how the management of the timing of outcome assessment also impacts 





Chapter 4 Defining Burn Wound Infection; a 
systematic review 
This chapter is based upon two papers:  
1. Davies A, Teare L, Falder S, Coy K, Dumville JC, Collins D, Moore L, Dheansa B, Jenkins 
AT, Booth S, Agha R et al Young A.E. Protocol for the development of a core indicator set 
for reporting burn wound infection in trials: ICon-B study. BMJ Open. 2019 May 
1;9(5):e026056.  
2. A systematic review of intervention studies demonstrates the need to develop a minimum 
set of indicators to report the presence of burn wound infection. In Press Burns journal. 
As senior author and lead for the national infection consensus in burns (ICon-B) project, I 
conceived the study, developed and defined the term, Core Indicator Set (CIS), for burn 
wound infection. I co-wrote the paper with AD who I supervise. Data production was by AD. I 
double-checked all data and oversaw the final dataset. The other members of the group 
inputted ideas, edited, assessed readability and data sign-off for the project. The papers were 
peer-reviewed. Excerpts from the paper are incorporated into this chapter. 
4.1 Introduction 
This chapter will answer:  
Thesis Objective 3: An analysis of how variation in the definition of a specific outcome 
(burn wound infection) across burn care trials impacts evidence synthesis. 
The work undertaken in Chapter Three, explored what makes one healthcare outcome 
different to another and how it might be possible to define a unique outcome(293). In this 
chapter, I will debate how challenges with the definition of a unique outcome impacts 
evidence synthesis. In this study, the example used is acute (before healing) burn wound 
infection (BWI). If varying definitions of this outcome are used across trials, difficulties will 
arise in collating trial data on interventions to detect and treat BWI (223, 294-296). This has 




acute renal failure(4, 297, 298). Variation in definition of the same outcome across trials is 
another example of outcome reporting heterogeneity (ORH). In Chapter Three, ORH was 
defined as “the reporting of multiple unique outcomes across trials within one healthcare 
condition”. The issue discussed in this chapter is different. The same outcome is reported 
































Studies use varying terms for describing the reporting of outcomes. In this chapter, the 
following terms have been listed here and defined for clarity. In the study, we use these to 
define one specific outcome (BWI), but they could equally apply to any other outcome. 
Unique outcome: this was defined in Chapter Three and a working description proposed:  
“a trial outcome is one that has original meaning and context”. 
Outcome reporting heterogeneity (ORH): this was defined in Chapter Three as: 
“the reporting of multiple unique outcomes across trials within one healthcare 
condition”(293).  
There are three types of ORH: 
• Variation in outcome choice and reporting across trials. 
• Variation in the definition of one unique outcome across trials.  
• Variation in the timing of outcome assessment within and between trials.  
Outcome measurement tool: An outcome measurement tool refers to how an outcome is 
assessed. It is the magnitude of the quality or quantity of an outcome. The tool can be a single 
question (pain score tool) or series of questions (quality of life tool), a score obtained through 
physical examination (scar assessment tool) or a laboratory measurement (C-reactive protein) 
for example(299-302). (https://www.cosmin.nl/tools/guideline-selecting-proms-cos/). 
The difference between a unique outcome and an outcome measure is explained by 
COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN; 
https://www.cosmin.nl/): “When selecting an outcome measurement instrument for research 
or clinical practice, first the outcome to be measured should be clearly defined. That is, one 
should define what to measure” (303). There are, in some instances, multiple definitions for an 
outcome, such as disability. The World Health Organization (WHO) defines disability as: 
“problems an individual may experience in functioning, namely impairments, activity 
limitations and participation restrictions”(304). The 2010 Equality Act defines disability as: “a 
physical or mental impairment that has a ‘substantial’ and ‘long-term’ negative effect on your 




equality-act-2010). Variation in the definitions for one unique outcome across trials is another 
version of ORH and impacts evidence synthesis. 
Clinical indicator: The definition of an outcome may require the reporting of a collection of 
clinical indicators. We have defined a clinical indicator, in the absence of any other descriptor, 
as one of the following: 
• A wound-related indicator (presence of pus). 
• A clinical observer reported sign (pyrexia). 
• A patient-reported symptom (increased local pain). 
• A laboratory test (white blood cell count or presence of bacteria in the wound). These are 
non-specific and report inflammation rather than clinical infection. 
• Wound microscopy to assess bacterial colonisation; the quantity and type of microbes in 
the wound.  
A minimum set of these indicators is required by health care professionals (HCPs), to diagnose 
and report BWI consistently across trials.  
Clinical consensus diagnostic tools: can be defined as a collection of indicators used to define 
the outcome, used as one criterion. Consensus on a small number of diagnostic tools for BWI 
has been achieved, but most are considered impractical in everyday clinical care(305).  
Composite measure: can be defined as the measurement of an unobservable variable or 
construct by means of aggregating scores on several observable variables into an overall score. 
This is different to the diagnostic tool, as it uses a score(306, 307). 
4.2 Background 
Infection is a common complication after burn injury. The loss of the protective epidermis 
which is a natural barrier to bacterial invasion, allows a direct entry route of bacteria into the 
wound. Burn wounds produce exudate (a liquid produced in response to tissue injury), which 
creates a moist, nutrient-rich environment for bacterial growth(308, 309). BWI results in pain, 
delayed healing, an associated increase in scar presence and quality, a risk of sepsis if 
untreated, and increased healthcare costs related to increased lengths of hospital stay and 
interventions (308, 310-312). Data from France indicates that 19% of inpatients with burns will 




burns(314). In those with burns of more than 40% of the total body surface area, it is 
estimated that 75% of mortality is related to infectious causes(305, 315).  
It is important to identify the effects of interventions to detect and treat BWI to prevent the 
increased morbidity and mortality in burn patients. This requires evidence from systematic 
reviews which summarise well-designed and conducted RCTs. One challenge with evidence 
synthesis is a variation in the definition of the same outcome across trials (Figure 1)(230, 316, 
317). If definitions of an outcome vary between studies, or are not stated, the validity of the 
aggregated data may be compromised(4, 318). There will be an associated risk of over or 
underestimating the true treatment effects. In the systematic review in Chapter Two, 166 ways 
of defining burn wound healing were reported across 147 studies. It is unclear if a similar 
heterogeneity in the definition of BWI exists across burn care research. 
One reason for hypothesising that a variation in the clinical indicators used to define BWI may 
exist across studies, is that there is no agreed objective method for the clinical diagnosis of 
BWI. Early accurate diagnosis is difficult, as this is based on clinician judgement, supported by 
data from non-specific clinical indicators (12, 14, 312, 319). There is no reference 
standard(320). The clinical indicators used, include those described in the nomenclature 
section above, including patient- and clinical-observer reported symptoms and signs, non-
specific laboratory tests for inflammation and wound microscopy. 
Quantitative bacterial counts from swab cultures are acknowledged as providing only 
supportive information, as wounds will be colonised with bacteria within 24-48 hours of 
injury(319, 321). This does not imply that there is clinical wound infection requiring treatment. 
Clinically important BWI requires critical colonisation of the bacterial bioburden or virulence. 
This is known as the tipping point of toxin release at which low-level colonisation progresses to 
invasive infection requiring urgent treatment(322). Acute wound infection has also been 
defined as the presence of a wound environment with microbes in sufficiently large numbers, 
or of sufficient virulence to provoke an immune response locally, systemically or both(323). 
Diagnosis of this state, is further complicated by the fact that many of the signs used in the 
diagnosis of BWI, such as pyrexia and tachycardia, are non-specific and may exist or co-exist 
as part of the normal systemic inflammatory response to a burn(305). Clinicians currently do 
not have access to a point of care tool to diagnose BWI(324, 325).  
To support a consistent diagnosis of BWI, clinical consensus diagnostic tools have been 




(CDC(326)). These are formal collections of indicators used for the diagnosis of BWI. There 
are, however, accepted practical limitations that preclude the routine use of these in clinical 
care. For example, the ABA and CDC criteria require the use of a wound biopsy. Evidence for 
the use of wound biopsy in burn care in the diagnosis of BWI is inconsistent and not 
commonly undertaken in Europe and low-income countries(319).  
These inherent difficulties with the diagnosis of BWI are likely to lead to the use of varying 
definitions to report BWI across trials in burn care. This issue is supported by three recent 
systematic reviews of the effect of antibiotic prophylaxis to prevent BWI and treatment for 
facial burns. These reviews found variation in the indicators used to define BWI across 
trials(220, 238, 239). In the Cochrane review of 36 RCTs evaluating the effectiveness of 
antibiotic prophylaxis in burn patients, 15 studies did not describe BWI diagnostic indicators, 
14 studies diagnosed BWI using swab culture or biopsy with or without clinical signs, four 
studies used wound signs or clinical observation, two studies used systemic signs and one 
study used chondritis to diagnose BWI(238). In the Cochrane review assessing topical therapy 
for facial burns, of three studies reporting BWI, three different indicators were used for 
diagnosis(239). One study used swab cultures, the second study used qualitative assessment of 
exudate and cellulitis, and the third study used the presence of chondritis. If the reporting of 
BWI is based on varying diagnostic indicators across trials, or if the diagnostic indicators used 
are not reported, the validity of a systematic review and the collation of evidence across trials, 
will be more challenging. Subjective decisions would need to be made regarding the similarity 
of definitions for BWI. For example, is redness around the wound the same as spreading 
erythema? Judgement will be required as to whether the outcome definitions are comparable 
enough across studies for the data to be brought together in a meta-analysis. The Cochrane 
Handbook states: “if there are differences between studies in the way the outcomes are 
defined and measured, this may be expected to lead to differences in the observed 
intervention effects”(327). 
The aim of this study is to assess the consistency of definitions for acute (defined here, as 
before healing) BWI across studies of interventions in burn care. This is undertaken through a 






Methods for this review were pre-specified through publication, and the protocol registered 
on the PROSPERO database: REF CRD4201809664(328). It is reported in accordance with the 
PRISMA statement for systematic reviews(329). 
4.3.1 Study identification and selection 
4.3.1.1  Inclusion and exclusion criteria 
Peer reviewed journal articles published between 1st January 2010 and 30th November 2016, in 
English, and meeting the following Population, Intervention, Control, Outcome, Study design 
(PICOS) criteria were identified: 
1. Participants: studies reporting data from patients with acute burn wounds (acute 
defined here as: before healing). Studies with mixed populations, where patients had 
both burn and other traumatic injuries, were excluded, unless data relating to patients 
with burns were presented separately.  
2. Intervention and control groups: Studies reporting any intervention (surgical, non-
surgical, psychological, homeopathic etc.) to treat patients of any age with burn injury 
and any comparator intervention or standard care were included.  
3. Outcomes of interest: Studies reporting BWI as an outcome in the abstract, methods, 
results or discussion sections were included. We accepted any study where the authors 
used the terms burn wound infection or wound infection, in patients with burns. 
4. Study design: Studies were included if they employed an RCT, controlled trial, 
observational study design, case control study or reported a protocol for a trial or 
observational study. (Note: observational studies were defined as a single group 
observed over time with impact of intervention observed; non-randomised studies 
were defined as a trial in which people are allocated to different interventions using 




4.3.1.2 Electronic search 
An electronic search of four databases was undertaken to identify relevant studies: Cinahl, 
Ovid Embase, Ovid MEDLINE and the Cochrane Register of Controlled Trials (CENTRAL). To 
identify studies that met the inclusion criteria, three groups of search terms were iteratively 
developed relating to burns, wound infection, interventions and trials. Medical Subject 
Headings (MeSH) were used where available. Synonyms for each term were combined using 
an OR term, and the groups of terms were combined using an AND term. Following piloting of 
the search strategy in two databases (Ovid Embase and Ovid MEDLINE), NOT terms were 
added to increase the specificity of the search, thus removing studies irrelevant to the topic 
(e.g. NOT Coxiella Burnetii, burnout). The search string used in MEDLINE is presented in 
Table 14. This was modified for each database. The search terms were applied to the title, 


















Table 13: Exclusion criteria for study selection. 
1. Duplicate 
2. Full text not available 
3. Not a full text 
4. Not about acute burn injuries 
5. Not written in English  
6. Not reporting BWI as an outcome 
7. Non-human participants (e.g. animal studies)  
8. Trial is not a clinical study (i.e. laboratory testing) 
9. Trial investigates bacterial surveillance or would colonisation only  
 
 
Table 14: Search strategy terms in Ovid MEDLINE. 
 
1. exp Burns/ 
2. burn*.tw 
3. Scald*.tw 
4. thermal injur*.tw 
5. exp wound infection/ 
6. wound infection*.tw 
7. infect*.tw 
8. bacteria*.tw 
9. exp clinical trial*.tw 






16. 1 or 2 or 3 or 4 
17. coxiella burnetii/ 
18. burnetii*.tw 
19. 17 or 18 
20. 16 not 19 









Selection of papers for inclusion: Search results were downloaded from each database and 
combined in an EndNote database (Clarivate Analytics version 8), where records were 
manually reviewed to remove duplicates. Citations were exported to a Microsoft Excel 
database for screening. Titles and abstracts were reviewed against the exclusion criteria. Full 
text articles of retained citations were obtained and screened using the same criteria. Twenty 
percent of all citations were double-checked by the author of this thesis (see the Disclosure 
Statement for this study). Discrepancies in agreement throughout, were resolved between the 
two researchers and, if necessary, a third senior reviewer. 
4.3.1.3 Data extraction 
A proforma to standardise data extraction was developed in Microsoft Excel by myself and 
piloted for comprehensiveness and clarity. Where the same dataset was reported across two or 
more studies, extracted data about the studies were combined as a single dataset. Data 
extraction from 20% of papers was checked by the author of this thesis.  
Extracted data to describe each study were:  
1. Study identifiers (title, authors, date and citation). 
2. Study design.  
3. Intervention/s evaluated.  
Extracted data to describe BWI reporting were: 
1. Whether a study reported that they planned to assess BWI as an outcome. 
2. Whether the study reported clinical indicators or a clinical consensus diagnostic tool 
for reporting BWI. Where studies reported use of clinical consensus diagnostic tools 
(e.g. the ABA(305) or CDC(326) consensus statements), the indicators used in the tool 
were not reported as separate indicators.  
3. A report of each clinical indicator used to define BWI was extracted verbatim. Each 
indicator was categorised under a label to allow summary and comparison of data (see 
below). The number of indicators used to define BWI were noted for each study.  
4. Whether there was consistency in the use of clinical indicators used to define BWI 
across included studies.  




6. Whether a method for combining data from several indicators to determine presence 
of BWI was specified (e.g. a count of the number of indicators present or a weighted 
scoring system). 
Grouping of clinical indicators with similar meanings: If the terminology used to describe the 
same indicator varied across studies, a process was undertaken by two reviewers (the author of 
this thesis and AD) to group indicators with the same meaning, under a consistent label. This 
was a similar technique to that for collating similar outcomes into domains in COS 
development studies. It was undertaken to enable an accurate count of different indicators 
used and to prevent double-counting. As an example, indicators included wound microscopy 
from swab, bacteria in wound identified using swab, swab of wound pus. These indicators have 
the same meaning and were assigned the same label.  
A small number of studies reported defining BWI with a clinical indicator that represented a 
group of signs or symptoms, for example clinical signs, cellulitis. These indicators were 
labelled using their verbatim terminology. While it is acknowledged that these indicators 
represent a group of signs and symptoms, since it is not known what signs and symptoms the 
authors referred to, they were counted as a single indicator.  
4.3.1.4 Data synthesis 
No risk of bias assessment of studies or meta-analysis of outcome data was conducted, since 
this review aimed to report the indicators used to assess presence of BWI across studies and 




4.4.1 Results of electronic search 
The electronic search identified 4,314 records, of which 2,056 were duplicates. Data from two 
related studies were combined into one dataset(330, 331). Following the two screening stages, 















4.4.2 Characteristics of included studies 
Data extracted on the included studies demonstrated the detail in Table 15. 
 
Table 15: Characteristics of included studies. 
Design of studies n=71 (%) 
RCT 37 (52) 
Controlled trial (without randomisation) 12 (17) 
Observational study 21 (30) 
Case control  1 (1) 
  
Interventions tested   
Antimicrobials/ Antifungals 3 (4) 
Dressings; comparisons of dressings versus topicals 17 (24) 
Enteral nutrition 
Faecal containment 
Grafting/ Skin flaps 















Other (1 each): Glutamine supplementation, hyperbaric oxygen, maggots, olive oil, phage 
therapy, pressure garments, probiotics, silk dressing, VersajetTM, biocide impregnated gauze, 













4.4.3 Extracted data on the reporting of BW 
1. Whether a study reported that they planned to assess BWI as an outcome: 
Fifty-nine studies (83%) described that BWI would be assessed as a study outcome in the 
methods. The remaining 12 studies (17%) did not report that they planned to assess this 
outcome in their methods (no methodological definition of BWI), despite reporting it in the 
results(332-343). 
2. Whether the study reported a clinical consensus diagnostic tool or individual indicators 
for diagnosis of BWI: 
Forty-four of the 59 (75%) studies that stated that they planned to assess BWI as a study 
outcome, provided a definition of BWI in the study methods or results. Fifteen of these studies 
(25%) stated that BWI would be assessed, but did not describe the clinical indicators used to 
define the outcome(344-358).  
Six studies (14%) reported that they had defined BWI using a clinical consensus diagnostic 
tool (359-364). Four studies used the ABA consensus statement(359, 362-364). Two studies 
reported that they had used criteria developed by Peck and colleagues(361, 365). One study 
combined Peck and colleagues’ criteria with criteria developed by Silla and colleagues(366). 
Three of the studies using a clinical consensus diagnostic tool, also reported the use of 
additional specific indicators(361, 362, 364). Therefore, of the 59 studies that stated that they 
planned to assess BWI, 41 (70%) defined it using one or more indicators of BWI. 
3. Numbers of indicators used to define BWI: 
The number of indicators used to define BWI within studies, ranged between one (27% of 









































The indicators used to define BWI in the 41 studies (70% of the total studies), that reported 
the use of one or more clinical indicators, are presented in Table 16. Twenty-seven different 
indicators were used to define BWI across all included studies.  
The most frequently reported clinical indicators used to define BWI, were presence of bacteria 
in the wound identified from swab of pus or exudate (n=25 studies, 61%), change in colour or 
volume of exudate (n=25 studies, 49%), spreading erythema (n=16 studies, 3%), wound 
oedema (n=10 studies, 24%), pyrexia and pain (n=9 studies, 22%).  
Eleven of 41 studies (27%) that reported indicators of BWI, reported the use of only one 
indicator (330, 364, 367-375). Of these, six (55%) used wound biopsy or tissue culture(362, 
364, 370, 371, 373, 376) and four (36%) used bacteria in the wound identified from swab of pus 
or exudate (330, 372, 374, 375). The remaining study, describing the use of a single indicator 
to define BWI, defined the indicator as cellulitis(369). As noted above, this represents a 
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Aramwit(380) 6 
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✓ 
Chahed(382)  9 














     
Chong(383) 2 




     
Finnerty(370) 1 
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✓ 
        
Genuino(385) 5 ✓ 
  
✓ 




   
✓ 





   
✓ 
              
✓ 
        
Hubik(387) 2 
   
✓ 
              
✓ 
        
Hyland(388) 3 
   
✓ 
              
✓ 
       
✓ 
Jeschke(364) 1 
                   
✓ 
       
Jeschke(363) 1 
                   
✓ 
       
Kahn(369) 1 
                          
✓ 
Kahn(389) 2 
                  
✓ 
       
✓ 
Kement(371) 1 
                   
✓ 
       
Khorasani(390) 3 












      
Lau(372) 1 
                  
✓ 
        
Lu(373) 1 
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Malik(374) 1 
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Mayes(391) 2 
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Nagoba(392)  9 
  
✓ ✓ ✓ 








    
Nasiri(393) 7 ✓ 
 
✓ ✓ 




    
✓ 
          
Park(361) 5 ✓ 








     
Rashaan(394) 7 ✓ 
 
✓ ✓ 








        
Rose(395) 3 
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Schiefer(396) 5 ✓ 
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Shahzad(266) 6 ✓ ✓ 
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Verbelen(249) 8 ✓ ✓ 
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Weissman(399) 3 
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✓ ✓ 
               
Yan(400) 3 
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✓ 
        
Yang(401) 3 ✓ 
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✓ 
        
Yuan(402) 3 
   
✓ 
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4. Whether there was consistency in the use of indicators to report BWI across studies.  
Thirteen studies (32%) reported BWI in the same way as at least one other study. Six of the 11 
studies (55%) that defined BWI with a single indicator, used bacterial presence (362, 364, 370, 
371, 373, 376). Of the nine studies using two indicators to define BWI, two (22%) used the 
same indicators: presence of bacteria in the wound from swabs, and a change in colour or the 
quantity of exudate(386, 387). Administration of antibiotics was used to define presence of 
BWI in two studies (4.9%)[58, 59]. 
 
5. Whether numerical values were reported for indicators to diagnose BWI. 
Of the 25 studies using presence of bacteria from wound swabs to define BWI, six (24%) 
described the numerical values used (more than 105 microbes per gram of tissue)(249, 361, 375, 
392, 401, 403). For tissue cultures, five of eight studies (63%) reported numerical values (more 
than 105 colony forming units per gram of tissue)(362, 364, 370, 376). The remaining studies 
did not report what numerical values were used for the presence of bacteria in the wound. 
One of the nine studies (11%) using pyrexia as a clinical indicator, reported the numerical 
values used to determine fever and high fever (>37.4°c and >38°c respectively)(380).  
 
6. Whether a method for combining data from several indicators to determine presence of 
BWI was specified (e.g. a count of the number of indicators present or a weighted scoring 
system).  
Seven of the 41 studies defining BWI (17%) used indicators that represented a group of signs 
and symptoms. Cellulitis was used as an indicator to define BWI in five studies(369, 381, 388, 
389, 404) (12.2%), and clinical signs and biological markers in one study (2.4% 
respectively)(405). Thirty-one studies (76%) used more than one indicator to define BWI. Of 
these, 10 (32.3%) reported a method for rating or combining data from the multiple indicators 
used to determine whether BWI was present. In four of these 10 studies (40%), BWI was 





The systematic review described in this chapter, was undertaken to identify whether BWI is 
defined consistently across studies assessing the effect of interventions in burn care and 
reporting BWI as an outcome. Across all included studies, 12 (17%) did not report that they 
planned to assess BWI in their methods, despite reporting data on BWI in the results. Of all 
the studies, 59 (83%) did describe planning to assess BWI as an outcome in the study 
methods. Of these, 15 (21% of all studies) did not state how they defined BWI. Of those studies 
that did describe the clinical indicators used to define BWI, 27 different indicators were used 
across the studies (range 1-9, median=3). Only 13 of 41 studies (32%) reporting the indicators 
that they used to define BWI, used the same indicators as at least one other study. Six studies 
(13.6%) reported that they had defined BWI using a clinical consensus diagnostic tool. 
There are three key findings from this review.  
1. BWI is commonly not defined in studies reporting it as an outcome. 
2. There is considerable heterogeneity in which clinical indicators are used for BWI when 
it is defined across studies. Several studies also used non-specific terms, including 
cellulitis, wound signs, and biological markers.  
3. The use of consensus tools is uncommon, possibly due to practical issues with their 
design. 
This lack of consistency in the definition of BWI, weakens the case for collation of data 
describing intervention effectiveness(407). If data from studies with varying outcome 
definitions are synthesised, the findings may not represent the truth about the magnitude of 
the effect of the intervention. The lack of specificity in the definitions of BWI, and other 
unique outcomes across studies, replicates the findings of other systematic review work in 
burn care. These findings include definitions of sepsis, scarring and wound healing (4, 408-
410). The impact of this problem has been highlighted in recent Cochrane Reviews for patients 
with burns. The authors reported that the validity of their findings was compromised, due to a 




• The use of antibiotic prophylaxis (“Outcome measures and follow-up times were 
heterogeneous, or not even defined, which made it difficult to interpret the results of the 
review and to determine their applicability”)(238). 
• Facial burn treatment (“Heterogeneity of interventions and outcomes prevented pooling of 
data”)(239). 
• Immuno-nutrition (“….. some of the outcome measures used are subject to a high degree 
of variability (e.g. time to healing).”)(241).  
A variation in the definition of one specific outcome has been found in systematic reviews of 
other health areas such as surgical site infections(223) and healthcare-associated 
infections(411). 
A further funding from this review is an over-reliance on the use of one specific indicator, with 
little clinical justification for its use. Six of the 11 studies used a single indicator to define BWI, 
the presence of bacteria in the wound. Recent studies investigating the reliability of the use of 
bacterial presence in wound swabs and tissue sampling as an indicator of BWI, reported 
difficulties(319, 321, 412, 413). More than one sample of the wound may be needed to obtain an 
accurate estimate of bacterial load, as correlation between swabs and biopsies is frequently 
poor and biopsies are invasive and costly. A further literature review supports the view that 
quantitative microbiology should not be used without reference to clinical signs and 
symptoms. It is suggestive that the 105 colony forming units/gram of tissue cut-off is arbitrary, 
since clinically relevant infection is more likely to be found at higher bacterial 
concentrations(319, 414). These data suggest that quantitative microbiology alone, may be an 
unreliable indicator of BWI and may overstate the incidence of BWI, since bacteria are 
frequently present in burn wounds without being clinically relevant (wound colonisation).  
Using a formal collection of more than one indicator has been attempted when reporting BWI. 
Clinical consensus diagnostic tools have been developed to standardise BWI reporting. 
However, only six of the 71 studies (9%) reported their use. This may relate to a lack of 
evidence for the individual parts of the tools and practical limitations of these tools in clinical 




scarring, and is infrequently used in some health care systems such as the UK NHS, as 
described above.  
A better solution would be a composite measure or scale to answer the yes/no question to the 
presence of wound infection. A composite measure has been defined as: “a variable, made up 
of two or more variables or measures, that are highly related to one another conceptually or 
statistically” (415). Another definition by Barclay et al. is: “measurement of an unobservable 
variable or construct by means of aggregating scores on several observable variables into an 
overall score”(416). Examples include the Hull reflex cough questionnaire and GHQ depression 
scale(417, 418). Ultimately, a composite measure would solve the problem of varying 
definitions of BWI using different clinical indicators. There is, however, currently not enough 
evidence to develop such a measure. Data is needed to provide an explanation of the reasons 
underlying the development of each indicator in the composite measure, including the choice 
of measure, different aims of the individual measures and the relationship between included 
clinical indicators.  
As we do not have enough evidence to produce a composite measure for BWI, the aim of this 
study was to identify the variation in reporting of clinical indicators for BWI across trials. The 
review has demonstrated the need for standardisation of reporting of this outcome. The use of 
a small number of the most important clinical indicators for reporting of BWI would achieve 
this; a Core Indicator Set (CIS).  
4.5.1 Strengths and limitations 
This literature review employed a systematic approach to the identification and selection of 
studies reporting BWI as an outcome. The use of four databases to identify RCTs, 
observational studies, case control studies and protocols, provided a comprehensive review of 
how BWI has been defined across studies. Other strengths included the double-checking of all 
screening and inclusion of studies and of data extracted. Limitations include the exclusion of 
studies published before 2010. This limit was placed to ensure that we identified reports 




excluded due to funding constraints. While unpublished literature was requested from 
interested parties, no additional studies or work in progress reports were put forward.  
Clinical decision-making about effective treatments for BWI requires that evidence is 
synthesised across relevant studies. Inconsistent definitions of BWI, a form of outcome 
reporting heterogeneity, creates noise in the data which may obscure the true effect of 
interventions and interventions that are effective may not be identified. There is a need to 
improve the consistency of how BWI is defined, and for this to be reported in the study 
methods and results. However, identification of a consistent definition is difficult as there is 
no objective diagnostic method for determining the presence of clinically relevant BWI. Until 
this is available, a minimum set of the most important indicators of BWI, a CIS, needs to be 
agreed and reported consistently.  
4.6 CONCLUSIONS 
This systematic review has shown that 38% of included studies did not report how BWI was 
defined, that there is considerable heterogeneity in the indicators reported to define BWI 
when it is reported, and limited use of existing clinical consensus diagnostic tools. The lack of 
an agreed definition and heterogeneity of clinical indicators used when BWI is defined, will 
limit the validity of evidence syntheses, preventing the identification of the most effective 
treatments for patients with burns. Until there is an objective method to diagnose clinically 
relevant BWI, development of a CIS is needed, to standardise reporting in trials reporting a 
BWI outcome. 
This chapter has described the second type of outcome reporting heterogeneity (ORH) 
presented in this thesis. In this example, one unique outcome (BWI), has been shown to be 
defined differently across trials. The following chapter will describe a third type of ORH. This 
is a variation in the timing of assessment of one unique outcome within and between trials. 





Chapter 5 Outcome definition: the effects of 
timing of outcome assessment 
This chapter is based upon a submitted article:  
Amber E. Young, Fatima Yaqub, Chris Metcalfe, Sarvnaz Sepehripour, Jane M Blazeby. Clinical 
trials in burns care primarily focus on short-term outcomes of uncertain longer-term patient 
benefit: a systematic review. 
I conceived the idea for the project. I co-wrote the paper, led on data extraction and analysis, 
with the support of co-authors Ms. Yaqub and Ms. Sepehripour. Professors’ Metcalfe and 
Blazeby inputted ideas, edited and assessed readability for the paper. The paper has not yet 
been peer-reviewed. It was returned from the Journal of Clinical Epidemiology prior to peer 
review, with the advice to submit the paper to a specialist burn injury journal.  
Excerpts from the paper are incorporated into this chapter. 
5.1 Introduction 
This chapter will answer:  
Thesis Objective 4: An analysis of how variation in the timing of the assessment of 
unique outcomes across trials, impacts relevance to patients. 
In Chapter Three, I discussed the concept of a unique outcome, as one requiring differences 
and originality in outcome meaning and context(293). In Chapter Four, the focus was on the 
impact of a variation in the definition of one unique outcome across trials. In this chapter, 
another aspect of outcome variation across trials will be explored; a variation in the timepoint 
of outcome assessment. In Chapter Two, the impact of timing of outcome assessment on the 




impact of variation in the timing of outcome assessment on trial relevance. Any field, 
including healthcare, should be measured from the customer’s perspective. It is now 
considered important in healthcare, that care should be assessed using patient-important 
outcomes(420-425). Porter et al. wrote about the Outcome Measures Hierarchy(426). He 
stated that: “outcomes should involve the health circumstances most relevant to patients”. 
Linking outcome timing and relevance, he reported that “the set of outcomes should cover 
both near-term and longer-term patient health, addressing a period long enough to 
encompass the ultimate results of care”. For chronic conditions, therefore, outcomes should 
be measured for periods long enough to reveal the sustainability of health, the incidence of 
complications and the need for additional care. In terms of patient-importance, these 
outcomes are likely to include quality of life, postoperative complications, and survival, among 
others(110). Despite the acceptance that patient-important outcomes should be prioritised, 
this is commonly not the case in healthcare research(148, 149, 427).  
The timing of assessment of reported outcomes, impacts evidence synthesis in terms of 
outcome reporting heterogeneity (as defined in Chapter Three), and in terms of relevance to 
patients.  
5.2 Background 
Well designed and conducted randomised controlled trials (RCTs) determine intervention 
effectiveness through an un-biased comparison of outcomes (428). To optimise the value of 
trial data, high quality outcome reporting is required. In terms of the timing of outcome 
assessment, the CONsolidated Standards of Reporting Trials (CONSORT) statement 
highlights the importance of reporting the timepoints of outcome assessment(429). It states 
that “when outcomes are assessed at several time points after randomisation, authors should 
indicate the pre-specified time point(s) of primary interest”. Selection of the time point of 
primary interest needs to reflect the research question(430), length of trial follow-up (and 
associated costs)(431, 432) and importance to patients(433). Patients often value longer-term 
outcomes (e.g. function, cosmesis, survival), more than short-term events (e.g. length of 




economic reasons, RCTs frequently focus on relatively short recruitment and follow-up 
periods(106, 151, 248, 431). The relationship between the reporting of short- and long-term 
outcomes, is therefore important (438-441).  
In burn care research, recent RCTs and systematic reviews, show that outcomes measured in 
the short-term include operative blood loss, ventilator days, wound infection, wound healing 
and length of hospital stay(4, 442-446). Although important at the time of treatment, it is 
unknown whether these short-term outcomes are important to patients. Patient-important 
outcomes can be defined as: “a characteristic or variable that reflects how a patient feels, 
functions or survives”, such as quality of life or physical function(150, 437, 447). Burn injuries 
are chronic conditions, with patients injured as children, managing disability for the rest of 
their lives, including neuropathic pain and itch, functional, cosmetic and psychological 
issues(448, 449). Despite this, there is evidence that effects of interventions are increasingly 
being assessed using short-term outcomes, sometimes making the assumption that these will 
reflect longer-term outcomes that are more important to patients (4, 30, 151, 450, 451).  
If the short-term outcomes reported in trials are reliable markers of longer-term outcomes, 
and are effected in the same manner by an intervention as a longer-term outcome outcome, 
then they could be legitimately used as surrogate endpoints (109, 452-456). A surrogate 
outcome is an outcome measured in the short-term (such as a laboratory measurement or 
physical sign) that does not measure the effect of primary interest, but is expected to reliably 
predict this (457). Surrogate outcomes need to be validated to test whether they are true 
proxies of the associated longer-term outcomes(438, 458, 459). A valid surrogate outcome has 
to have a strong association with the real outcome of interest (158, 460). It is known that 
short-term outcomes are increasingly being used as surrogates without evidence reliably 
linking them to longer-term patient-important outcomes (124, 137, 461). It is also known, that 
short-term outcomes used in trials in other clinical areas, frequently do not predict important 
longer-term outcomes, and neither do they translate well onto important longer-term 
outcomes (e.g. tumour response and survival, glycated haemoglobin HbA1c and co-morbidity 




The aim of this chapter is to explore the timing of outcome assessment in RCTs assessing 
interventions in burn care. It will debate whether authors that report short-term outcomes, 
are implicitly, or explicitly, using these as surrogates of longer-term patient-important 
outcomes. 
5.3 Methods 
Methods for this review were specified in advance and the protocol registered on the 
PROSPERO database: reference CRD42019150513. The review adheres to the PRISMA 
statement for reporting systematic reviews [37]. This review updates the review presented in 
Chapter Two to provide a more recent assessment of the timing of outcomes in burn RCTs. 
 
5.3.1 Study Eligibility 
Studies were included using the following Patient, Intervention, Comparison, Outcome, 
Setting (PICOS) characteristics:  
Type of study: Full text RCTs, RCT protocols and RCT pilot studies were included. Protocols 
and pilot studies were deemed relevant, as this review is focused on the outcomes themselves, 
rather than the results of intervention effects. Pilot studies were excluded, if the full RCT was 
published within the time period specified in this review. Feasibility studies without an 
external pilot RCT, were excluded, as they generally report outcomes relating to the 
practicalities of a full RCT such as screening issues, recruitment etc. Conference proceedings, 
abstracts, non-English language publications and studies not involving humans were also 
excluded.  
Participants: Study participants consisted of patients of any age, with cutaneous burns of any 
aetiology or size requiring treatment in a healthcare facility. If a study population contained 
patients with combined thermal and mechanical injuries, the study was only included if 




patients with carbon monoxide poisoning alone, chemical ocular or caustic oesophageal burns 
were excluded, as they did not involve cutaneous burns and would be managed differently, 
with different outcomes reported.  
Intervention: Trials were included if they reported surgical or non-surgical burn care 
interventions with any comparator. 
Outcomes: All outcomes reported by clinical observers and/or patients were included. These 
included physiological, cosmetic, psychological, functional, metabolic or histological findings, 
adverse or mortality events and quality of life or long-term indicators of patient well-being. 
Financial outcomes were excluded. No distinction was made between primary and secondary 
outcomes in terms of data extraction. The timing of the last assessment of each outcome was 
assessed. 
 
5.3.2 Identification of studies 
Ovid MEDLINE, Ovid EMBASE, Web of Science and The Cochrane Library were searched 
electronically, for a time period commencing 1 January 2017 to 22 March 2019 for RCTs 
relating to burn care. Medical subject heading and free text terms included burn, scald, 
thermal injury and RCT. The search terms were adapted by the thesaurus vocabulary of each 
database. Details of exact terms and the search strategy can be found in Table 17. The time 
period was restricted to include outcomes relevant to recent burns trials, and to evaluate the 
degree of heterogeneity or consistency in outcome timing within a two-year timeframe, whilst 










Table 17: Search strategy for Ovid MEDLINE. 
Ovid MEDLINE search strategy 
1. Burns/ (MESH) exp  
2. Burn*.tw 
3. Scald*.tw 
4. Thermal* adj injur* 
5. 1 OR 2 OR 3 OR 4 
6. Heartburn 
7. Burnout 
8. Burn* adj out 
9. Burning 
10. Burnetii 
11. Burnish*  
12. Burnet* 
13. 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 
14. 5 NOT 13 















5.3.3 Study selection process 
Reference management with Endnote (Clarivate Analytics version 8) was used for compilation 
of titles based on initial searches. Duplicates were removed and abstracts were screened 
against predetermined eligibility criteria (Figure 13). Full text articles were retrieved for all 
abstracts appearing to meet inclusion criteria. The full texts were read in their entirety 
independently by the author of this thesis and another reviewer (AD), and assessed for 
eligibility. This resulted in final decisions for inclusion or exclusion, with decisions recorded. 
Disagreements were resolved by discussion. Reasons for exclusion were ordered hierarchically 
from most to least important (Figure 13). The most important reason for exclusion met by a 
paper was recorded as the reason for exclusion.  
 
5.3.4 Quality assessment 
Quality assessment of RCTs was not undertaken, as it was not relevant to the data extracted.  
 
5.3.5 Data extraction and analysis  
A Microsoft Excel data extraction form developed specifically for this review was refined 
iteratively and piloted prior to formal data extraction. Data were independently extracted by 
the author of this thesis and another reviewer (AD). Judgements were compared. Any areas of 
discrepancy, were resolved by discussion amongst the two reviewers.  
5.3.5.1 Study data extracted 
Study design: RCT, pilot RCT or RCT protocol. 
Study details:  




• Participant numbers.  
• Recruiting country. 
• Number of recruiting sites. 
5.3.5.2 Outcome data extracted 
Outcome detail: for each study, all reported unique primary and secondary outcomes were 
extracted verbatim from the trials’ abstracts, methods, results, tables or figures as discussed in 
Chapter Three(464). In terms of recording the timing of assessment, no distinction was made 
between primary and secondary outcomes, or if the outcomes were clinical observer or 
patient-reported. All outcomes were treated equally. The timings of assessment were 
categorised as below. 
Timing of assessment for each individual outcome across studies: for each extracted outcome in 
each included study, the timing of the last assessment from the time of burn injury was 
recorded.  
Outcome assessment timings were categorised into time periods: 
• Less than or equal to six months after injury. This was defined as short-term. 
• More than six months after injury. This was defined as longer-term.  
Further classification of short-term outcomes in relation to the time of injury, was undertaken:  
• Less than or equal to 24 hours. 
• From 24 hours up to and including two days. 
• From two days up to and including one week. 
• From one week up to and including two weeks. 
• From two weeks up to and including one month. 
• From one month up to and including three months. 
• From three months up to and including six months. 




• More than six months up to and including one year. 
• From one year up to and including three years. 
• From three years. 
Timepoint of assessment for each outcome: If the timing of the study outcome, in relation to 
injury, was not clearly stated, we used pre-agreed decision rules to estimate timings. 
Frequently, the time of outcome assessment was linked to the length of hospital stay. If this 
was not stated, it was calculated as two days per percent total body surface area of the burn 
(465-467). If a range of burn sizes were given, the last assessment was based on the largest 
burn size. If the article did not provide enough data to determine the timing of outcome 
assessment, the timing was reported as not stated (NS).  
Outcome assessment timing for each whole study: Whole studies were classified as reporting 
short-term or longer-term outcomes, using the six-month cut-off as defined above. Studies 
reporting longer-term outcomes were explored in more detail. 
Authors’ reported views of the association between short and longer-term outcomes: Reasons for 
the use of short-term outcomes were extracted verbatim from each article. The use of the term 
surrogate outcome was extracted, if it was stated. Implications for the use of the short-term 
outcomes to predict longer-term outcomes, were extracted verbatim if reported. Any details of 
validation testing performed for an early outcome to act as a surrogate was noted. 
5.3.5.3 Data analysis 
Numerical data are presented as summary statistics. A narrative synthesis was applied to the 






5.4.1 Included studies  
The initial search strategy identified 2,243 records. Following de-duplication, a total of 1,742 
records remained. Scrutiny of the titles and abstracts identified 313 potentially relevant articles 
for full text review. Of these, 210 studies did not meet the inclusion criteria and were 



















5.4.2 Study and outcome detail 
Of the 103 included studies, 90 (87%) were reports of full RCTs, 7 (7%) were pilot studies and 
six (6%) were study protocols (Table 18). The number of patients recruited per trial ranged 
from nine to 352 (median 50; IQR 30–73) for full and pilot RCTs. Of full and pilot RCTs, 46% 
recruited fewer than 50 participants. Most studies, (83 (81%)) recruited (or planned to recruit) 
participants on one site alone. Studies were undertaken across the five continents, with most 



















Table 18: Study and outcome details. 
 Studies 
Study Type (n=103): 
 
Number of RCTs 
Number of Pilot studies 




90  (87%) 
7     (7%) 
6     (6%) 











47   (37%) 
26   (25%) 
11     (18%) 
9     (9%) 
8     (9%) 









36   (35%) 
48   (47%) 














5.4.3 Timing of assessment for each individual outcome across 
studies 
Of the 1,021 outcomes reported across all 103 included studies, 706 (69%) were last assessed at 
less than, or equal to, six months, 179 (18%) were last assessed at more than six months, 48 
(5%) were assessed at more than a year after injury and for the other 136 (13%), outcome 
timings were not clearly stated (Figure 14). 
 
5.4.4 Outcome assessment timing for each whole study  
Of the total of 103 included studies, only 29 (28%) were classified as long-term, with outcomes 
assessed at more than six months after injury(394, 468-495) (Table 19). Of the 29 studies, 19 
clearly reported that the study outcomes were assessed at more than six months after injury. 
Two were determined using the decision rules described above. Of these 21, four reported 
outcomes at between six months and one year, 13 between one and three years inclusive, and 
only one at more than three years after injury.  
In the other eight studies that did not state the timing of outcome assessment at all (classified 
as not stated), there was sufficient evidence to demonstrate that the outcome assessment was 
made long-term after injury and related to scar management (468, 469, 474, 480, 482, 484, 
491, 495). For these studies, time from randomisation, rather than injury, was more commonly 
reported. The time after injury was long-term but the time after randomisation was either 
































































but time after 
injury not stated. 





Alsharnoubi(468)   Hypertrophic 
scarring treatment. 
Outcomes last measured 
at three months post-
randomisation. 
Bashir(469)   Contracture 
treatment. 
Outcomes measured last 
at 14 days post-
randomisation. 
Boyce(470)  One year   
Douglas(471)  Three years   
Elrashid(472) Not stated. No burn 
size stated. 
Intervention more 
than two months after 
healing. Intervention 
for one month. 
Outcome assessed 
after intervention; 




   
Frew(473)  One year   
Gal(474) 
 
  Participants had 
mature scars. 
Outcomes measured last 
at 12 months post- 
randomisation 
undertaken on mature 
scars. 
Gottschlich(496)  One year   
Herndon(497)  Two years   
Hibbard(477)  Two years   
Holmes(478)  One year   
Holmes(479)  One year   
Hosseini(480)   During 
reconstruction for 
burn contractures. 
Six months post- 
randomisation. 
Legemate(481)  One year   




Six months post- 
randomisation. 
Moiemen(498)  One year   
Muangman(484)  One year   
Nedelec(485)  33 months   
Pena(486)  One year   
Perera(487)  One year   




Rivas(488) 8.5 months.    
Ro(489)  1 year   
Samal(490) 
 





Not stated but post-
operative complications 
and graft take. 
Approximately 1 month 
maximum from 
randomisation. 




1 year after intervention. 
Sveen(492)  1 year   
Wiseman(493)   Burn reconstruction. 
Type not stated. 
6/12 post-intervention. 
Zacharevski(494) 6 months    
Zoheiry(495) Likely to be > 6 
months; intervention 
after discharge of 
patients with burns of 
> 30% BSA and 
intervention lasts 3 
months. 














5.4.5 Authors’ views of the use of short-term outcomes as surrogate 
outcomes 
Of the 74 studies that assessed short-term outcomes, only 19 (26%) made comments that 
linked the short-term outcomes reported, to longer-term outcomes that had not been 
measured. These comments were not supported with any surrogate outcome validation data 


























Table 20: The use of short-term outcomes to predict longer-term outcomes. 
Note: verbatim extraction of data from included studies. 
Comments on the use of short-term outcomes to predict long-term outcomes. 
 
“Secondary outcomes including knee height was measured as a surrogate measure of the height.” (500)  
“Instead, we used the presence of hypertrophic scarring determined by a burn care provider, as well as the need for further 
interventions, as surrogates of quality of scar appearance.” (501)  
 
“In addition, as thermal burn is associated with scarring, so the healing process should decrease the scar and its related 
problems.” (502) 
“Changes in parameters which are seen on first few days of acute burns have a long-term effect.” (503) 
“One of the main limitation of our study was that our sample size was not adequately sized to comment on the long-term 
benefits of administering tranexamic acid like 6 months or 1 year mortality rate, graft failure rate, renal failure rate, etc.” 
(504) 
“Indeed, difficulty walking, running, feeling of weakness, and fatigue have been reported in burn patients as much as 17 
years post-injury.” (505) 
“Pain from burns early in life has been found to have potential long-term effects on pain processing linked to the 
developing nervous system.” (506) 
“The extent of injured and unhealed wound burden is the greatest contributor to mortality in burns. Hence, any process 
that inhibits wound healing or results in less than optimal graft take after definitive surgery can theoretically impact 
overall outcomes. The study was not powered or designed to detect a difference in mortality.” (507) 
“The resulting morbidity inhibits patients’ return to normal societal activities and reduces quality of life.” (508) 
“Low physical work and muscular strength are major obstacles in allowing burned children to return to school and to 
perform activities of daily living. interventions.” (509) 
“The poor control of pain is associated with physiological and psychological results, including intractable pain, depression, 
and post-traumatic stress, and also extensively with suicidal thoughts.” (510) 
“For children especially, the long-term physical and psychological con- sequences of these scars can be devastating.” (511)  
“Numerous retrospective studies have demonstrated the number of transfusions burns patients received was associated 
with infectious episodes, organ dysfunction, length of hospitalisation and mortality.” (512)  
“If acute pain is not adequately managed, it can lead to altered long-term pain perception and maladaptive coping 
strategies, which can persist into adulthood. Previous research also suggests that inadequate pain control can lead to the 
development of anticipatory anxiety for future medical procedures. Therefore, optimising pain management during the 
acute phase of a paediatric burn is critical not only for the physical and cosmetic outcome of the injury but also for the 
child’s well-being at the time and in the long-term.” (513) 
“This is based on studies that show that there is a correlation with hypertrophic scarring in those children with scald 
burns who take more than 14 days to heal.” (514) 
“Clinical practice has confirmed that improper wound disposals can induce infection easily, which can delay wound 
healing or even deepen it and scar hyperplasia is comparatively serious even though the wound is healed.” (515) 
“Anticipatory anxiety can delay in wound healing and recovery process, disturb metabolic and immunologic process.” 
(516) 
“Having higher levels of anti-oxidants in plasma is realistically advisable, but this needs to be linked to absolute 
improvements in clinical outcome.” (517) 








The systematic review presented in this chapter, explored the timing of outcome assessment 
reported in burn care RCTs. Included were 103 RCTs that reported a total of 1,021 unique 
outcomes. Most outcomes, (69%), were last assessed at less than six months after injury. Of 
the 103 whole studies, only 28% reported outcomes last assessed at more than six months 
after burn injury, and only one study followed patients for more than three years. Of the 74 
studies assessing short-term outcomes, 26% mentioned implications for the longer-term 
impact of the observed short-term outcomes, but none used validated surrogate outcomes.  
Outcomes measured shortly after injury have undoubted importance in assessing surgical 
technique, health care costs or adverse events, and trials with these measures are important. 
Most patients, however, are more interested in the impact of interventions on their life many 
years after injury (106, 149). Evidence shows that patients want knowledge of the impact of 
burn injury and its treatment, on longer-term functional ability including the capacity to 
work, cosmesis, psychological adaptation and quality of life overall(519-522). If short-term 
outcomes, shown by this review to be more commonly reported in burn care research, can be 
validated as useful surrogate outcomes and represent a true proxy for longer-term outcomes, 
then it will be possible to extrapolate data from short-term studies to understand impact on 
patient longer-term outcome. 
Validating an outcome as a surrogate for a longer-term outcome, is challenging and time-
consuming. Prentice was one of the first to define this relationship: “a surrogate endpoint is a 
response variable, for which a test of the null hypothesis of no relationship to the treatment 
groups under comparison, is also a valid test of the corresponding null hypothesis based on 
the true endpoint”(523). Prentice’s criteria to assess the validity of a surrogate outcome 
requires the surrogate to be formally correlated with the true clinical outcome, but also for the 
treatment effect on the surrogate to predict the treatment effect on the true clinical outcome. 
This requires high quality trials assessing both the surrogate and the longer-term outcome, for 




Without this undertaking, interventions that have a positive effect on a surrogate outcome, 
may have no effect, or a harmful effect, on the longer-term outcome or vice versa(525). This 
may lead to implementation of interventions without positive (or with potentially harmful) 
effects on patient survival or quality of life. This is illustrated in oncology research, where the 
validation of surrogate end points is increasingly being explored. In a study to determine the 
strength of the surrogate-survival correlation for cancer drug approvals, the authors found 
that the use of surrogate end points often lacked formal verification of the strength of the 
surrogate-survival association(526).  
Certain surrogate outcomes do have supporting evidence to promote their use as true proxies 
for longer-term outcomes. A meta-analysis of individual-patient data for 830 patients from 11 
randomized trials evaluating four intervention types was undertaken. The authors showed 
that, a lower risk for doubling of serum creatinine level, end-stage renal disease, or death, was 
associated with an early decline in proteinuria at nine months (short-term) and this was 
consistent across studies(440). Currently there are no validated surrogates for burn injury. 
It is understandable why short-term outcomes are being used in RCTs in burn care. They are 
easier to measure, and trials are shorter and cheaper(124). If longer-term trials are too difficult 
or costly to undertake, research in burn care needs to establish the relationship between the 
more commonly measured short-term outcomes and the longer-term patient important 
outcomes, as described above. This would allow short-term outcomes to be reliably used as 
surrogates for patient important outcomes. Some work has started in this area; there is 
evidence to support the link between wound healing (surrogate outcome) and the longer-term 
outcome of scar presence or quality (527, 528). However, this research is at an early stage, and 
similar work has not been undertaken on other commonly measured outcomes, such as the 
impact of early pain on future psychological outcomes or fluid over-resuscitation on longer-
term lung function(450, 529, 530). A future research area could determine if there is a need 
for trials in burns care to follow up patients for more than six months, so that the effectiveness 




5.5.1 Strengths and limitations 
The strengths of this review are that the protocol and data extraction proforma were pre-
specified, and the literature search was systematic and comprehensive, including four major 
healthcare trial databases. Limitations include the exclusion of publications in languages other 
than English. However, international publications were included to reduce the risk of 
selection bias. The search was also time-limited, which may have excluded outcomes from 
older studies. The reason for the time limitation, was to identify research relevant to recent 
burn care. There is also evidence from an earlier review of burn care RCTs, that a selection of 
trials published earlier would not change the outcome of this review(4). Another limitation 
was in excluding studies that followed-up RCT populations (n=3). This was undertaken to 
prevent the use of duplicate data. In future work however, it would be useful to look in more 
detail at these studies, to increase the understanding of longer-term patient follow-up after 
burn care RCTs. The use of assumptions to report the last timings of assessments for included 
outcomes was also a limitation. This calculation for length of hospital stay is likely to be too 
simple to account for all the factors that impact on hospital stay and on the last time-point of 
the outcomes assessed. The length of stay association with burn size, is also likely to vary 
between burn services. In the USA and Europe, some centres will achieve better outcomes 
such as, one day (rather than two days) hospital stay per percent burn size(11, 467). In lower-
income countries, the hospital stay relating to burn size is likely to be longer, but this is 
difficult to ascertain from the literature(531-534). However, our assumptions, even if incorrect, 
would only have resulted in an error of weeks, not months or years.  
Research into interventions in burn care should aim to improve patient care(158). To achieve 
this, trials (specifically pragmatic and clinical effectiveness studies) are required to assess 
outcomes that reflect importance to patients in terms of timing of assessment. If limitations to 
research funding, trial length or fast-changing technology precludes this, then more work will 
need to be undertaken to understand how surrogate outcomes reliably impact on longer-term 





This review has shown that most trials of burn care interventions report short-term outcomes, 
that are not validated surrogates for longer-term patient-important outcomes. More trials are 
needed in which longer-term patient important outcomes are assessed, or work needs to be 
undertaken to validate surrogates for longer-term outcomes in burn care research. 
In Chapter Six, evidence from this and the preceding four chapters, will be used to suggest a 
possible solution to these methodological issues relating to outcome reporting: choice of 
different outcomes, varying definitions of the same outcome and varying outcome assessment 
timepoints across trials. These issues impact evidence synthesis and patient relevance for burn 
care research. The work undertaken for Chapter Six, will aim to resolve these challenges 




Chapter 6 An International Core Outcome Set 
for burn care research (COSB-i); shared 
decision-making in outcome choice to improve 
research outputs 
The methodology for this chapter is based upon the published protocol.  
Young A, Brookes S, Rumsey N, Blazeby J. Agreement on what to measure in randomised 
controlled trials in burn care: study protocol for the development of a core outcome set. BMJ 
Open. 2017 Jun 1;7(6):e017267. Changes from this protocol are highlighted in the text below.  
I conceived the project with the support of JMB. I wrote the paper cited above. The other 
members of the group contributed ideas, editing, readability and data sign-off for the project. 
The full details for collaboration for the project are listed in the Disclosure section. Excerpts 
from the paper are incorporated into this chapter. 
 
6.1 Introduction 
This chapter will answer the following thesis objective through the development of an 
international Core Outcome Set (COS) for use in burn care research:  
Thesis Objective 5: A consensus on which burn care outcomes are most important to 






The provision of evidence to support clinical decision-making relies upon data from 
randomised controlled trials (RCTs) collated in systematic reviews(535-537). One issue that 
challenges evidence synthesis, is a variation in outcome reporting across trials. This has, in 
this thesis, been termed outcome reporting heterogeneity (ORH) and has been discussed in 
detail in Chapter Three (71, 538). ORH makes it difficult to synthesise evidence from trials. 
Different outcomes are measured in different studies using different definitions and different 
timepoints of assessment, as discussed in Chapters Four and Five. This makes data difficult to 
interpret. It results in research waste (539-541). The issue of waste in burn care research is 
illustrated by a systematic review undertaken for this thesis in Chapter Two(4). The review 
identified 955 different outcomes extracted from 147 included articles. Of outcomes, 810 were 
reported in only one study. No single outcome was reported across all studies. Other burn care 
systematic reviewers have reported difficulty combining evidence due to ORH(8, 10, 89, 237, 
238). As evidence collated from well conducted RCTs is required to resolve the persisting 
clinical uncertainty regarding the optimal management strategy of patients with burns, ORH 
limits effective clinical decision-making. There is, therefore, an urgent need to agree a 
minimum set of the most important outcomes to standardise, but not restrict, outcome 
reporting in burn care research. This requires the development of a COS(71).  
A COS is a minimum group of outcomes to be reported in all trials of a specific condition (71, 
542, 543). COS are identified scientifically by stakeholders, as being the most important 
outcomes in determining the effects of an intervention or treatment in one healthcare 
condition(115, 544). COSs should include outcomes relevant to international clinical practice 
and patient need. This COS project was conceived following NHS England discussions 
regarding Key Performance Indicators in burn care with UK health care professionals (HCP) 
and patients, in which the author of this thesis was involved. Participating patients and carers 
were vocal about the outcomes that were important to them and which they felt were 
overlooked by HCPs. This highlighted the need for shared decision-making between clinical 
staff and patients, to inform the development of a COS for burn care research. It was agreed 




shared, between both groups. Shared decision-making is “a process in which clinicians and 
patients work together to select tests, treatments or management based on clinical evidence 
and the patient’s informed preferences” 
(https://www.nice.org.uk/Media/Default/About/what-we-do/SDM-consensus-statement.pdf). 
The concept was introduced in the Institute of Medicine report: Crossing the Quality Chasm, as 
a key approach to improving the quality of American health care(545). Historically, shared 
decision-making was regarded as the means to protect patient autonomy and to move way 
from paternalism in healthcare(546). More recently, there has been a shift to investigate the 
impact of shared decision-making on patient outcomes, which has been shown to be 
beneficial(547). In the view of the author of this thesis, the next step, is to use shared decision-
making to agree the most important outcomes to report in healthcare research. Shared 
decision-making is different to incorporating patients’, and carers’ views into decisions already 
taken by HCPs. The term is used in this chapter, to express the need to put equal weight on 
both groups’ views with respect to outcome choice in research. Without such engagement, 
there is a risk that trial data will be based on outcomes, that may not represent what is most 
important to patients and HCPs, particularly in effectiveness trials.  
Once the core outcomes have been agreed, the intention is that all future studies on that 
condition report these outcomes, in addition to any other outcomes relevant to the research 
question (115). This is supported by work from Ioannidis, and a linked editorial by 
Koroshetz(548, 549). They argue that, agreed core outcomes should be reported in trials in a 
clinical area, for each medical intervention, regardless of the intervention tested. The basis of 
the argument is that data from one trial can be used to support data from another, if the 
outcomes are common to the two studies, even if the trials test different interventions. The 
research costs will, therefore, be used to greater benefit. 
The aim of this study, is to present the development of an international COS for burn care 




6.3 Methods  
Current recommendations are that the development of a COS requires the identification of all 
potential outcomes in one clinical area(115). These outcomes are then prioritised in terms of 
importance and relevance, to determine the core set. This is undertaken through a consensus 
process. To achieve relevance, it is important that COS stakeholders should include patients, 
carers and multidisciplinary HCPs and researchers.  
This COS (Core Outcomes in Burn Care Research international (COSB-i)) was registered on 
the Core Outcome Measures in Effectiveness Trials (COMET) database (http://www.comet-
initiative.org/studies/search/). It has been developed and reported in accordance with 
recommendations of the Core Outcome Set-STAndards for Developing and Reporting (COS-
STAD and COS-STAR) and the COMET handbook (115, 288, 550). Changes to the published 
protocol are highlighted and explained. The systematic review informing the COS, was 
registered on Prospero CRD42017060908 and has been published(4). Ethical and other 
research permissions were obtained from the South West-Frenchay Research Ethics 
Committee, reference 17/SW/0025 (Appendix D). The study sponsor was the University of 
Bristol (Appendix E).  
The need for this study was demonstrated by the heterogeneity in outcomes reported across 
trials demonstrated through the systematic review in Chapter Two. On searching, the COMET 
database showed no evidence of an existing COS for burn care research (http://www. 
cometinitiative.org/studies/search/ accessed Autumn 2016). 
Study objectives: 
1. To determine a comprehensive list of clinical and patient-reported outcomes after burn 
injury. 
2. To prioritise these outcomes from patient, carer and HCP viewpoints. 
3. To achieve consensus on a minimum set of the most important and relevant outcomes for 
burn research reporting; the COS for burn care research (COSB-i). 




• Patients of, or over the age of, 10 years, with a cutaneous burn of any size and type. 
• UK parents or carers of burned children of any age with any burn size and type.  
• Burn care professionals of any discipline, burn care commissioners, research funders, 
journal editors and researchers from international settings.  
For the interviews described below, patients, carers and HCPs from the UK only, were 
included. 
Participant exclusion criteria: 
• Children of less than 10 years of age, due to difficulties in younger children participating in 
interviews, and independently undertaking a questionnaire survey.  
• Those who lack the capacity to consent to qualitative interviews or questionnaires.  
• Those who do not speak or read English. 
Study setting: 
Semi-structured interview patients and HCPs were recruited from four geographically separate 
National Health Service (NHS) burn services and burn support groups hosted by these 
services. These included: 
• Bristol Royal Hospital for Children, University Hospitals, Bristol NHS Foundation Trust. 
Frenchay After Burns (FAB) support group. 
• North Bristol NHS Trust. 
• Chelsea and Westminster NHS Foundation Trust. Burns Family Group and the London 
Area Burns Adult Support Group. 
• The Welsh Burn Centre for Burns & Plastic Surgery, Morriston Hospital, Swansea Bay 
University Health Board. Welsh Dragons Burns Club. 
Delphi HCP respondents were from international burn care research and clinical settings. 
Scope: The COS is intended for use in all efficacy and pragmatic research studies comparing 
the effects of interventions for the treatment of patients with burn injuries. This is regardless 




surgical and non-surgical (including psychological) care, across all settings and countries of all 
World Bank income groups.  
Study Phases: The study is a mixed-method design, involving the use of qualitative and 
quantitative methodologies. The methods used to develop a COS are important, as they may 
influence the final core outcomes(71, 284). The methodology used in this study, is consistent 
with that prescribed by COMET, and the standards recommended by COS-STAD (published 
midway through the work undertaken to develop COSB-i)(115, 288).  
Development of the COSB-i involved three phases. 
1. Phase 1: generation of a comprehensive long-list of outcomes in burn care, and a 
questionnaire. Phase 1 aimed to identify all possible outcomes in burn care RCTs, 
supplemented by outcomes reported and considered important to, and reported by,  
patients. These outcomes were grouped into domains and operationalised into 
questionnaire items.  
2. Phase 2: a Delphi survey involving two questionnaire rounds, to prioritise outcomes in 
terms of importance to both international HCPs and UK families. 
3. Phase 3: COS production. Using a modification to the Delphi process, the COS was 
finalised in Phase 3, by undertaking a consensus meeting to agree the most important 
outcomes(551, 552). The methodology, any changes to the agreed protocol and patient 
involvement, was overseen by an independent steering group.  
Steering group: The COSB-i steering group comprised of four patient representatives (three 
adult burn patients of which one was burned as a child, one as a teenager and one as an adult, 
and one parent of a child with a burn), two burn researchers, three COS researchers, one 
commissioner, one Cochrane wounds group representative, three burn surgeons, a burn nurse 
consultant, a burn psychologist, a burn therapist and the national burn database chair as 
recommended by other COS researchers (553). The committee was chaired by an independent 





Patient, parent and public involvement (PPI): Patients and carers were involved in co-designing 
the study protocol, through active participation in the steering group, through interviews to 
inform the COS long-list, through domain decision-making, through participation in the 
Delphi survey, through participation in the consensus meeting, in scientific paper writing and 
in on-going dissemination and implementation of the COS. 
International status: After discussions with NHS England at a meeting to present the COSB-i 
study in Bristol in January 2017, it was agreed to internationalise and broaden the clinical 
stakeholder group for the Delphi survey. This was achieved by including as diverse a range of 
Delphi survey HCP participants, from as many disciplines and countries of varying healthcare 
income status, as possible. Such international involvement is being increasingly recognised in 
COS development(554). It was unfortunately not possible to include international patients, as 
this would require translation of the questionnaire. Due to the time and funding needed, this 
was not possible for this study. This is the aim for a future project (Future research in Chapter 
Seven). 
 
6.3.1 Phase 1. Generation of a long-list of outcomes, domain 
creation and development of a questionnaire 
Outcomes were identified from three sources(4, 159, 162): 
1. A systematic literature review of clinical outcomes reported in RCTs (Chapter Two). 
2. Semi-structured interviews with patients and HCPs. 
3. Two published systematic reviews on patient-reported outcomes (PROs) in burn care. 
 
6.3.1.1 Information sources, outcome long-list 
Long-list creation: Outcomes were combined across each of the three data sources into an 




in Chapter Two. Extraction of outcomes from the patient and HCP interviews and outcome 
domains from the PRO systematic reviews are detailed below.  
Semi-structured interview outcome extraction: Qualitative research is one method for 
researchers developing COSs to inform the long-list of outcomes, through the exploration of 
the views of patients, carers, HCPs and other stakeholders. Qualitative research can help to 
identify what outcomes are important to stakeholders, why some outcomes may be more 
important than others, identify appropriate language for use in the Delphi survey and inform 
comparisons between patient, carer and clinician views(555, 556). In COSB-i, the qualitative 
research was through individual semi-structured interviews (555). The interviews were 
conducted to identify outcomes important to patients with burn injuries and clinicians 
working with these patients. As in two other COSs (CONSENSUS (COS for oropharyngeal 
cancer) and mOMEnt (COS for otitis media with effusion in children)), the interviews were 
structured as a chronological narrative of recovery after the injury(557, 558). In this way, both 
patients and HCPs were able to relate how outcomes that were important early after injury, 
sometimes differed to those that were important at later stages. The interviews were also 
structured to understand why an outcome is important to patients or carers. In the 
PARTNERS2 COS (for schizophrenia or bipolar disorders), employment was found to be an 
important outcome for patients(559). However, it was reported that suitable employment was 
more important than employment per se. Finally, it was important to compare outcomes 
collected from patients, carers and healthcare professionals, to understand and report areas of 
disagreement(560, 561).  
Potential interview participants were identified by four UK NHS specialised burn services and 
associated burn support groups, as described above. Participants satisfying the inclusion 
criteria, were recruited to the qualitative study (Appendices F and G for participant consent 
and patient information details).  
Sample size was determined by data saturation. Non-probabilistic purposive sampling for 
patients was undertaken, to ensure maximum variation, based on age, sex, ethnicity, burn 
severity (size and depth), aetiology, time after injury and management at different burn 




phases of patient recovery. No interview was undertaken within one month of injury or during 
an acute period of hospitalisation. Professional participants included doctors of different 
background specialty, therapists and nurses.  
Interviews were conducted on a one-to-one basis by the author of this thesis. As the 
participants were geographically dispersed, interviews were conducted face-to-face or via the 
telephone. There is no evidence that data quality is diminished by telephone interviews, when 
compared to face-to-face meetings(562). All interviewees gave signed, informed consent (by 
email, hard copy through the post or in person) before the interviews. The interviews were 
audio-recorded and transcribed verbatim, checked and anonymized before being analysed. 
Carers were invited to be present for interviews with children between the ages of 10 and 15 
years of age, if the children preferred this. However, a focus on the experience and self-reports 
of the children themselves were maintained whenever possible.  
The interview topic guide was informed by the data emerging from the systematic reviews 
(clinical and patient-reported) and developed iteratively. Interviews were conversational, 
involving a mix of open questions and more focused prompts. Patients were encouraged to 
introduce and discuss topics (in terms of recovery outcomes) that were most important to 
them. All aspects of the patients’ life were covered, including, but not limited to, those 
affecting function, cosmesis and psychological health. Discussion centred around outcomes 
affected by healthcare treatment, and issues affecting daily life at different time points after 
injury. Patients who were interviewed earlier after injury were prompted for their thoughts on 
potential longer-term issues. (Please see Appendix H for the interview topic guide).  
Data analysis: A thematic analysis of the transcribed interviews was undertaken. The aim was 
to identify patterns, or outcome themes, in the interview data(563). The process typically has 
five steps: data familiarisation, assignment of preliminary codes, pattern or theme searching, 
theme review and theme defining and re-naming. In terms of this project, themes were 
outcomes patients felt important in their recovery from a burn injury.  
The transcribed interviews were read through to get an overview. More detailed reading of the 
transcripts followed, allowing familiarisation and initial coding. Outcomes important to 




Coding (grouping themes or outcomes) was undertaken by the author of this thesis, with a 
second reviewer (AD) coding 10% of interviews, to assess agreement. Following a systematic 
approach to coding, analysis was informed by the constant comparative method, with iterative 
updating of initial codes, allowing improved specificity and clarity. The constant comparative 
method involves breaking down the data into discrete incidents (or themes) and coding these 
into categories (564). Preliminary codes from the transcribed interviews were reviewed, and 
the final codes applied and grouped into themes reflecting outcomes. By constantly 
comparing the transcripts, a theory (collection of outcomes and their relative importance) was 
developed inductively. The framework method of data management was used to chart coded 
data(565, 566). The framework method of data management allows data to be reduced into a 
matrix output of rows and columns. Rows represent cases (different participants in this case). 
Columns represent different themes identified in the raw data.  
Data analysis was run in parallel with data collection, so that emerging themes (outcomes) 
were used to input in an iterative manner into subsequent interviews. In other words, 
emerging themes would lead to prompts for future interviewees. The appropriateness of 
outcomes and their respective domains was reviewed and agreed. A final set of outcomes was 
reviewed, agreed and inputted into the overall outcome long-list.  
Patient-reported outcome extraction (PRO): PROs were extracted from two systematic reviews 
reporting PROs in burn care for adults and children. The review relating to PROs in children 
and adolescents was published in 2015 and that relating to adults in 2017(159, 162). The 
reviews report both generic and burn-specific tools. Most of the generic measures reviewed, 
had only been validated with adults derived from the general population, meaning they were 
unlikely to be sufficiently sensitive to identify health outcome changes in a burn 
population(163). It was decided to use outcomes and outcome domains from the burn-specific 
PRO tools, on advice from the Centre for Appearance research team led by Professor Di 
Harcourt at the University of the West of England 
(https://www1.uwe.ac.uk/hls/research/appearanceresearch.aspx), that had undertaken the 
original reviews. All the outcomes from these tools were assessed with their respective 
domains for appropriate linkage. The outcome domains reported were added to the list of 




In the systematic review of PROs: in child and adolescent burn research, searches of MEDLINE, 
Social Sciences Index, Cinahl, Psychinfo, Psycharticles, and Allied and Complementary 
Medicine, were used to identify articles using English-language PROs from January 2001 to 
March 2013. The inclusion criteria were met by 23 articles reporting 32 different PRO tools. Of 
these, 31 were generic and one was burns-specific. In the systematic review assessing PRO use 
in adult burn care, searches of the same databases were used to find PROs from January 2001 
to September 2016. In this review, 116 studies met the inclusion criteria and reported 77 
different PRO tools. Of these, 71 were generic and six were burns-specific.  
The only burns-specific scale identified in review assessing PRO tools for children and 
adolescents, was: 
• The Children’s Burn Outcomes Questionnaire (CBOQ) for patients aged 11–18 years of 
age(567). This tool has 52 items which assess physical, psychological and social function 
outcomes, covering 12 domains (groups of outcomes with similar meanings). The 
outcomes were generated from a review of the literature and by expert clinician input. 
Interviews with child and adolescent burn patients were not conducted. All outcome 
domains were extracted. 
Of PROs used with adult burn patients, only four of the six burn-specific PROMs had been 
validated in English with adults with burns. These were the Burn Specific Health Scale–
abbreviated (BSHS-A), the Burn Specific Health Scale-Brief (BSHS-B), the Young Adults Burns 
Outcomes Questionnaire (YABOQ) and the Burn Specific Pain Anxiety Scale (BSAS)(568-571). 
• BSHS-A is an abbreviated version of the Burn Specific Health Scale assessing quality of life 
after a burn. It has 80 outcomes covering seven domains. The items were developed using 
a literature review and expert clinician views. Patient interviews were not conducted. 
However, a group of burn patients reviewed a draft of the scale and suggested additional 
outcomes.  
• BSHS-B is an abbreviated version of the BSHS-A and the BSHS-R (a revised version 




• YABOQ measures health outcomes in young adults with burns. It has 47 items covering 15 
domains. These outcomes were developed from clinician views and a literature review. 
Patient interviews were not conducted.  
• BSPAS-A measures anxiety related to pain during or after medical treatment for a burn. It 
is a shortened version of the Burn Specific Pain Anxiety Scale. The outcomes were 
developed from adult burn patient interview data.  
We extracted all the outcome domains from the five tools extracted from the two systematic 
reviews. The outcome domains were de-duplicated and added to the original list of domains. 
 
6.3.2 Domain creation 
Outcome domains: are defined as broad concepts that group similar individual outcomes 
together(232). The clinical outcomes extracted from the systematic review in Chapter Two 
had already been grouped into 54 domains. Additional outcome domains from the interviews 
and PRO data, were added if the domains extracted did not fit into the existing list(464). A 
second researcher (AD) and I, carried out this process independently and then met to discuss 
how the outcomes and domains had been merged. A patient representative and independent 
burn research nurse assisted in the process of categorizing the outcomes into domains and 
agreeing domain names.  
Decision-making regarding the granularity of the outcome domains is challenging. Too many 
criteria will result in too long a list of domains to operationalise into questions, which is likely 
to reduce the number of successful survey completions(573). Too restrictive a method will 
potentially exclude key outcomes. The aim for this COS, was to be inclusive, but to limit the 
domains to less than 100, in-line with other COSs(573, 574).  
6.3.3 Questionnaire formation 
The final domains were operationalized into questionnaire items, using lay language with 




practice was discussed and agreed with our patients at a COSB-i steering group meeting. 
Patients preferred the sentences and to be clear and understandable at first reading (i.e. 
without the medical terms in the main sentence). They also appreciated the practical 
examples under the question. Clinical staff were happy to have the medical term in 
parentheses. A number of staff commented on the fact that using lay language clarified the 
issue for themselves as well as the patients. Items were grouped into short-term (before 
healing) and long-term (after healing), requiring some duplication of items across the 
questionnaire. This was to improve the ease of understanding and to highlight the recovery 
phase in which the outcomes may be important. The questionnaire was designed with the 
input of the COSB-i steering group, including patients, carers and HCPs. It was also discussed 
with the Bristol Young Peoples Advisory Group (https://generationr.org.uk/bristol/), local 
nursing and medical teams, and friends and families.  
Participant information and consent: a plain English video was conceived and developed by the 
author of this thesis. This was undertaken, with support from a specialist medical illustrator, 
to explain the study in plain English: (https://www.youtube.com/watch?v=9DYH072uPrQ ). 
The video was included at the start of the survey alongside age-appropriate written patient 
information.  
Scoring: For each included item, a 9-point Likert-type response scale was provided, with text 
anchors above the scale to support comprehension, whereby 1 = not at all important, 5 = 
important but not vital, and 9 = very important. A zero option was provided for participants to 
indicate that they did not have an opinion about the outcome. One reason for this could be 
HCPs who did not come across a specific outcome in their work. A coloured traffic-light 
spectrum to facilitate comprehension among young people was used, following pilot feedback, 
where red indicated that the item was not at all important, amber represented important but 
not vital and green indicated very important. At the end of the survey, an option was provided 
to allow additional outcomes to be suggested. These additional outcomes were reviewed by 
the author of this thesis and an another researcher, to determine whether they had been 
included in previously defined items, or whether they were new items to incorporate into 




Piloting: The questionnaire survey was piloted in three stages.  
1. Initial cognitive interviews were undertaken with six parents. Parents read several 
questions and fed back to the research nurse what they understood by each question. The 
questionnaire was modified as a result of this work.  
2. Adults (aged over 16 years) and young people aged 10-15 years completed and reviewed the 
survey, to assess usability, face validity, and acceptability.  
3. Following feedback, the survey was piloted again with adults (friends and family), young 
people and HCPs. The survey was modified as a result of their feedback. 
The final questionnaire survey was set up as an online survey using REDCap (Research 
Electronic Data Capture (https://www.project-redcap.org/)). The set-up was by Ms Alison 
Hone with input though twice weekly meetings with myself and Dr Anna Davies. Study data 
were collected and managed using the REDCap electronic data capture tools hosted at the 
University of Bristol(576, 577). REDCap is a secure, web-based software platform designed to 
provide: 
• An intuitive interface for validated data capture for research studies. 
• Audit trails for tracking data manipulation and export procedures. 
• Automated export procedures for seamless data downloads to common statistical 
packages. 
• Procedures for data integration and interoperability with external sources.  
Consent was taken at the start of the survey after the patient information details, prior to 
progression to the demographic and outcome sections (Appendix I). To ensure that we had 
not missed important outcomes, we included an open question at the end of the round 1 
questionnaire. Examples of the questionnaire are shown in Figures 15 and 16. The full versions 

















6.3.4 Phase 2: Prioritisation of outcomes; achieving consensus 
Methods used by COS researchers to collect opinions, and to develop consensus on outcome 
prioritisation, include expert panel meetings, Delphi surveys (modified or not), nominal group 
techniques, focus groups and individual interviews(71, 578-580). The recommendations from 
COS-STAD, emphasise that transparency and pre-specification in the consensus process is 
important, to ensure that the COS has been developed in a rigorous and unbiased way(288). A 
Delphi survey is an increasingly used method to achieve this(71, 288, 554, 573). The Delphi 
technique (procedure or process), is a method of collating opinion, with the aim of coming to 
a group consensus.  
It is an iterative process using a systematic progression of voting rounds. It is effective for 
determining expert group consensus where there is little definitive evidence and where 
opinion is important. The process was originally developed by Dalkey and Helmer, at the Rand 
Corporation in the 1950s(115). It can be undertaken without a physical meeting, although the 
modified Delphi process includes a final consensus meeting(581). One of the strengths of the 
method, is that, since the responses of the participants are anonymous, opinions are more 
likely to be true views(582). Performing an anonymous Delphi study by email, may also avoid 
dominance of certain persons in face-to-face group meetings. Other limitations found with 
decision-making processes in groups or committees, include, but are not limited to, cost and 
time constraints(583). Delphi survey feedback is provided in a controlled manner(584-586). 
The general format of the modified Delphi process, and that used in this COS (known from 











Before undertaking a Delphi survey in a COS development study, the following issues need to 
be considered: 
• Participant type (patients, carers and/or HCPs). 
• The number of Delphi survey rounds. 
• Design and structure of feedback for future rounds. 
• Sample size. 
• Data analysis and pre-specified criteria for keeping or excluding outcomes. 
 
Delphi survey participants in the COSB-i study, were multi-disciplinary international HCPs 
working with patients with burns from any setting and at any part of the care pathway. This 
included clinicians from multiple disciplines, burn researchers, journal editors, research 
funders, UK health commissioners. UK burns patients aged 10 years or older and UK carers of 
burned children of any age were also included. Recruitment was through a personal or group 
email invitation or via social media (Facebook and Twitter). Both included a link to the on-
line REDCap survey (https://www.researchgate.net/). 
Several methods were used to identify eligible international HCP participants. These included:  
• National and international professional burn, plastic surgery and injury organisations. 
• UK burn organisational networks. 
• National and international burn charitable organisations. 
• Key country collaborators known to be leaders in burn care or burn care research, 
recruited as collaborators to disseminate the survey. 
• International burn care contacts of the author of this thesis approached via ResearchGate 
or personal email. 
Number of survey rounds: The COSB-i protocol proposed three rounds. The methodology was 
amended to shorten this to two rounds (named as round 1 and round 2), to reduce potential 





Design and structure of feedback: In round 2 of the survey, all participants who had completed 
their email address in round 1 of the survey, were emailed a personalised link to round 2 using 
the REDCap database. This was detailed and consented for in round 1. The round 2 survey 
used the same format as the round 1 survey, with the following modifications: 
• For each item, a value was given indicating the participant’s importance rating for the item 
in the previous round. 
• For each item, a value was given indicating the median importance rating score for the 
item in the previous round. While the median was given, this was referred to as the 
average, to facilitate comprehension among participants.  
• For each item, a histogram of other participants’ responses to the item was provided 
(Figure 18). The graph indicates responses from patients and HCPs using separate colours. 
Zero responses (no opinion) were not included in the graph. Qualitative work was 
undertaken with a small group of patients and parents in the burns outpatient clinician in 
one hospital site as part of public and patient engagement work to agree this feedback 
format. The patients and parents were presented with a pie chart and two different types 
of histogram. The version illustrated in Figure 18 was chosen as the most favoured as the 
most easy to understand. 
• Additional inormation was given to participants for round 2 at the start of the survey. The 
participants were provided with the top ten outcomes from round 1 on a front (cover) 
sheet to the survey. They were given the following information before this: “ In the table 
below are the most important outcomes as rated by clinicians, patients and parents. These 
outcomes are highlighted in the survey questions in green.  
o When you complete the survey please consider carefully how important you think 
these most important are:  
o If you agree these are the most important outcomes to be included in future 
research trials, please rate them as a ‘9’ (very important).  
o If you think they are not the most important outcomes to include, please rate them 





Sample size: There are no agreed sample size guidelines for the number of participants 
necessary for consensus methods when developing a COS. The COMET handbook states that 
“the more participants representing each stakeholder group the better, both in terms of the 
COS being generalisable to future patients and in convincing other stakeholders of its value” 
(115). In the absence of agreed methodology, and based on the COMET Handbook, other COSs 
and the fact that burn injuries are common, we aimed for recruitment of 150 UK patients 














6.3.5 Data analysis 
Any individual completing the consent form, providing an email address, and rating at least 
one survey item was considered a study participant.  




o Number of years in burn care 
o Country of origin 
o World Bank income status of country of origin 
• Patients and carers: 
o Background: 
 Sex 
 Adult, child or carer 
 Ethnicity 
 Education 
o Details of injury: 
 Mechanism of burn  
 Burn severity 
 Time since burn injury 
Item data: For the item ratings, any completed datapoint was included, to prevent loss of data. 
For each item, data were produced consisting of:  
• Number of participants completing each item. 
• Descriptors of central tendency for items (mean, median). 





Where the item was rated as zero (no opinion on the outcome), these data were excluded 
from the analyses. This may be due to the specialist background of the respondent or the 
timepoint in the recovery pathway for patients or HCPs. Data were tabulated for the overall 
sample, and according to stakeholder group. Participants were grouped as HCPs or 
patients/carers.  
Dropping and modification of items between Delphi survey rounds 1 and 2: Criteria for selection 
of items to be carried through to round 2 were pre-defined and published(229).  
Items for which at least 50% of the overall sample rated it above 7-9, and fewer than 15% of 
the sample rated it as 1-3, were carried through to round 2.  
Attrition between survey rounds: Median and mean round 1 survey scores were compared for 
those who did and did not complete both rounds of the survey. Mann Whitney U tests were 
used to compare scores, since all outcomes were skewed. The significance level was set at 
p<0.05. 
Selection of items for the final consensus meeting: After round 2 of the survey, more stringent 
criteria were applied for selection of items to carry through to the consensus meeting.  
Those items rated 8-9 by more than 70% of the overall sample, or more than 70% of either 
patients or professionals were carried through to the consensus meeting for further 
discussion.  
Items duplicated for reasons of timing of outcome assessment were combined for the 
consensus meeting. 
 
6.3.6 Phase 3: Consensus meeting to agree the final COS 
A half-day consensus meeting was held in London, UK on October 9th, 2019. An independent 
chair was appointed from a charity supporting burn care research, Dr Charlotte Coates, 
research manager, Scar Free Foundation https://scarfree.org.uk/). International HCPs or UK 




part. Steering group members were invited. Attendance was in-person or by Skype call. Non-
professional attendees were met face-to-face or via a telephone call, prior to the meeting, to 
explain the planned processes and their role. On-line voting software 
(https://turningtechnologies.com accessed December 2019) was used to enable remote voting 
at the meeting. Outcome wording was shortened and simplified for the consensus meetings, 
to allow for ease of reading on Microsoft PowerPoint slides. These were visible to both in-
person and telecon attendees, with verbal clarification as needed. 
Outcome merging: Prior to voting, a discussion was conducted to determine if any items (from 
now on called outcomes) could be merged, or combined, due to similarity of meaning. 
Consensus meeting voting: The final set of outcomes (agreed after the merging exercise) were 
presented to the meeting to agree the final COS. Two rounds of voting were carried out on the 
importance of these outcomes. Voting results for each item were presented immediately in the 
form of a histogram. Outcomes were voted in or out, with real-time results shown to all 
participants (Figure 19).  
Decisions regarding maintaining, dropping and agreeing final outcomes through the two 
voting rounds, were pre-specified prior to the consensus meeting, through steering group and 
local team meetings involving patients. After the voting for round 1, outcomes where more 
than 50% of participants had voted it in to include in the COS, were carried through to the 
next round of voting. For round 2, a more stringent criterion was used to select items to 
include in the final set. When more than 60% of the participants rated the outcome as 
important (voted in), it was included in the final COS. The final set of outcomes was presented 
to the participants for sign-off. 
Data collection and analysis: Data were collected on participant demographics in terms of 
country of origin, HCP, patient or carer and HCP profession. Voting was recorded as inclusion 
(in or out) for each outcome. Voting results for each round were analysed in terms of pre-











6.4.1 Phase 1: Outcome long-list, outcome domain generation and 
questionnaire creation 
The outcome long-list consisted of outcomes from the three sources detailed above.  
• For detailed information of the results of the systematic review of clinical outcomes, please 
see Chapter Two and the published paper(4).  
• The PRO domains were extracted from two systematic reviews as described above. 
Outcome domains from these PRO tools are shown in Table 21.  
• Semi-structured interviews were conducted with 25 participants. This included 10 burn 
care HCPs (one consultant, three nursing staff, four therapists and two other staff), 14 
adult patients and one child and parent combination. Interview outcomes are shown in 
Appendix K. Outcome-related domains from the interviews are shown in the final list of 
domains in Table 22.  
Examination of all three data sources identified 1,187 outcomes which after de-duplication 
across the sources left 1,021 unique outcomes. These outcomes were grouped into outcome 
domains (n=68) based on the initial 54 clinical domains described in Chapter Two. Additional 
domains were added for PROs that did not fit into the existing set. The outcomes extracted 
from the PRO reviews, from the other two sources and the resulting outcome domains are 
shown in Table 22. 
The 68 outcome domains were converted into 88 questionnaire items, with some necessary 








Table 21: Outcome domains extracted from systematic reviews of PROs in burn care. 
PRO tool, author and 
reference. 
PRO domains (n=45) 
CBOQ 
Daltroy et al(567) 
Self-esteem/self-worth/sense of mastery 
Physical function/athletic competence/mobility/physical health 
Physical Appearance/self-image/weight satisfaction 
Behavioural conduct/social skills/problem behaviours/intrapersonal 
development/compliance 
Personality/coping styles/emotional functioning/psychological health 
Pain 
Itching 
Satisfaction with treatment/symptoms/status 
Impact on family 
Parental concern 
Quality of life 
Sense of community 
BSHS-A 
Munster(568) 





Family and Friends 
Sexual activity 
BSHS-B 











Ryan et al(569) 
Physical function 
Fine motor function 
Pain 
Itch 






Satisfaction with symptom relief 












Table 22: Final domains with associated outcomes from each source. 
 
Count of PROM 
outcomes 






Ability to carry out daily tasks 3 3 9 




Adherence to treatment 1 
  
Anxiety about medical procedures 1 4 1 
Anxiety about and appointments 
   








Body temperature issues 1 
 
1 
























Burn wound healing 
 
160 7 
Burn wound infection 
 
86 2 
Burn wound pain 2 48 4 
Comfort of dressings 
 
2 2 




Complications of treatment 
  
4 




Death from any cause 
 
13 1 











Donor site outcomes 
  
1 
Donor site pain 
 
10 1 
Donor site problems after healing 6 23 
 




Effect of scar on movement 
  
3 


















Generalised anxiety 2 1 5 
Growth after injury 
  
1 





















Length of hospital stay 
 
6 4 
Length of stay in intensive care unit  
 
3 1 













Mobility 3 11 3 








Pain during procedures 
 
7 1 
Personal cost for patient 
  
1 
Psychological wellbeing 7 1 15 






























Treatment for scars 
 
2 10 
Understanding of planned care 
  
3 
Use of medicines to treat symptoms 1 4 1 







6.4.2 Phase 2: Delphi process to prioritise outcomes 
6.4.2.1  Round 1 Delphi survey 
Response rate: In round one of the Delphi survey, 794 participants took part.  
Participant demographics: Of all participants, 668 (84%) were international HCPs and 126 
(15%) were patients or carers. Participants’ demographics for the Delphi survey round 1, are 
provided in Tables 23 and 24, along with those for round 2. For round 1, HCP participants 
originated from 77 countries from five continents. Of these, 166 (25%) came from lower 
middle- and lower-income countries (Figures 20 and 21). Of the HCPs, 303 (45%) were 
doctors, 158 (24%) were allied health professionals, 100 (15%) were nurses and 88 (13%) were 
burn care researchers. Of these, 377 (56%) worked with adults and children. Of the patients, 
97 (77%) were adults, 28 (22%) were carers of a child with a burn injury and one was a young 
person (1%). Eighty (63%) were of white British origin, and 52 (41%) had a university 
education. The mean time since injury in the children of carers who responded was 5.5 years 
(SD 10.7), and for adult patients it was 12.8 years (SD 15.3).  
Voting responses (Table 23): In round 1, of all 88 items, 85 were rated as very important (7-9 
on the Likert scale), by at least 50% of the sample. Two items did not reach the 50% threshold 
across both groups (thirst, burn smell). However, more than 50% of the patients and carers, 
independently of the HCPs, rated these items as very important (7-9), and they were therefore 
carried through to round 2. One item did not reach the 50% threshold for the overall sample, 
or for either patient/carer or HCP group independently, (mild complications), and was 
removed. Thirteen additional new outcomes were suggested by participants in round 1. One 





Figure 20: Round 1 Delphi survey: country of participant origin. 
 







Table 23: Delphi survey round 1 items and voting percentage. 
Notes:  
• Sorted by % of the total sample scoring the item 7-9. 
• Green text: outcomes repeated before and after healing. BH= before healing, AH=after healing.  
• Shading: one item at the bottom, rated below 50% by the total sample, and by both patients and 
carers or clinicians, that was not carried through to round 2 (mild complications). 
• Percentages given to two decimal places due to sample size. 
 





Death attributable to the burn injury 94.4% 95.4% 94.3% 
Serious complications (e.g. blood clot in lungs or legs) 94.1% 93.5% 94.2% 
Sepsis 92.1% 91.6% 92.2% 
Burn wound infection 91.8% 92.0% 91.7% 
Scar contractures 91.6% 87.5% 92.3% 
Ability to carry out daily tasks 90.2% 85.2% 91.1% 
Time for a grafted wound to heal 90.1% 91.7% 89.9% 
Multiorgan dysfunction 89.7% 88.5% 89.9% 
Multiorgan failure 89.7% 90.4% 89.6% 
Time for the burn wound to heal 89.4% 90.4% 89.3% 
Pain in the scar 88.1% 91.2% 87.6% 
Breathing and lung function 87.7% 86.5% 87.8% 
Appearance 86.9% 87.0% 86.9% 
Serious kidney dysfunction 86.4% 85.0% 86.6% 
Return to work/ school/ previous function 86.3% 81.3% 87.2% 
BH Death attributable to any cause 85.7% 83.0% 86.2% 
Pain during medical procedures 85.1% 89.7% 84.3% 
Length of time on a ventilator 84.9% 85.1% 84.9% 
Pain when treatment is not taking place 84.7% 86.8% 84.3% 
Walking 83.4% 78.4% 84.2% 
Length of stay in intensive care unit 83.3% 79.4% 83.9% 
Ability of the body to fight infection 83.2% 86.1% 82.7% 
Anxiety about the future 82.8% 87.7% 81.9% 
BH Functioning of the heart and circulation 82.1% 85.3% 81.6% 
BH Anxiety about the future 81.1% 86.1% 80.2% 
Physical wellbeing 80.6% 82.5% 80.3% 
Donor site infection 80.6% 84.1% 80.0% 
Amount of fluid given 80.2% 70.5% 81.9% 
BH Effect of burn on metabolism 79.7% 73.4% 80.8% 
AH Itch after healing 79.1% 78.6% 79.2% 
AH Anxiety about treatment 78.8% 82.6% 78.1% 
Growth 78.7% 74.8% 79.4% 
Impact on personal relationships 78.5% 79.5% 78.3% 
BH Dignity of the patient during and after treatment 77.9% 86.5% 76.3% 
BH Anxiety about treatment (e.g. dressing changes, surgeries) 77.6% 82.7% 76.7% 
Fitness 77.5% 79.3% 77.2% 
BH Number of surgical treatments needed 77.4% 84.5% 76.1% 
Comfort of dressings 77.1% 80.9% 76.5% 




Length of stay in hospital 77.0% 67.3% 78.6% 
AH Understanding of treatment 76.5% 80.9% 75.7% 
Time for the donor site to heal 76.4% 73.4% 76.9% 
Liver function 75.6% 77.6% 75.3% 
Muscle strength 75.4% 77.7% 75.0% 
AH Number of surgical treatments needed 75.1% 76.3% 74.9% 
Number of scar reconstructions 74.7% 72.3% 75.1% 
Stomach and bowel function 73.9% 71.0% 74.4% 
Sleep quantity and quality 73.6% 79.5% 72.5% 
Understanding of treatment 73.5% 85.0% 71.5% 
Pain in the donor site 73.5% 73.5% 73.4% 
Other infection (e.g. Urinary Tract Infection, Chest infection) 73.2% 66.7% 74.3% 
Inflammatory markers 73.1% 79.2% 72.1% 
AH Adherence to treatment 73.0% 77.4% 72.2% 
Minor kidney dysfunction 72.7% 71.6% 72.8% 
BH Itch before healing 72.3% 70.6% 72.6% 
AH Dignity of the patient 71.8% 81.4% 70.1% 
BH Adherence to treatment 70.8% 80.9% 69.0% 
Donor site problems 70.8% 74.8% 70.1% 
Number of creams and dressings, time spent in pressure garments 69.6% 75.7% 68.6% 
AH Costs to the patient and their family 69.4% 70.5% 69.3% 
AH Death attributable to any cause 69.4% 71.2% 69.1% 
Need for long-term medication (e.g. pain relief) 68.3% 65.2% 68.9% 
Texture of the scar 68.2% 67.3% 68.4% 
BH Body temperature regulation 68.1% 73.0% 67.3% 
Cognitive functioning (e.g. memory, concentration) 67.1% 74.5% 65.8% 
Need for blood transfusion 66.8% 75.0% 65.3% 
BH Weight maintenance  66.3% 57.4% 67.8% 
Moderate complications (e.g. allergy to medication, bleeding under skin graft) 66.3% 60.6% 67.2% 
BH Costs to the patient and their family 65.8% 71.7% 64.8% 
AH Body temperature regulation 65.4% 75.7% 63.6% 
Number of dressing changes 64.8% 74.3% 63.1% 
AH Functioning of the heart and circulation 64.7% 70.3% 63.7% 
Scar size 64.3% 65.5% 64.1% 
AH Effect of burn on metabolism 63.8% 60.0% 64.5% 
Amount of exudate from the wound 62.4% 73.2% 60.4% 
Amount of medication needed 61.7% 68.8% 60.5% 
BH Costs to the NHS 60.1% 47.6% 62.2% 
Hair loss 58.5% 67.3% 57.1% 
Nature of exudate from the wound 58.3% 66.1% 56.8% 
Burn scar colour 57.7% 61.9% 56.9% 
AH Weight Maintenance 54.9% 46.2% 56.3% 
AH costs to the NHS 53.7% 48.1% 54.6% 
AH Number of outpatient appointments needed 52.7% 59.6% 51.4% 
BH Number of outpatient appointments needed 51.9% 58.2% 50.8% 
Bone density and strength 51.2% 67.9% 48.4% 
Thirst 44.9% 60.0% 42.4% 
Smell of the burn wound 41.4% 55.4% 39.2% 






6.4.2.2 Round 2 Delphi survey 
Response rate: Of those participating in round 1, 431 participants (54%) undertook round 2.  
Demographic characteristics of participants: Of all participants, 53 were patients or carers 
(42% of those completing round 1), and 378 were HCPs (56% of those completing round 1). 
These data are shown in Tables 24 and 25. 
Items for voting and responses: These are shown in Table 26. They consist of those items 
carried forward from round 1, as well as the 13 additional outcomes added after round 1. The 
voting is the percentage of respondents  





















 Survey round 1 n = 668  Survey round 2 n = 378 
 n % n % 
HCP occupation     
Doctors     
Consultant burn care (burn surgeon, 
plastic Surgeon, paediatrician, 
trauma, pain specialist) 
173 25.9 87 23.0 
Anaesthetist/ intensivist 84 12.6 46 12.0 
Pathologist 1 0.2 0 0 
GP 2 0.3 2 0.5 
Junior doctor/ registrar 43 6.4 21 5.6 
Medical student 1 0.2 1 0.3 
Allied Health Professional (AHP)     
Burn AHP: Physiotherapist, 
occupational therapist, dietician, 
psychologist, play, speech & 
language, laser, social worker. 
158 23.7 97 25.7 
Paramedic 2 0.3 2 0.5 
Nursing     
Burn care nurse/ research nurse/ 
theatre nurse 
100 15.0 56 14.8 
Burn researchers     
Burn researcher 88 13.2 58 15.3 
Other     
Burn charity 1 0.2 1 0.3 
Commercial 1 0.2 1 0.3 
Burn commissioner/ service manager 2 0.3 2 0.5 
Medical education 4 0.6 2 0.5 
NIHR 1 0.2 1 0.3 
Not stated  5 0.7 1 0.3 
Time spent in Burns care     
6-12 months 45 6.7 18 4.8 
>1-3 Years 76 11.4 36 9.5 
>3-5 years 77 11.5 44 11.6 
> 5 years 466 69.8 278 73.5 
Not stated 4 0.6 2 0.5 
World Bank Income Group     
HIC 473 70.8 306 81.0 
UMIC 71 10.6 32 8.5 
LMIC 95 14.2 26 6.9 
LIC 25 3.7 12 3.2 




Table 25: Delphi surveys rounds 1 and 2. Demographics of patients and burn type. 
 Round 1 survey n = 126  Round 2 survey n = 53 
 n %  n % 
Young person 1 0.79  0.0 0.0 
Adult patient 97 77.0  42 79.2 
Parent of child with burn 28 22.2  11 20.7 
Sex      
Female 83 65.9  36 67.9 
Male 43 34.1  17 32.1 
Ethnicity      
Asian/ Asian British 1 0.8  1 1.9 
Black/ Black British 3 2.4  1 1.9 
White British/ White other 114 90.5  48 90.6 
Mixed ethnicity 5 4.0  1 1.9 
Other 3 2.4  2 3.8 
Missing 1 0.8  0 0.0 
Education      
No formal qualifications 5 5.0  2 3.8 
GCSE or equivalent 23 18.3  10 18.9 
A Levels or equivalent 19 15.1  11 20.8 
University degree 52 41.3  20 37.7 
Vocational qualifications 10 7.9  5 9.4 
Higher degree 11 8.7  4 7.6 
Other 4 3.2  1 1.9 
Missing 2 1.6  0 0.0 
Mechanism of burn      
Scald 46 36.5  20 37.7 
Contact 8 6.4  2 3.8 
Flame 54 42.9  26 49.1 
Chemical 5 4.0  2 3.8 
Other 13 10.3  3 5.7 
Total Body Surface Area of burn     
0-10% 44 34.9  21 39.6 
11-20% 20 15.9  7 13.2 
21-40% 21 16.7  9 17.0 
More than 40% 30 23.8  11 20.8 











Table 26: Round 2 Delphi survey items for voting. 
Notes: 
• Sorted by % of the total sample scoring the item 8-9. 
• Green: outcomes repeated before and after healing; BH = before healing; AH=after healing. 
• Shading: items carried through after round 2. 
• *items added to the survey in round 1. 







Death attributable to the burn injury 96.8% 92.0% 97.5% 
Serious complications (e.g. blood clot in lungs or legs) 96.3% 98.0% 96.1% 
Sepsis 95.3% 98.0% 94.9% 
Multiorgan failure 92.9% 85.4% 93.9% 
Scar contractures 92.2% 91.5% 92.2% 
Ability to carry out daily tasks 91.9% 91.5% 92.0% 
Burn wound infection 90.1% 96.1% 89.3% 
Multiorgan dysfunction 89.9% 87.8% 90.2% 
BH Death attributable to any cause 87.9% 90.0% 87.6% 
Time for the burn wound to heal 85.8% 82.4% 86.3% 
Pain in the scar 83.9% 87.0% 83.5% 
Time for a grafted wound to heal 83.6% 85.7% 83.3% 
Breathing and lung function 79.5% 79.6% 79.5% 
Pain during medical procedures 79.3% 87.2% 78.3% 
Serious kidney dysfunction 77.5% 75.0% 77.9% 
Appearance 75.3% 78.7% 74.8% 
*Patient psychology 74.6% 75.5% 74.5% 
Pain when treatment is not taking place 74.6% 76.6% 74.4% 
Length of time on a ventilator 73.7% 65.3% 74.9% 
Growth 73.5% 71.7% 73.8% 
Return to work/ school/ previous function 73.5% 67.4% 74.3% 
Walking 72.8% 72.3% 72.9% 
Length of stay in intensive care unit 69.9% 69.4% 70.0% 
Amount of fluid given 68.1% 57.1% 69.7% 
Physical wellbeing 68.1% 76.1% 67.1% 
Donor site infection 68.0% 81.6% 66.1% 
BH Dignity of the patient during and after treatment 67.4% 63.8% 67.9% 
AH Anxiety about the future 66.8% 71.7% 66.1% 
BH Anxiety about the future 66.3% 70.2% 65.8% 
Impact on personal relationships 65.9% 63.0% 66.3% 
Time for the donor site to heal 65.1% 73.5% 64.0% 
Length of stay in hospital 65.0% 59.2% 65.8% 
Comfort of dressings 65.0% 66.0% 64.8% 
AH Death attributable to any cause 64.0% 53.3% 65.4% 
BH Functioning of the heart and circulation 63.0% 66.0% 62.6% 
Ability of the body to fight infection 62.2% 76.5% 60.2% 
BH Number of surgical treatments needed 62.0% 70.2% 60.9% 
Other infection (e.g. Urinary Tract Infection, Chest infection) 60.8% 66.0% 60.1% 
BH Effect of burn on metabolism 60.8% 54.0% 61.8% 
AH Understanding of treatment 60.1% 80.9% 57.3% 
Fitness 59.8% 68.1% 58.7% 
AH Anxiety about treatment 58.9% 70.2% 57.3% 
AH Itch after healing 58.6% 69.6% 57.1% 
Liver function 57.9% 62.5% 57.2% 
AH Dignity of the patient 49.9% 54.3% 49.3% 
Pain in the donor site 48.7% 52.2% 48.3% 




BH Anxiety about treatment (e.g. dressing changes, surgeries) 47.6% 50.0% 47.3% 
BH Itch before healing 47.1% 44.7% 47.4% 
Number of scar reconstructions 47.0% 45.7% 47.2% 
Understanding of treatment 46.7% 61.7% 44.7% 
*Scar elasticity 46.7% 67.3% 43.9% 
*Suicide rate 43.8% 64.6% 41.0% 
AH Number of surgical treatments needed 42.6% 46.8% 42.0% 
AH Adherence to treatment 42.5% 59.6% 40.2% 
Sleep quantity and quality 40.9% 33.3% 41.9% 
Muscle strength 40.9% 53.2% 39.2% 
*Impact on family 40.7% 56.6% 38.5% 
BH Costs to the patient and their family 40.1% 44.7% 39.4% 
*Satisfaction with care 40.0% 49.1% 38.7% 
Cognitive functioning (e.g. memory, concentration) 38.5% 58.7% 35.8% 
AH Costs to the patient and their family 38.0% 45.7% 37.0% 
Donor site problems 38.0% 45.7% 37.0% 
BH Body temperature regulation 37.9% 50.0% 36.2% 
BH Adherence to treatment 37.9% 53.2% 35.8% 
Texture of the scar 37.6% 47.8% 36.3% 
Stomach and bowel function 37.3% 34.0% 37.7% 
*Dysphonia 37.2% 60.0% 34.1% 
*Intensive care unit neuropathy 35.3% 36.0% 35.2% 
Need for blood transfusion 35.3% 43.8% 34.1% 
Inflammatory markers 34.9% 42.9% 33.7% 
*Dysphagia 34.7% 48.0% 32.9% 
Number of creams and dressings, time spent in pressure garments 33.8% 51.1% 31.5% 
Scar size 33.2% 34.0% 33.1% 
Hair loss 33.2% 47.7% 31.4% 
Need for long-term medication (e.g. pain relief) 33.1% 46.8% 31.2% 
*Unplanned readmission to hospital 32.6% 52.0% 30.1% 
*Substance Abuse 32.1% 38.0% 31.3% 
AH Body temperature regulation 32.1% 61.7% 28.0% 
Moderate complications (e.g. allergy to medication, bleeding under skin graft) 31.9% 36.0% 31.4% 
Minor kidney dysfunction 31.1% 36.0% 30.4% 
BH Costs to the NHS 30.9% 26.1% 31.5% 
BH Weight maintenance  30.1% 27.1% 30.5% 
*Breast development 29.9% 52.3% 27.2% 
*Enteral feeding intolerance 29.8% 45.8% 27.7% 
AH Effect of burn on metabolism 29.2% 21.3% 30.3% 
Number of dressing changes 28.9% 42.6% 27.0% 
AH Functioning of the heart and circulation 28.0% 34.0% 27.1% 
*Fatigue 26.5% 32.0% 25.8% 
Amount of medication needed 26.4% 36.2% 25.1% 
Burn scar colour 24.4% 30.4% 23.6% 
AH costs to the NHS 24.2% 22.7% 24.4% 
Amount of exudate from the wound 24.1% 31.4% 23.1% 
AH Number of outpatient appointments needed 22.1% 31.9% 20.8% 
BH Number of outpatient appointments needed 21.3% 34.0% 19.5% 
Nature of exudate from the wound 20.8% 35.3% 18.7% 
AH Weight Maintenance 19.2% 17.0% 19.5% 
Bone density and strength 16.0% 27.7% 14.4% 
Smell of the burn wound 14.4% 30.4% 12.2% 







Voting responses: Using the more stringent criteria described above for items to be carried 
through to the consensus meeting, 31 outcomes reached the criteria, of which 20 had been 
voted 8-9 by > 70% of all participants (HCPs and patients or carers) combined (LIST A). An 
additional 11 outcomes were voted as more than 8-9 by > 70% of either patients or HCPs (LIST 
B). This resulted in 31 outcomes to be taken to the consensus meeting (Tables 26, 27 and 28). 
Attrition of participants between rounds: Demographic characteristics of participants 
completing both rounds and only round 1 were similar. (Tables 24 and 25).  
Analyses examining differences in outcome ratings between participants that completed round 1 
only or rounds 1 and 2, were undertaken using Mann Whitney U tests. This demonstrated that 
24 outcomes were significantly different at p<0.05 (Table 29). However, closer inspection of 
















Table 27: Outcomes rated 8-9 by more than 70% of patients AND HCPs after round 2. 
Note: List A. 
Outcome % rating 
outcome 
8-9 
 Outcome % rating 
outcome 
8-9 
Death due to burn injury 96.8  Scar pain 83.9 
Serious complications (e.g. thrombosis) 96.3  Time to heal a (grafted) wound 83.6 
Sepsis (bloodstream infection) 95.3  Breathing and lung function 79.5 
Multi-organ failure  92.9  Pain during procedures (dressing changes) 79.3 
Scar contractures 92.2  Kidney function 77.5 
Daily tasks 91.9  Appearance 75.3 
Wound infection 90.1  Pain in the burn wound  74.6 
Multi-organ dysfunction 89.9  Patient psychology 74.6 
Death from any cause 87.9  Growth (achieving expected height) 73.5 
Time to healing 85.8  Walking 72.8 
 
Table 28: Outcomes voted as 8-9 by more than 70% of HCPS OR patients after round 2. 
 Note: List B. 
Outcome % Patients rating outcome as 
important (8-9) 
% Clinicians rating outcome as 
important (8-9) 
Infection in donor site 81.6 66.1 
Understanding of treatment received 80.9 57.3 
Well-being 76.1 67.1 
Donor site healing 73.5 64.0 
Anxiety 71.7 66.1 
Number of surgeries needed 70.2 60.9 
Anxiety about the future 70.2 65.8 
Length of stay in ICU 69.4 70.0 
Time to return to work/school/ previous 
occupation 
67.4 74.3 
Length of time on ventilator 65.3 74.9 







Table 29: Outcomes for which there was a significant difference at round 1, between those who did or 
did not complete both rounds of the survey. 
Note: Green: outcomes repeated before and after healing; BH = before healing; AH=after healing. 
 Completed round 1 only Completed rounds 1 and 2 
Questionnaire Item N Mean SD Median 25th % 75th % N Mean SD Median 25th % 75th % P 
Ability of the body to 
fight infection 330 7.82 1.47 8 7 9 415 7.63 1.49 8 7 9 0.04 
Amount of fluid given 325 7.03 1.76 7 6 9 398 6.56 1.79 7 5 8 0.0002 
Nature of exudate from 
the wound 321 6.93 1.89 7 6 9 398 6.46 1.88 7 5 8 0.0003 
Need for blood 
transfusion 322 7.17 1.78 8 6 9 397 6.99 1.68 7 6 8 0.05 
Mild complications 328 6.17 1.84 6 5 7 414 5.85 1.88 6 5 7 0.03 
BH Functioning of the 
heart and circulation 320 7.77 1.33 8 7 9 407 7.49 1.46 8 7 9 0.007 
Liver function 300 7.46 1.59 8 7 9 392 7.25 1.61 8 6 9 0.05 
Inflammatory markers 309 7.39 1.48 8 7 9 394 7.09 1.59 7 6 8 0.02 
BH Costs to NHS 309 6.85 2.07 7 5 9 392 6.46 2.19 7 5 8 0.02 
Number of dressing 
changes 325 7.23 1.59 7 6 9 408 6.72 1.80 7 6 8 0.0002 
BH Number of 
outpatient appointments 
needed 325 6.63 1.71 7 6 8 413 6.33 1.79 6 5 8 0.02 
Smell of the burn wound 319 6.17 2.06 6 5 8 405 5.75 2.15 6 4 7 0.007 
BH Adherence to 
treatment 327 7.32 1.52 7 6 9 413 7.08 1.62 7 6 8 0.05 
Pain when treatment is 
not taking place 322 7.57 1.40 8 7 9 416 7.84 1.23 8 7 9 0.01 
Pain during medical 
procedures 322 7.67 1.39 8 7 9 415 7.93 1.24 8 7 9 0.01 
BH Costs to patient and 
their family 321 7.22 1.72 8 6 9 412 6.98 1.62 7 6 8 0.01 
Bone Density and 
Strength 315 6.50 1.91 7 5 8 407 6.19 1.86 6 5 8 0.03 
AH Costs to NHS 313 6.73 1.98 7 5 9 397 6.27 2.15 7 5 8 0.007 
AH Effect of burn on 
metabolism 322 7.11 1.58 7 6 8 411 6.81 1.68 7 6 8 0.02 
AH Functioning of the 
heart and circulation 319 7.13 1.59 7 6 9 411 6.85 1.64 7 6 8 0.02 
AH Adherence to 
treatment 335 7.47 1.42 8 7 9 420 7.10 1.59 7 6 8 0.002 
Number of creams and 
dressings, time spent in 
pressure garments 333 7.30 1.49 7 6 9 418 7.01 1.66 7 6 8 0.04 
AH Number of 
outpatient appointments 
needed  332 6.69 1.62 7 6 8 414 6.40 1.74 6 5 8 0.02 
AH costs to the patient 





6.4.3 Phase 3: COSB-i Consensus meeting  
Participant demographics: The meeting was attended by 28 HCPs and 4 patients and carers, 
with 19 international HCPs joining by teleconference. Details of the consensus meeting 





















Table 30: Consensus meeting. Participant type and country. 
Country of participant  n  (%) 
UK 28 (60) 
Australia 6  (13) 
USA 4  (9) 
Belgium 1   (2) 
Indonesia 1   (2) 
Japan 1   (2) 
Netherlands 3  (6) 
Norway 1   (2) 
Sweden 1   (2) 
Not reported 1   (2) 
  
Participant group  
Health care professional including commissioners, researchers, charity sector staff 43 (92) 
Patient or carer 4  (9) 
  
Participant group profession / role  
Researcher, academic or journal editor 11  (23) 
Consultant plastic surgeon involved in burn care 5  (11) 
Registrar/junior doctor with at least 6 consecutive months’ burn care experience 2  (4) 
Burn care research nurse or nurse 8  (17) 
Psychologist or counsellor working with patients with burns 1   (2) 
Physiotherapist or occupational therapist working with patients with burns 5  (11) 
Patient and carers 4  (9) 














De-duplication of outcomes due to repetition in short and long-term sections: Prior to 
discussion on outcome merging and the subsequent voting, the final set of 31 items (from now 
on called outcomes) were de-duplicated (for outcomes repeated in short- and long-term 
sections). This resulted in one outcome listed at both times being combined (anxiety about 
the future).  
Merging of outcomes: A discussion to determine outcomes that could be merged due to 
similarity in meaning was undertaken. Items were merged in List A (Table 27) and in List B 
(Table 28). 
The following nine merging actions were taken: 
1. To combine death due to the burn with death from other causes. 
2. To combine multi-organ failure and multi-organ dysfunction into organ dysfunction, as 
these terms are often used interchangeably. 
3. To combine kidney and lung function into the organ dysfunction outcome. 
4. To expand burn wound healing, to incorporate burn wound, grafted wound and donor site 
healing. 
5. To combine procedural and background pain under one heading (acute pain). 
6. To combine scar pain with itch (both address long-term pain, differentiated from acute 
pain) into neuropathic pain. 
7. To merge length of stay in ICU with length of time on a ventilator. 
8. To combine anxiety with psychological impact into psychology. 
9. To merge complications under one heading, with the formal inclusion of sepsis, wound 
infection and thrombosis.  
Of the 20 outcomes, rated as very important (8-9) by more than 70% of both patients and 
HCPs in List A, merging outcomes with a similar meaning resulted in 11 outcomes to vote on 
(Table 31). It was also agreed that any outcomes that were voted as being important by either 
patients or HCPs (List B) should be added to the voting after a similar merging exercise (Table 
32). This resulted in another resulting in six outcomes to add to the voting list. The final list of 




Table 31: Merged Outcomes from List A to vote on in the consensus meeting.  













• Death (all causes) 
• Serious complications (to include sepsis, wound infection) 
• Multi-organ dysfunction (combined with multi-organ 
dysfunction, lung and kidney dysfunction) 
• Scar contractures 
• Ability to do daily tasks (to include walking) 
• Time to heal (combined healing of burn wound and healing of 
grafted wound) 
• Long term pain (to include itch) 






• Wound infection- this was merged under serious complications in 
List A 
• Understanding of treatment received 
• Physical well-being  
• Number of surgeries needed 
• Length of stay in ICU – this was merged with length of time on 
ventilator 
• Immune response to fighting infection 
• Time to return to work/school/previous occupation 
• Anxiety about future, anxiety – these were merged under 
psychology. 
• Donor site healing - this was merged under ‘wound healing’ in List 
A above  
 
Table 32: Merged outcomes (in bold) from List B to be added to List A.  




The final group of 17 outcomes to be voted on, agreed after the merging exercise, are shown in 
Table 33.  
 
6.4.3.1 Consensus meeting voting 
Round 1: Of the 17 outcomes voted in on round 1 of the consensus meeting, those where at 
least 50% of the participants stated that they should be included in the COS, were carried 
through to round 2. Using these criteria, five outcomes were removed prior to the round 2 
vote of voting. Twelve outcomes were carried though to round 2 (Table 33).  
Round 2: In round 2 of the consensus meeting voting, 45 people joined (range 43-45 votes per 
item). Table 34 shows the 12 items that were voted on in round 2 and the seven outcomes 
reached the criteria to be included in the final COS.  
It is important to note that outcomes 1,2 and 4 are short-term and outcomes 3,5,6 and 7 are 
longer-term in relation to the burn injury. 













Table 33: Consensus round 1 outcomes and definitions and percentage voting. 
Shading indicates outcomes not meeting the 50% cut-off for inclusion in consensus meeting 
voting round 2. 
Outcome Definition n voting n (%) voting 
on inclusion in 
COS 
Death Death of a patient from any cause soon after the 
patient is injured. Death due directly to the burn 
injury soon after the patient is injured.  
For example: death due to 'burn shock' or due to a 
burn wound infection or sepsis or death from a heart 
attack. 
41 36 (88) 
Organ failure/ 
dysfunction 
Whether the burn causes several of the patient's 
organs to fail/not work at all or stop working well 
(dysfunction).  
For example: kidney failure alongside liver failure, 
where it is unlikely to get better, or will need long-
term care or poor kidney function and poor liver 
function at the same time. This is likely to get better 
following treatment.  
39 28 (72) 
Serious complications Includes: blood clot, sepsis, wound infection but 
not organ dysfunction/failure.  
39 36 (92) 
Scar contractures The effect of the burn scar on a patient's ability to 
move joints (contractures).  
For example: inability to straighten arm, difficulty 
moving fingers normally, limited range of motion of 
joints.  
41 28 (68) 
Daily tasks A patient's ability to carry out normal daily tasks. 
This includes walking.  
For example: dressing, washing, making food or 
drinks. 
41 36 (88) 
Time to heal (incl. 
wound graft and donor 
site) 
How quickly a patient's burn wounds heal. This 
includes wounds after receiving a skin graft (A skin 
graft is when healthy skin is taken from another 
party of the body and placed over the burn wound 
to help it heal).  
For example: how many days or weeks does it take 
for the burn to heal completely or how well a burn 
that has needed a skin graft heals. 
41 29 (71) 
Pain acute Pain in the burn wound. This includes background 
and procedural pain.  
For example: pain all the time, pain at night. 
39 23 (59) 
Pain long-term The amount of pain caused by a burn scar. This 
includes itch. 
41 31 (76) 
Appearance Patients' appearance after a burn injury.  
For example: appearance of the scar, facial 
appearance, body image.  
44 27 (62) 
Patient psychology The psycho-emotional effect a burn has on patients. 
Distress and anxiety can often be consequences of a 
burn and affect patient well-being.  
For example: anxiety triggered by reminders of how 
the burn happened or low self-esteem in case of a 
visible scar. 




Growth The effect a burn has on a child's growth.  
For example: not achieving potential height, slowing 
of growth. 
43 4 (9) 
Understanding 
treatment 
How much a patient understands of the treatment.  
 
43 8 (18) 
Physical wellbeing General Physical well-being 
 
42 20 (47) 
Immune response Ability to fight infections 42 6 (14) 
Number of surgeries Number of surgeries 43 16 (37) 
Time to return to 
work/school/previous 
occupation 
Time to return to work/school/previous occupation 43 34 (79) 
Length of stay in ICU This includes length of time on a ventilator.  
 




Table 34: Consensus meeting voting round 2 outcomes. 
Shading shows those outcomes to be included in the final COS. 
Outcome Numbers 
voting 
Numbers (%) voting 
to include in COS 
Death 43 34   (79) 
Organ failure/ dysfunction 44 20   (46) 
Serious complications including wound infection, 
sepsis or thrombosis 
45 41    (91) 
Scar contractures 44 23    (52) 
Ability to do daily tasks 44 36    (82) 
Time to wound healing (including graft or donor 
site). 
44 27    (61) 
Pain acute 45 21    (46) 
Pain long-term including itch 45 30    (67) 
Patient psychology 45 37    (82) 
Physical wellbeing 45 15    (33) 
Time to return to work or school or previous 
occupation 
44 37   (84) 










The seven outcomes reaching the threshold for inclusion were presented to the meeting and 
agreed as the final core outcome set and are shown in Table 35. The final COS was sent to the 
group after the meeting via a consensus report so that people could have further time to 
consider their decisions and confirm (Appendix L). Participants confirmed agreement. All 



























Table 35: COSB-i Final Core Outcomes. 
1. Death: to include death from any cause and death from the burn. 
2. Serious complications: to include wound infection, sepsis, venous 
thrombosis. 
3. Ability to do daily tasks: to include walking. 
4. Time to heal: to include wound healing, grated wound healing and donor 
site wounds. 
5. Neuropathic pain and itch. 
6. Patient psychology: to include anxiety and anxiety about the future. 





This study is the first to develop a COS to standardise, but not restrict, outcome reporting in 
trials of burn care interventions. It was developed throughout, using shared decision-making, 
by UK patients and international HCPs. The COS was prioritised from an initial list of 1,021 
clinical and patient-reported outcomes, generated systematically from three information 
sources. These individual outcomes were grouped into 88 questionnaire items. To achieve 
prioritisation of these items in terms of importance to stakeholders, a modified Delphi survey, 
consisting of two on-line questionnaire rounds with a final face-to-face consensus meeting 
was undertaken. Using a web-based survey to achieve consensus, meant that many 
international stakeholders were able to participate. Voting in the final consensus meeting 
generated a COS that all stakeholders supported. The final COS of seven outcomes is 
illustrated in Table 35. The COSB-i COS is a new COS for burn care research. It is hoped that 
the chosen  outcomes, should be assessed and reported, in all trials assessing the effect of 
interventions in burn care.  
New COS are increasingly being developed, and are widely recognised in specialties such as 
dermatology, rheumatology, paediatric, breast and colorectal surgery(111, 419, 541, 587-590). 
Funding bodies are now advocating the use of COSs, and uptake among triallists is 
increasing(591). Importantly, COSs are now more commonly developed using international 
participants, with the recognition that global agreement will increase dissemination of the 
COS, support the applicability of the COS in global healthcare settings and make it more likely 
that they will be used in future trials wherever these take place (554, 592, 593). The COMET 
Handbook highlights the logistical and organisational challenges of international COS 
development projects, as well as issues regarding generalisability of small international 
participant numbers(115). This COS included 794 Delphi survey participants of which 668 
were international HCPs, researchers, journal editors and commissioners, from 77 countries of 
all four world income groups. The large numbers of international participants, and variation in 
country income status and participant type recruited in this COS, compared to other COSs, 




The core outcomes chosen for this COS, clearly reflect priorities in recovery for both patients, 
carers and HCPs. The likely reason for this, was the shared decision-making used throughout 
the development of the COS. This diversity of stakeholder involvement is increasingly 
common in COS development(554, 598). Shared-decision making has a more traditional 
definition as discussed earlier in this chapter. The author of this this thesis believes that the 
use of the term, implies joint decisions in study methodology and outcome choice, weighing  
the views of all stakeholder groups equally. This is the way this COS has been developed. 
Interestingly, stakeholders agreed on outcomes that span both short and long-term recovery. 
Death, pre-specified acute complications including infection and time to heal, are outcomes to 
measure the effect of interventions in short-term efficacy RCTs. The other four outcomes, 
(ability to undertake tasks of daily living, neuropathic pain and itch, psychological well-being 
and time to return to work, school or previous occupation), are patient-important and more 
likely to be of value when assessing clinical interventions in longer-term pragmatic trials. A 
remaining question, is whether all the COSB-i core outcomes should be in be used in all trial 
types? In other words, would it be useful to develop or encourage the use of the short-term 
outcomes in efficacy trials and the longer-term outcomes in pragmatic trials. This is an area 
for future work after completion of this thesis. 
The outcomes chosen, are similar in type and number to those agreed in other trauma-related 
COSs. In a COS for traumatic dental injuries, the outcomes chosen include healing, pain, 
complications (side effects), functional status of teeth and quality of life including return to 
work. It is interesting that this COS also covers outcomes in both short and longer-term 
recovery(599). The COSB-i outcomes are also similar to the core outcomes chosen for trials of 
interventions in hip fracture management(600). These include mortality, pain, activities of 
daily living, mobility, and health-related quality of life. The participants for the whiplash 
injury COS agreed on six core outcomes: physical functioning, perceived recovery, work and 
social functioning, psychological functioning, quality of life, and pain(601). The differences are 
in the increased granularity of the outcomes in COSB-I, compared to those in the whiplash 
COS. Interestingly, our COS also overlaps with outcome choice for COSs in non-traumatic 
healthcare areas(602, 603). This implies that many core outcomes are similar across different 




6.5.1 Strengths and limitations 
The broad range of stakeholders that participated in the Delphi survey is one of the strengths 
of this study (553). Diversity is present in terms of UK patient (and carer) age, cause, severity 
of burn, time after injury, and the involvement of international HCPs of different disciplines 
and from a variety of countries of different income status. A related strength is that every stage 
of the process, including merging, addition and exclusion of outcomes, and final decision-
making, was performed by consensus and always included patient and/or carer 
representation. The impact of involving multidisciplinary clinical staff, researchers, 
commissioners, patients, parents and charitable organisation representatives to be involved in 
all aspects of this study, will allow easier and more influential and effective dissemination, a 
more meaningful result for international research and an emerging shared decision-making 
burn network researching outcomes after injury(604).  
Further strengths lie in the comprehensive search for potential outcomes, through three 
sources, including patient-reported outcomes. The study has followed the standards set for 
COS development and previous practice endorsed by the COMET initiative. Methodology 
changes from the published protocol, including the involvement of international HCPs and a 
change from three survey rounds to two, were based on consensus being achieved earlier than 
anticipated. All protocol changes have been explicitly described and agreed by the steering 
group. We agreed at steering-group level that outcomes would be dropped from the first 
Delphi survey round if they did not fulfil pre-specified and published criteria. There is 
discussion in the academic literature as to whether this is the correct methodology. Dropping 
outcomes from round one allows round two to be shorter and less burdensome to 
participants. Maintaining all the round one outcomes for round two, will allow aprticpants to 
see other participants’ views on outcomes that may have been dropped if the former 
methodology is followed.  
A potential study limitation is that the descriptive text detail for the semi-steucture interviews 
could have been broadened to give more detail on the qualitative methodology. The aim of 
this work was to extract outcomes to add to the COS long-list and not to develop in-depth 




at this stage. A further limitation of the study was the impracticality of including international 
patients. Recruiting global patients incurs costs and time for questionnaire translation and 
validation, along with ethical research permissions to achieve in many countries. This was 
beyond the scope of this project and pre-specified. We would aim to consider international 
patients’ views in a future study, with several countries already expressing interest. 
Other next steps will include agreement on the timing of outcome assessment, definitions and 
parameters of the individual outcomes and the agreement of measures to assess the seven 
chosen outcomes.  
Evidence to support burn care decision-making is vital, as burn care is currently inconsistent. 
This impacts patient management and results in varying healthcare outcomes. Reporting data 
for these core outcomes, will make burn trial design more relevant, the ability to synthesise 
evidence more effective and reduce research waste. 
6.6 Conclusion 
This is the first study, using rigorous methodology and international shared decision-making, 
to agree a minimum set of core outcomes to be reported in trials assessing burn care 
interventions. The development of this COS was undertaken to promote the standardised 
reporting of outcomes and facilitate the robust evaluation of burn care. It is recommended 
that future trials include measures of these seven outcomes. This will enable consistent 
reporting and effective data synthesis to support evidence-based healthcare for patients with 
burns. Future work is needed to validate the COS internationally and determine how these 
outcomes are best measured and timed. 
The next chapter will summarise the work presented in thesis, answer the thesis research 




Chapter 7 Discussion 
7.1 Introduction 
The aim of this thesis is to explore the reasons that limit researchers’ ability to synthesise data 
in global burn care.  
The research question that this thesis has aimed to answer is:  
Is it possible to increase the provision of data from burn care randomised controlled trials, that 
can be synthesised into evidence to answer clinical questions, through the development of a Core 
Outcome Set (COS)?  
A COS is a scientifically agreed set of the most important outcomes. These outcomes are 
intended to be reported consistently across trials of one healthcare area, and developed to 
improve evidence synthesis(71). Effective evidence synthesis will inform global burn care 
treatment strategies. The knowledge will reduce wasted research effort and improve patient 
outcomes through standardisation of evidence-based care. The research presented here has 
demonstrated specific challenges in aggregating data from RCTs in burn care research. All the 
issues relate to outcome reporting. The work has highlighted the need to understand how to 
resolve these issues, to achieve a true understanding of the effects of interventions in burn 
care. One solution to the methodological challenges presented in this thesis is the 
development of an international COS for burn care.  
This chapter summarises and critically explores the work conducted for the thesis. The 
context and relevance of the research findings are considered in the setting of the global 
challenge of burn injury. The impact of the research findings on burn care is presented, 
alongside current evidence in other clinical areas. This chapter examines the benefit to clinical 
decision-making, by optimising outcome selection, definition and timing of outcome 
assessment in RCTs, through the development of a COS. Ideas to take the work forward after 




The following are the main thesis findings, which are detailed in Table 36. The strengths and 
limitations of the research are separately presented for each study, in each chapter.  
The under-pinning methodological work in this thesis has demonstrated, through four 
literature reviews, a variation in outcome reporting in burn care. This is novel. Although 
variation in burn care clinical practice and patient recovery outcomes, has been well 
recognised, the challenges with outcome reporting heterogeneity have not been studied.  
The systematic reviews showed that: 
1. There is a wide variation in the choice of outcomes across trials in burn care research. 
2. Investigators have difficulty in defining a unique outcome, through: 
a. A variation in numbers and type of indicators to define one outcome (e.g. burn wound 
infection (BWI)).  
b. A variation in the timepoints for assessment of the same outcome across trials in burn 
care.  
This work has proposed that one solution to these methodological challenges, is the 




7.2 Summary of findings. 
Table 36: Summary of findings from the work presented in this thesis. 
Thesis objective. Study undertaken to 
answer thesis 
objective. 
Study findings. Clinical implication and 
impact of the findings. 
Comments and future work. 
1. An exploration of the 
variation in clinical 
outcome reporting 
across burn care 
RCTs. (Chapter 
Two). 
Systematic review (SR) 
of clinical outcomes 
reported in burn care 
RCTs over five years.  
Numbers of burn care RCTs 
across a recent five-year 
period reported 955 unique 
outcomes extracted from 
147 trials. This study 
demonstrated a variation in 
clinical outcome reporting 
across RCTs in terms of 
outcome choice, timing of 
assessment and definition 
of each outcome. 
The magnitude of the 
variation of clinical outcome 
reporting will impact on 
evidence synthesis and limit 
the evidence base in burn 
care research. This limit to 
the evidence produced from 
trials will maintain the 
variation in patient care and 
outcomes. This is the first 
study to demonstrate this in 
global burn research. 
Challenges and future work: 
• The level of granularity required to define a single (unique) 
outcome. 
• Understanding and agreeing the above, would allow an 
accurate determination of the magnitude of outcome 
variation across trials (defined as ORH in Chapter Three). 
• Variation in the timing of outcome assessment impacts the 
numbers of outcomes reported across and within trials. 
There is a need to agree a small number of assessment 
timings for each core and non-core outcome. 
• Definitions of the same outcome vary across trials. There is a 
need to agree international definitions for core and non-core 
burn outcomes for consistent reporting across trials. 
2. The development of 
an understanding of 
what makes an 
outcome unique. 
(Chapter Three). 
SR to examine methods 
used to extract and 
combine outcomes with 
the same or similar 
meaning, from 
published research 
papers to inform how to 
establish a reproducible 
Methods were proposed for 
the grouping of similar 
outcomes into unique 
outcomes, following 
verbatim outcome 
extraction from a literature 
review to develop a COS.  
 
Clarifying what makes one 
outcome different from 
another; what makes an 
outcome unique. This 
knowledge directly impacts 
the magnitude of outcome 
reporting variation across 
trials. 
The start of an international attempt to propose a definition for a 
unique healthcare outcome and how this impacts COS long-lists 
and ORH. This work will be taken further through COMET and 





list of unique outcomes. 
Work to define a unique 
outcome and define 
outcome reporting 
heterogeneity (ORH).  
Working definition was 
proposed for a unique 
outcome and ORH.  
3. An analysis of how 
the variation in the 
definition of a 
specific outcome 
(acute burn wound 
infection (BWI)) 




SR to explore how 
challenges with the 
definition of one unique 
outcome (BWI) impacts 
evidence synthesis. 
The number and type of 
clinical and patient-
reported indicators to 
define BWI across trials 
varied significantly.  
Proposed definitions for 
clinical indicator and Core 
Indicator Set were 
discussed through this 
work. 
This is another type of 
variation in outcome 
reporting that impacts data 
collation and comparison. It 
limits the ability to interpret 
effects of interventions in 
burn care to detect or treat 
BWI. 
A pilot study to determine a CIS (minimum set of indicators 
required to be reported when using BWI as an outcome) has been 
undertaken separately from this thesis. Further work is required 
to agree this internationally.  
4. An analysis of how 
variation in the 
timepoints for the 
assessment of unique 
outcomes across 
trials impacts 
relevance to patients 
(Chapter Five). 
SR to understand any 
variation in outcome 
assessment timing 
across trials of burn care 
interventions and the 
relevance of this to 
patients.  
Timing of outcome 
assessment is used in a 
variable manner to define 
unique outcomes. 69% of 
outcomes were last 
assessed at less than six 
months after injury. Only 
one study followed patients 
for more than three years. 
This is the third type of 
variation in outcome 
reporting across trials. It 
impacts aggregation of data 
and patient relevance.  
Timing of outcome assessment is not an important determinant 
of a unique outcome (as discussed in Chapter Three). However, 
when used to determine the measure for the final COS, it is 
important in terms of collation and comparison of data, in terms 
of relevance to patients and in the use of the outcome in 
effectiveness or efficacy trials. 
 
Further work needs to determine whether a short and long-term 
COS for burn care research is required. 
5. A consensus on 
which burn care 
outcomes are most 
important to 
patients, carers, and 
international burn 
HCPs (Chapter Six). 
Development of an 
international Core 
Outcome Set for burn 
care research (COSB-i).  
A consensus on which burn 
care outcomes are most 
important to stakeholders 
has been achieved.  
Seven outcomes were 
agreed. 
 
The COSB-i will standardise 
outcome reporting in burn 
trials, while not limiting the 
reporting of other outcomes. 
This will allow more effective 
evidence synthesis, impacting 
positively on patient care and 
outcomes. 
Future work to implement the COS: 
• Agree the measures for COSB-i. 
• Validate the COS with international patients. 
• Implement the COS though work with international 
stakeholders to ensure uptake and embedding into future 




7.3 Relevance and context of research findings 
It was known that there was a lack of standardised care for patients with burns, prior to the 
work undertaken for this thesis. Outcomes for these patients vary internationally, in terms of 
function, cosmesis and psychological well-being, despite the same injury severity. It is 
accepted that a lack of evidence-based care impacts on this variation in patient outcomes.  
Recent publications provide the evidence to support this issue. Research shows that burn 
management varies within and between countries in terms of mortality, surgical and scar 
management and rehabilitation provision (13, 30, 605-607). Kazis has shown that adherence 
to 36 pre-specified burn care process indicators varies across the United States (50). The 
variation was shown to occur in burn evaluation, resuscitation, debridement, critical care, 
psychosocial and pain control, and reconstruction surgery. Papers, written by the author of 
this thesis, link a similar variation in UK practice with variation in patient outcomes.  
• Patients with the same severity small area burns vary in their need for skin grafting and 
future scar presence and quality.  
• Outcomes of patients managed with different fluid management with the same severity 
burns vary in terms of length of hospital stay. 
• Variation exists in the diagnosis of burn wound infection (BWI) and the use of antibiotics 
(11, 12, 208, 608). 
Advances in clinical practice have led to improved patient outcomes after burn injury. These 
advances have resulted from internationally agreed principles in resuscitation, improved 
coverage of wounds, treatment of infections, better management of the hypermetabolic 
response and early functional and psychological rehabilitation(16, 609). However, high quality 
evidence, in terms of valid data from systematic reviews, is still lacking for the clinical detail of 
these strategies(610-613). New surgical techniques and advances in understanding of the 
wound environment, critical care and dressing technology, continue to be introduced(522, 
614). Synthesised evidence from well-conducted and reported RCTs, for short and longer-term 




Achieving high quality evidence to answer clinical questions is known to be challenging in 
burn care research. Since 2000, 12 Cochrane reviews have had direct relevance to the 
management of patients with cutaneous burns(8, 10, 89, 237-245). None could draw firm 
conclusions due to methodological issues including heterogeneity of outcome reporting. Table 
37 highlights issues with outcome selection, measurement and reporting in Cochrane reviews 
directly related to burn care. 
If clinical-effectiveness cannot be determined through evidence-based medicine, care will not 
be optimised, and patient outcomes will remain variable. Blocks to effectively synthesising 
evidence will result in persisting clinical uncertainty and research waste(616-620). One of the 
blocks or challenges to evidence synthesis is the variation in outcomes reported across trials 
and the need for a COS in burn care research  





Table 37: Methodological issues in outcome reporting in burn care Cochrane reviews. 
Cochrane reviews on 
burn care listed in 
ascending date order. 
Outcomes assessed Outcome reporting methodology (extracted verbatim) Conclusion 
Hyperbaric oxygen 
therapy for thermal 
burns (HBOT)2004. 
(242) 
• Mortality rate. 




• “There were no outcome measures in common with the two included 
trials so pooling of data was impossible.” 
“This systematic review has not found enough 
evidence to support or refute the effectiveness 
of HBOT for the management of thermal 
burns.” 
Early versus delayed 
enteral nutrition 
support for burn 
injuries 2006. (243) 
• All-cause mortality at 
end of follow-up.  
• Length of hospital 
stay. 
• Frequency of 
infection. 
• Number of adverse 
events. 
• “There was wide variation amongst the studies in …. the type of 
clinical, metabolic and hormonal outcome measures used to 
determine effectiveness.” 
“…. need for ongoing future research that 
includes conducting large multi-centre, 
randomised, double-blind studies, coupled 
with a number of key outcome measures is 
needed which in turn would allow for pooling 





protein, high-fat enteral 
feeds for burns. 2012. 
(245) 
• Mortality. 
• Incidence of sepsis or 
pneumonia. 
• Time to healing. 
• Number of days on 
ventilator. 
• “No conclusions could be drawn about the risk of death in patients 
receiving the different feeding regimens.” 
• “No meta-analysis could be performed on the remaining outcomes 
data due to lack of similar outcomes reported between the two 
available studies.” 
“The available evidence is inconclusive 
regarding the effect of either enteral feeding 
regimen on mortality.” 
Dressings for superficial 
and partial thickness 
burns 2013. (8) 
• Time to complete 
wound healing 
/proportion of burns 
completely healed in 
a specified time 
period. 
• Change in wound 
surface area over 
• “The studies summarised in this review evaluated a variety of 
interventions, comparators and clinical endpoints and all were at risk 
of bias.” 
• “The studies summarised in this review evaluated a variety of 
interventions, comparators and clinical endpoints and all were at risk 
of bias.” 
“In conclusion, a number of dressings may 
have some benefit over other products in the 
management of superficial and partial 
thickness burns. However, our confidence in 
these conclusions is reduced by the low 
quality of the evidence and small sample sizes 





wounds partly healed 
in a specified time 
period. 
• “The evidence for the effectiveness of the different dressings …..is 
limited by the inconsistent measurement and reporting of this 
outcome.”  
• “……the time to wound healing data …… were often not reported in a 
way that allowed the results to be reproduced by the review authors.”  
• “Poor measurement of outcomes that are important”.  
• “The limited use of objective outcome measures and insufficient 
reporting of results makes the analysis and usefulness of these results 
doubtful.” 
Antibiotic prophylaxis 
for burn wound 
infection 2013. (238) 
• Burn wound 
infection. 
• Invasive infections.  
• Infection-related 
mortality. 
• Adverse events.  
• “Consensus is needed amongst researchers and clinicians regarding 
valid and reproducible criteria for diagnosis of infection of the burn 
and a consistent and standardised approach to outcome reporting.” 
• “The results given in this review are still limited; few data could be 
pooled in most comparisons.  
• “Outcome measures and follow-up times were heterogeneous, or not 
even defined, which made it difficult to interpret the results of the 
review and to determine their applicability.” 
• “There was a high degree of heterogeneity between studies in terms of 
interventions evaluated, types of burn, and outcomes assessed. This 
made it difficult to determine the effectiveness of antibiotic 
prophylaxis.” 
“The available evidence is limited …….” 
Topical treatment for 
facial burns. 2013. (239) 
• Time to complete 
wound healing. 
• Change in wound 
surface area over 
time, or the 
proportion of the 
burn wound surface 
area that had healed 
within a specified 
time period. 
• Wound infection. 
• “Heterogeneity of interventions and outcomes prevented pooling of 
data.”  
• “Future trialists might give some extra thought to the outcome wound 
healing, as this outcome can be reported in numerous ways and it is 
not always analysed correctly (i.e. survival analyses).” “Four studies 
included time to complete wound healing as an outcome of interest 
but differed in their definition of this outcome.” 
• “Ideally, all trialists should use the same measurement for wound 
healing, and as a result, allow comparisons to be made.” 
• “Heterogeneity of studies with regard to interventions and outcomes 
prevented assessment of reporting biases and limited data synthesis 
to a narrative overview, structured by the type of comparison.” 
“There is insufficient high quality research 
and evidence to enable conclusions to be 
drawn about the effects of topical 
interventions on wound healing in people 





growth hormone for 
treating burns and 
donor sites. 2014. (237) 
• Burn wound healing.  
• Donor site healing.  
• Wound infection (as 
defined by the trial 
authors). 
• Mortality rate. 
• “Not all trials reported on all outcome measures.”  
• “Twelve of the excluded studies addressed none of the pre-specified 
outcome measures.”  
• “The included studies often could not be pooled because they used 
different methods to measure outcomes.” 
• “For the primary outcome of the healing rate of burn wounds in 
adults, four studies …. measured the outcome in three different ways.” 
• “Burn scar formation: Three of the studies involving children reported 
this outcome, but these studies could not be pooled because they 
used different methods to measure the outcome.” 
“This evidence is based on studies with small 
sample sizes and risk of bias and requires 
confirmation in higher quality, adequately 
powered trials.” 
Negative pressure 
wound therapy for 
partial thickness burns 
(NPWT). 2014. (10) 
• Time to complete 
healing. 
• Rate of change in 
wound area. 
• Proportion of wound 
completely healed 
within the trial 
period. 
• “We undertook a narrative synthesis of results, as the absence of data 
and poor reporting precluded us from carrying out any formal 
statistical analysis.” 
• “Time to complete healing: no data were reported for this outcome. 
• “Proportion of wounds completely healed within the trial period: no 
data were reported for this outcome.”  
• “Other weaknesses included: the absence of reporting on clinically 
relevant outcomes, such as rate of healing, time to complete healing, 
rate of change in wound area, and proportion of the wound 
completely healed within the trial period; lack of clarity regarding the 
definition and reduction of oedema formation.” 
“There was not enough evidence available to 
permit any conclusions to be drawn regarding 
the use of NPWT for treatment of partial-
thickness burn wounds.” 
Immuno-nutrition as an 
adjuvant therapy for 
burns. 2014. (241) 
All-cause mortality. • “Overall mortality rate was reported in 13 studies but was not reported 
in three. Fourteen studies reported hospital length of stay, but two 
did not.”  
• “One study reported only hospital length of stay as “Length of stay per 
percentage burn”.”  
• Five studies reported on rate of burn wound infection. Rates of other 
non-wound infections such as pneumonia, urinary tract infection and 
bacteraemia were reported in four studies.”  
• “….some of the outcome measures used are subject to a high degree of 
variability (e.g. time to healing). It is for this reason that only four 
included outcomes were used in this review, with the greatest 
quantity of evidence found for mortality and length of stay.” 
“Although we found evidence of an effect of 
glutamine on mortality reduction, this finding 




• “Many articles were excluded because they reported only biochemical 
markers of immune activity—not clinically significant outcomes.” 
Interventions for 
treating phosphorus 
burns 2014. (244) 
• Death. 
• Time to complete 
wound 
healing/proportion 
of burns completely 
healed in a specified 
period of time. 
 
“Neither study reported the primary outcome of wound healing.” “The conduct of high-quality randomised 
controlled trials to address the uncertainties 
around the management of people with 
phosphorus burns, is highly desirable…”. 
Intravenous lidocaine 
for the treatment of 
background or 
procedural burn pain. 
2014. (240) 
• Pain measured by a 
visual analogue scale 
(VAS) or verbal 
rating scales (VRS), a 
numerical rating 
scale, or other 
validated assessment 
tool. 
• Time to re-
medication. 
• Requirements for 
rescue analgesia. 
• “No information is available from the published RCTs or CCTs on 
clinically relevant primary outcome measures which can influence 
current burns care practice and management.” (2007 version) 
• 2014 version: only one RCT included. 
“As current clinical evidence is based on only 
one RCT as well as case series and reports, 
intravenous lidocaine must be considered a 
pharmacological agent under investigation in 
burns care, the effectiveness of which is yet to 
be determined with further well-designed and 
conducted clinical trials.” 
Antiseptics for burns 
2017.(89) 
Primary outcomes were 
wound healing and 
infection. 
• “Primary outcomes were not reported or were reported incompletely.” 
• “Most studies reported some data on wound healing with this being 
presented in different ways.”  
• “Usable data on key outcomes were limited and often unavailable.”  
• “Much of the evidence is of low certainty or very low certainty 
because of indirectness and imprecision.” 
“It was often uncertain whether antiseptics 
were associated with any difference in 




7.4 Impact of the research findings 
The primary output from this thesis, is a COS for burn care research. Methodological work on 
outcome reporting, has under-pinned this work. The impact of both are described below. 
 
7.4.1 Methodological work 
7.4.1.1 Impact of the variation in outcome choice across trials in 
burn research (relating to Thesis Objective 1) 
The literature review undertaken in Chapter Two, is the first to demonstrate, using systematic 
methodology, the scale of heterogeneity of outcome reporting in global burn care research(4). 
Across 147 RCTs, 955 different, unique outcomes were reported. The high number of 
outcomes reported across the studies, is supported by reviewers of burn care RCTs, who have 
consistently shown that there is difficulty in collating evidence to support clinical care, despite 
increasing numbers of trials(8, 219, 220, 240, 446).  
A published literature search, including 50 studies (1966–2003) on short-term and long-term 
functional outcomes after burn injury, was unable to summarise current knowledge due to the 
variety of outcomes assessed across trials. The authors stated that “the current state of 
knowledge on the functional outcome of burns was hard to summarise, due to the wide 
variety in study designs and outcome assessment methods”(150). A Cochrane review of 30 
randomised controlled trials (RCTs) concluded that it was impossible to draw firm 
conclusions about the effectiveness of burn dressings, as the studies evaluated a variety of 
clinical end points(8). A 2012 systematic review on scarring, identified 48 articles. Most had 
methodological limitations including a lack of standardised outcome measures, which was a 
major barrier to the authors drawing conclusions(33). Between 2012 and 2017, nine Cochrane 
reviews with direct relevance to the management of patients with burns were published(8, 10, 
89, 237-241, 245). None of the reviews could draw firm conclusions about the topic studied, 




undertaken in burn injury over the last three years. One reason for this is likely to be the scale 
of inconsistency in outcome choice across burn trials, demonstrated by the systematic 
literature review in Chapter Two.  
Burn care research is not an outlier in terms of the presence and scale of this variation in 
outcome reporting. Inconsistency in outcome choice and reporting across trials is supported 
by the literature in other healthcare areas(227, 621-623). In studies, looking at pediatric 
eosinophilic esophagitis, sub-arachnoid haemorrhage, Hirschsprung’s disease and colorectal 
cancer surgery, the number of outcomes reported across the included reviews varied from 25 
(from 11 studies), 95 (from 35 studies), 285 (from 129 studies) and 766 (from 194 studies) 
respectively. In the literature review in Chapter Three, the number of reported outcomes 
across studies in COS development reviews, varied from 12 to 5,776 (median: 82 IQR: 261). 
The variation in numbers of outcomes reported is striking. Possible reasons for this variation 
are discussed further below, and in Chapters Two and Three.  
The impact of this finding in burn research, is the need for an international agreement on a 
minimum set of the most important outcomes through the development of a COS. Data on 
these outcomes, despite the intervention chosen, need to be reported in all trials of burn care. 
 
7.4.1.2 Impact of the need to understand the nature of a unique 
outcome (relating to Thesis Objective 2) 
The variation in outcome choice and numbers of outcomes reported in COS development 
literature reviews, can be partially explained by the difficulty in determining what makes an 
outcome unique. In other words, what makes one outcome different to another. Difficulties in 
understanding the nature of a unique outcome is an important challenge when developing a 
valid long-list for COS development, and in reporting an accurate magnitude of the variation 
in outcome reporting across trials. It also impacts the identification of trials reporting the 
same outcome, and comparison and collation of treatment effects across trials.  
In this thesis, the definition of an outcome reported by Chan et al. was initially used: “a 




(116). The use of this, and other definitions, by COS researchers, explain what a generic 
outcome is. They do not explain the difference between one unique outcome, and another 
outcome with a similar meaning. Different researchers define a unique outcome in different 
ways. The results of the review in Chapter Three illustrate this, by demonstrating a variation 
in the methods used in COS development studies to combine outcomes with the same 
meaning. The work in Chapter Three makes the definition of an outcome by Chan difficult to 
use in COS development literature reviews and in this thesis. The work undertaken suggests 
that this should be amended to:  
“a trial outcome is one that has original meaning and context”, 
 with the word outcome as defined by Chan:  
“a variable measured to assess the efficacy or harm of an intervention.” 
The COMET Initiative has identified a lack of clarity in other aspects of COS development: the 
scope, stakeholder involvement and consensus processes (284, 285, 288, 289). COMET has 
worked to provide methodological guidance for these COS stages, through the COMET 
Handbook and Standards for COS development (COS-STAD) (115, 286-291). They have not 
focussed to a similar degree on the early part of COS development. Verbatim outcome 
extraction is recommended: “The first step is to group these different definitions together 
(extracting the wording description verbatim) under the same outcome name” (71, 115). 
However, a lack of detail exists in the COMET methodology for grouping similar outcomes 
and variation in the level of granularity used in the grouping process is common(574, 624). 
Some researchers developing COSs, use a high-level of outcome definition (e.g. wound 
infection), while others report more detailed outcomes in their long-lists (e.g. numbers of 
bacteria in the wound). A reproducible and quantifiable COS long-list of unique outcomes is, 
therefore, difficult to produce. This results in inaccurate numbers of unique outcomes 
reported across trials.  
The magnitude of outcome reported heterogeneity (ORH) quoted by COS researchers, will 
depend upon outcome grouping methodology (definition of a unique outcome) and the 
inclusion criteria for the systematic review(625). The work in Chapter Three, demonstrates 
that no true understanding of the scale of outcome reporting variation can be presented in 




number without scale or context. It will not be possible to quantify this variation in burn care 
or other research areas, until a definition of a unique outcome and consistent methodology for 
grouping similar outcomes is agreed.  
A further impact, is that there is no guidance on determining when outcomes that appear to 
be similar, are similar enough to combine and inform a meta-analysis. From the Cochrane 
handbook: “meta-analysis should only be considered when a group of studies is sufficiently 
homogeneous in terms of participants, interventions and outcomes to provide a meaningful 
summary”(626). Clinical heterogeneity is defined as “differences in participant, treatment, or 
outcome characteristics or research setting”(627). Clinical heterogeneity can lead to statistical 
heterogeneity, inaccurate summary effects and findings. The latter can be mitigated by using, 
for example, pre-planned subgroup analyses. The better option would be to use the whole 
sample and ensure that outcomes are reported in a standardised and consistent manner.  
The inability to determine a magnitude for ORH, will prevent prioritisation of the topics 
requiring a COS. This is important, as the costs and researcher time for COS development, are 
significant and should be channelled into those healthcare areas that are most needy in terms 
of the scale of ORH across trials. The novel work in Chapter Three aimed to resolve this issue 
by suggesting a working definition for defining a unique outcome and ORH. Draft 
methodology for the grouping of verbatim-extracted outcomes into unique outcomes is also 
proposed.  
Chapters Four and Five, describe two other types of heterogeneity in outcome reporting. In 
these examples however, the variation is regarding a single outcome, rather than the choice of 
different outcomes, across trials.  
 
7.4.1.3 Impact of a variation in the definition of one single 
outcome across trials (relating to Thesis Objective 3) 
Another challenge to outcome reporting, is the variation in the definition of a single outcome 
across trials. An example is burn wound healing, which was defined in 166 different ways 




Understanding and standardising terminology for defining an outcome is an important impact 
of the work undertaken for Chapter Four. Clinicians use one or more indicators to diagnose 
burn wound infection (BWI), as there is no reference standard for the clinical diagnosis. A 
clinical indicator was defined in Chapter Four, as a clinical sign, laboratory test or patient-
reported symptom. There is no agreement on the type or number of indicators required to 
define BWI in the research literature. Some authors have used a formal collection of indicators 
(a clinical consensus diagnostic tool) for reporting. However, these tools are not in standard 
clinical use and incorporate several practical challenges. The review in Chapter Four showed 
that more than one third of studies reporting BWI as an outcome, did not report how this 
outcome was defined, despite reporting data on its presence. In those studies that did report a 
definition for BWI, there was considerable heterogeneity in the numbers and types of 
indicators used. This issue will impact the assessment of treatment effect sizes across trials 
and is a novel finding. 
This heterogeneity in the definitions of one outcome across trials, in other clinical areas, is 
common. Bruce et al. describes 41 different definitions of surgical site infections in 90 studies 
which reported this as an outcome(223). The Centres for Disease Control and Prevention 
criteria are the most widely implemented standard definition for surgical site infection(628). 
Another frequently used quantitative scoring system for surgical site infection is the ASEPSIS 
score (Additional treatment, presence of Serous discharge, Erythema, Purulent exudate, 
Separation of the deep tissues, Isolation of bacteria and duration of Stay)(629). However, 
despite more clarity in the definition of wound infection in surgical sites compared to burns, 
the incidence of surgical site infection across trials, still differs according to the definitions 
used(630).  
In COS development, Blencowe et al., in a review of outcomes reported in trials of 
oesophagectomy management, showed that anastomotic leak was assessed in 80 articles. 
Definitions were reported in 28 of the 80 studies. Of these, only six were similar. In another 
paper by Bruce et al., a total of 56 definitions for anastomotic leak were identified from 97 
studies. This was observed, despite publication of a standard definition two years before the 
beginning of the review(224). Similar findings were noted by Jacxens and Potter in varying 
and inconsistent definitions for post-surgical complications, including humeral loosening and 




The impact of heterogeneity in the definition of one outcome, will limit the validity of 
evidence synthesis in the size of the effects of interventions on the presence of this outcome. 
This will hinder the identification of the most effective treatments for patients with a common 
complication after burn injury. The impact of this work has led to the need to develop a Core 
Set of indicators (CIS) to pre-specify and standardise reporting in trials in which data for BWI 
is presented. A systematic review demonstrating the need for such a CIS, undertaken outside 
of this thesis, has been accepted for publication. The methodology to develop a CIS has been 
published in protocol form and is discussed in future work below(328). 
 
7.4.1.4 Impact on variation in the timing of assessment of one 
outcome across trials (relating to Thesis Objective 4)  
A final challenge in standardising the reporting of unique outcomes in trials, is the use of the 
timepoint of outcome assessment, as part of the definition of a unique outcome.  
The literature review undertaken in Chapter Two, showed that if the same outcome measured 
at different timepoints across the 147 RCTs were included as different unique outcomes, then 
2,743 outcomes would have been reported, instead of 1,494. If the timing of outcome 
assessment is included in the definition of a unique outcome in some COS literature reviews 
and not in others, the magnitude of ORH will not be comparable. There is no consensus in the 
literature about this issue. 
Whether or not to include a timing element to the definition of an outcome is explored in 
Chapter Three. Chan recommends this by adding a temporal element to the definition of a 
trial outcome: “a variable measured at a specific time point to assess the efficacy or harm of an 
intervention” (116). However, the work in Chapter Three suggests that this is not useful when 
measuring the numbers of unique outcomes at the early stages of COS development. In 
contrast, at the later stages of COS development, the core outcomes will ultimately need a 
timepoint for their measurement. The COMET handbook states: “Many COS developers have 
identified an agreed set of outcomes to measure, leaving the timing of assessment as an issue 
for trialists to decide subsequently depending on their particular context of use”(115). In terms 




relevant to the chosen outcome. Examples of timepoints for outcome assessment could 
include:  
• Immediate: showing the very short-term impact of the intervention (e.g. blood loss). 
• Intermediate: weeks to months (e.g. wound healing). 
• Longer-term: 12 months or longer (e.g. scarring).  
These timepoints will relate to the outcome chosen and may relate to national reporting 
timepoints or times of routine follow-up. As shown by the work undertaken for this thesis, 
there is a difference, in terms of the use of the timing of outcome assessment, in the definition 
of a unique outcome, the calculation of ORH across studies and the measurement of a core 
outcome. 
This work demonstrates, that, as well as a need to standardise timing of outcome assessment 
across trials to improve collation of data, it is also important that that patient relevance is 
considered in terms of the timing of outcome assessment. Outcomes measured shortly after 
injury have importance in assessing surgical technique, health care costs or adverse events. 
Most patients are, however, more interested in the impact of interventions on their life many 
years later (106, 149).  
There is a need for validated surrogate outcomes in burn care to ensure patient relevance. The 
systematic review presented in Chapter Five, explored the impact of timing of outcome 
assessment on relevance to stakeholders. The review showed that, of the 103 included studies, 
only 29 (28%) reported outcomes last assessed at more than six months after burn injury. 
Only one study followed patients for more than three years. This finding has important 
implications. It is well known that longer-term outcomes are more important to patients. For 
this reason, whilst it is appropriate that efficacy trials include shorter-term outcomes, there is 
a need to get longer-term data as well. There are financial and practical constraints to 
collecting this information. If longer-term data capture collecting cannot be achieved through 
time or funding constraints, then more research on the formal associations between surrogate 
and longer-term burn care outcomes needs to be undertaken. If short-term outcomes can be 
validated as surrogate outcomes and represent a true proxy for longer-term outcomes, then it 
will be possible to extrapolate data from short-term studies to understand impact on patient 




This finding highlights the need for trials in burns care to agree a standardised set of outcome 
assessment timings for each core and non-core outcome. When debating this, consideration of 
the trial design and the relevance to patients is important. 
This work demonstrates three different challenges to evidence synthesis. This is illustrated 









7.4.2 The impact of the development of an international Core 
Outcome Set for burn care research (COSB-i) (Thesis Objective 5) 
A potential solution to the methodological challenges in outcome reporting described above, 
is the use of a minimum set of the most important outcomes to be reported in all trials; a Core 
Outcome Set (COS)(71, 632).  
“The choice of outcome is critical when testing a hypothesis, and significant energy is devoted 
by investigators to ensure that their prespecified outcomes are appropriate, relevant, and 
support or disprove the stated hypothesis”(633). “A lack of adequate attention to the choice of 
outcomes in clinical trials has led to avoidable waste in both the production and reporting of 
research”(318). These two contrasting quotes from papers on trial outcomes, show that 
although individual researchers may spend much time in choosing outcomes, little effort has 
been spent to date on understanding the impact of individual researcher outcome choice. The 
issue of multiple researchers choosing different outcomes in the same healthcare area impacts 
negatively on evidence synthesis. The work on developing COSB-i is an important step to 
resolve this gap in burn care research. 
One of the first attempts to standardize outcome reporting in clinical trials was by the World 
Health Organization in 1981, when Miller and colleagues published recommendations for 
standardised approaches to recording data for cancer patients(634). His statement “The 
guidelines (in outcome reporting and patient demographics) given here are meant to be 
minimal requirements, leaving the investigator free to add any variable he deems necessary”. 
This fits particularly well with the subsequent development of COSs. Since 1992, Outcome 
Measures in Rheumatology (OMERACT, http://www.omeract.org) has led COS 
development(111, 160, 253, 254, 635-639). This work is thought to have begun as an 
international initiative in 1992, in collaboration with the World Health Organization 
(WHO)(640).  
The beneficial impact of standardising outcome reporting has been illustrated by Kirkham and 
colleagues. The authors reported that uptake of a COS in trials in one healthcare area, 
supported by the OMERACT Initiative (rheumatoid arthritis), increased from 40% in 1995 to 




arthritis studies. After introduction of the COS, meta-analyses were able to include 87% of 
trials and 93% of patients(642, 643). In contrast, a review of systematic reviews with meta-
analyses of reno-protection (a COS was only agreed in this healthcare area from 2014) showed 
that from 66 reviews, 609 outcomes had been reported for 20 outcome domains(538). The 
median proportion of reviews in which these outcomes had been meta-analysed was 8%.  
The development of COSs has rapidly grown over recent years with the support of the COMET 
Initiative(115, 644-648). At the end of 2015, there were 720 COSs listed in the COMET 
database(286). The GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) group (http://www.gradeworkinggroup.org) have recognised the need to identify 
core outcomes. COMET is working with the GRADE working group of the Cochrane 
Collaboration to achieve three strategic goals:  
• To increase the number of COS developed using evidence-based methods. 
• To increase their impact on the quality of research by raising awareness and increasing 
their use. 
• To establish methods for the development of COS(649).  
This work is supported by the WHO, in developing guideline recommendations(650, 651). The 
Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) statement also 
recommends the use of core outcome sets where they exist(652).  
In burn care, agreeing a COS by triallists, has been hampered by a multiplicity of outcomes, by 
a lack of agreement between clinical professionals, by limited patient involvement and by 
varying national and international practice. The work presented in this thesis, has shown that 
these challenges in burn care and in other healthcare areas, can be overcome. Patients and 
international professional collaborators have shown that they understand the concept and 
problem of ORH in research. They have shown themselves to be keen to overcome the issue, 
through the development of a COS. This has been demonstrated by the ability to recruit 
hundreds of HCPs across 77 countries to prioritise outcomes. UK patients have also been vocal 
and interested in taking part in the research. A set of seven important outcomes for consistent 




The most common outcome domains reported in the trials included in the systematic 
literature review in Chapter Two were:  
• Burn wound healing (48% of studies) 
• Burn wound infection (43% of studies) 
• Complications of treatment (42% of studies).  
Death was reported in 21% of studies. These commonly reported outcomes align well with 
three of the agreed COS outcomes. In contrast, ability to carry out daily tasks and return to 
school or employment were reported in only one study each. Chapter Five reported that 
longer-term patient-important outcomes are less commonly reported in burn care RCTs. 
There may, therefore, be challenges in implementing the whole COS in every trial. This will be 
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1. Death: to include death from any cause and death from the burn. 
2. Serious complications: to include sepsis, wound infection, thromboses. 
3. Ability to undertake daily tasks: to include walking. 
4. Time to heal: to include wound healing, grafted and donor site wound healing.  
5. Long term pain and itch. 
6. Patient psychology: to include general anxiety and anxiety about the future. 
7. Time to return to work/school/previous occupation. 





The outcomes chosen for COSB-i are similar, in terms of numbers and topic area, to other 
recent COSs (Table 40). In the COS for shoulder disorders (OMERACT group), the following 
outcomes were agreed: pain, physical function/activity, global perceived effect and adverse 
events including death, emotional wellbeing, sleep and participation (recreation and 
work)(635). In the COS for hip fracture trials, consensus supported five outcomes: mortality, 
pain, activities of daily living, mobility, and health-related quality of life (HRQL)(600). In 
bariatric surgery the following nine COS outcomes were agreed: weight, diabetes status, 
cardiovascular risk, quality of life (QOL), mortality, technical complications of the specific 
operation, any re-operation/re-intervention, dysphagia/regurgitation, and micronutrient 
status(654). Other examples are shown in the table above.  
It is interesting to note that several outcomes are important across different COSs. Examples 
include daily activities and pain. Other core outcomes are healthcare area-specific such as 
time to wound healing. A number of these outcomes imply a shorter time to assessment than 
the burn care core outcomes. One reason for this could be that burns commonly happen in 
childhood and the impact is therefore life-long and that longer-term outcomes are more 
important to patients. Interestingly, only one of the COSs in Table 40, discussed or reported, 
the timepoint of assessment of the agreed core outcomes. Allin, when reporting the 
gastroschisis COS, proposed that: “Appropriate time-points for reporting these core outcomes 
were also discussed, and it was unanimously agreed that these should be kept as close as 
possible to standard time-points for reporting surgical and paediatric outcomes. In order to 
make future meta-analysis more meaningful, studies using the developed COS should report 
on outcomes using at least one of these time points.” 
The use of a COS in burn research, will advance the volume and relevance of research able to 
inform clinical practice and improve patient outcomes. It will also allow improvements in 
medical indexing, referencing, and identifying relevant clinical trials and reviews though 
keywords and MESH terms(655). Other impacts will include linking the agreed core outcomes 
with the national burn database (iBID; international burn injury database; 
http://www.ibidb.org/ ) and, through this, to NHS England quality indicators in burn care (the 
burn injury dashboard https://www.england.nhs.uk/wp-content/uploads/2018/03/specialised-
burn-care-adults-metric-definitions-2018-19.pdf). These have the benefit of being endorsed 




reliable and efficient. They allow for comparisons across providers and can be aggregated 
across multiple providers to generate data on trends in process and outcomes. The author of 
this thesis was the first chair of the NHS England commissioning group for burns, and co-
developed the first quality dashboard for burns, agreeing process and outcome indicators. 
Through this, and her role as a burn network lead, she worked closely with the chair of the 
national burn injury database. This work has begun, out with this thesis, and is discussed 
further in future research (section 7.5).  
 
7.4.3 Dissemination of the Core Outcome Set for burn care research 
(COSB-i) 
Dissemination of the COSB-i will be improved by the diversity of stake-holders involved in its 
development(643). The stakeholders include a senior member of the Cochrane wounds group, 
national and international burn and plastic surgery professional groups, research funders and 
burns journal editors, all of whom have been involved with the development and have 
committed to assist in implementing the COS. One way to actively collaborate with such 
stakeholders is to develop an initiative such as CROWN (CoRe Outcomes in WomeN's health; 
http://www.crown-initiative.org/ )(656). One of the aims of CROWN, is to “Facilitate 
embedding of core outcome sets in research practice, working closely with researchers, 
reviewers, funders and guideline makers”. In 2014, CROWN had the support of the editors of 
over 50 journals related to women's health. There are other similar initiatives including 
OMERACT (described above), the Cochrane Skin Group Core Outcome Set Initiative (CSG-
COUSIN), the Standardised Outcomes in Nephrology-Haemodialysis (SONG-HD) and the 
Harmonising Outcome Measures for Eczema (HOME) groups(232, 648, 657). This approach 
would be an important method to take forward and facilitate the dissemination of the COSB-i 
project. 
Global stakeholder involvement in COS development has been limited until recently (642). 
Increasing stakeholder diversity has been achieved through the COSB-i project by working 
with more than 750 participants across 77 countries from all World Bank income statuses and 




be through publication in widely-read and high quality peer-reviewed journals. At the time of 
writing, publication has been achieved for: 
• Two protocols (COSB-i (Chapter Six)) and the BWI definition project (ICon-B) (Chapter 
Four). These have both been published in BMJ Open(229, 328).  
• The systematic literature review of clinical outcomes reported in burn care RCTs has been 
published in BMJ Open(293).  
• The study to define a unique outcome was published in the Journal of Clinical 
Epidemiology(293).  
• The systematic review for Infection Consensus in burn care (ICon-B) has been accepted for 
publication in the Burns journal (March 2020).  
• The COSB-i final paper is ready for submission to PLOS Medicine.  
The work has been presented at international conferences including COMET (Amsterdam, 
November 2018), the British and Canadian Burn Associations (Leeds May 2019; Toronto, 
October 2018), International Clinical Trials Methodology Conference (Brighton, October 
2019) and the European Paediatric Burn Association (Cologne, September 2018).  
We have formal support for COSB-i development, from the British Burn Association, the 
American Burn Association, the Australia and New Zealand Burn Association, the African 
Burn Association, the UK Paediatric Intensive Care Society, the Reconstructive Surgery Trials 
Network, the Swansea Centre for Global Burn Injury, the Hong Kong Children’s burn support 
group, the Calgary Firefighters’ Burn Treatment Centre, the European Scar Academy, the USA 
Phoenix patient burn society, the Surgical Society of Kenya, and other international burn and 
plastic organisations. Researchers from Cochrane wounds, the Burns journal editor and a 
member of the NIHR Health Technology Assessment funding team were also collaborators in 
this study (please see the collaborator list Appendix M). 
Important research to implement the COSB-I, will be undertaken after submission of this 






7.4.4 Patient and public involvement in COSB-i 
Implementation requires support from patients, their carers and charitable burn care 
organisations. These stakeholders have been involved in all study aspects, including the 
methodology (and publication of the protocol), the consensus process (the Delphi survey and 
final consensus meeting) and in the readability and understanding of all written materials. 
Outcomes were included for discussion at the final consensus meeting if they fulfilled the 
inclusion criteria by patient or HCP prioritisation. Young people and adult burn patients were 
vocal at the consensus meeting about the need to exclude scar contractures but instead to 
include the longer-term outcome of function (ability to do daily tasks) and the exclusion of 
acute pain, but instead to include the longer-term outcome of neuropathic pain and itch. 
A large group of interested patients in the UK has been engaged with, as a result of the COSB-i 
work. We are planning to increase this patient population, with international patient and 
carer input. We have already started to develop contacts through international burn support 
groups (see future work). Global patient input in the future, will be facilitated by (as requested 
by burn support groups internationally) a translation of the Delphi survey. We have had to 
date, requests from Hong Kong, Germany and Brazil to do this. As a result of the inclusion of 
more than 120 UK burn care patients and carers and members other international patient 
organisations, we now have a global network of patients, carers and charitable burn support 
groups, who are all willing and keen to be involved in burn research and the implementation 
of COSB-i. This is a significant achievement for this project. 
 
7.5 Future research 
The work presented in this thesis, is the beginning of a potentially much larger programme of 
research. Ideas for possible future projects are presented in the following sections. The aim of 
the work presented in this thesis is to increase usable data from burn care trials. Follow-on 
work will aim to further improve the ability to aggregate data from well-conducted RCTs. In 
this way, the volume and validity of systematic reviews in burn care and other healthcare 




1. Primary work: To operationalise and implement COSB-i for burn care research.  
2. Secondary work: To address the methodological challenges relating to outcome reporting 
as identified in this thesis. 
 
7.5.1 Primary work: to operationalise and implement COSB-i 
For COSB-i to achieve benefits in burn care research, it needs to be operationalised and 
implemented. While a COS is important in determining what outcomes should be measured 
consistently across trials in research, it does not describe how these key outcomes should be 
defined and measured, and at what timepoints they should be measured. Operationalisation 
will need to agree these important next steps(658). Agreeing the measure for each core 
outcome is known as developing a Core Measurement Set (CMS); the how in COS 
development. International collaboration and involvement will impact on measures chosen in 
burn care and will need to be carefully considered through the work described below. If new 
technology allows outcomes to be measured accurately and consistently, a compromise will 
need to be made in the use of a different outcome measure in a low-income country. In this 
case, it would be important to undertake work to ensure comparability between the two 
methods(659).  
The COSMIN (COnsensus-based Standards for the selection of health Measurement 
Instruments; https://www.cosmin.nl/ ) have agreed methodology to assist and standardise the 
process to agree core outcome measures(303, 660). COSMIN aims to improve the selection of 
outcome measurement instruments, both in research and in clinical practice, by developing 
methodology and practical tools that select the most suitable outcome measurement tool. The 
OMERACT filter and OMERACT Handbook provide important methodological help for this 
process(642, 661, 662). The Harmonising outcome measures for eczema roadmap (HOME) 
also provides information on processes and decision-making regarding outcome 
measures(648).  
The work to agree a Core Measurement Set (CMS) for COSB-i, will involve SRs, a Delphi 




CMS including outcome definition and timepoint of assessment(111, 648, 663, 664). This will 
be the most important work to be undertaken after thesis submission.  
The work is being planned and will consist of three work packages (WP): 
WP One: Systematic reviews: 
1. An SR will be required to identify all relevant measurement instruments, and gaps where 
new tools are needed, for the seven core outcomes in COSB-i. The existing review of 
clinical outcomes (reported in Chapter Two) will need to be updated and a verbatim list of 
reported outcome definitions, outcome measures, timing of outcome measurement and 
methods for measurement, extracted by two researchers. Extracted data will be reviewed 
for completeness and relevance, prior to progression to WP 2. 
 
2. An SR of the measurement properties of patient-reported outcome measures (PROs) 
developed for, or validated in, patients with burns, will also be required. An update to the 
two systematic reviews published in 2015 and 2017 and used in Chapter Six to identify 
PROs for COSB-i will be undertaken(665). Tables will be constructed to summarise study 
and instrument characteristics, measurement properties and interpretability(666). The 
COSMIN checklist will be used to assess the methodological quality of included 
studies(667). If more than one instrument is considered valid, details of candidate 
instruments will be included in the Delphi process to determine which tool should be 
used. If no suitable instrument is identified, this will be acknowledged. 
 
WP 2: Delphi consensus process: 
A Delphi process to establish consensus among stakeholders (patients and healthcare 
professionals) regarding which outcome definitions, measurement instruments and 
standardised timepoints for assessment should be used. The methodology will be similar to 
that used to develop the COSB-i detailed in Chapter Six. The need for this work is illustrated 
by a COS on peri-operative outcomes after hip fracture(668). Despite the short-term nature of 
this COS, and the involvement of stakeholders in its development, there is still an issue about 
definitions and measures for several of the outcomes chosen for this COS. There are 




hospital, or peri-operatively(633). The group have agreed that until further work is 
undertaken, they will maintain consistency between the national groups regularly reporting 
hip fracture outcome data, and report 30 day, 120 day, and one year mortality. This pragmatic 
methodology is in-line with the work by Allin et al., as discussed above(654). There are no 
agreed reporting times for burn care clinical outcomes. Further work will need to be 
undertaken to agree these timepoints and link them to practical patient reviews or national 
benchmarking data timepoints. 
Agreeing the timing of outcome assessment needs to ensure engagement, in terms HCPs and 
patients and carers. There needs to be an understanding and agreement about research 
undertaken for efficacy trials and the more patient-important effectiveness trials. The former 
trials are less costly in terms of funding and time. However, the latter will make the greater 
impact on patient care, as discussed in Chapter Five and in the paper by Tunis and 
colleagues(318). 
WP 3: A final consensus meeting: 
 This will be undertaken to agree and ratify the decisions on outcome definitions, 
measurement instruments and standardised timepoints of assessment. It will be held after the 
conclusion of the Delphi survey.  
COSB-i bolt-on projects: It has become clear through the work in this thesis and through other 
COSs, that the first generic COS for burn care may require bolt-ons or supplements. It is 
possible that we will need to work on a more detailed short-term COS assessing outcomes for 
efficacy trials. This work has achieved further funding, out with the work for this thesis 
through the Scar Free Foundation, and will be finalised this year. There may also need to be 
different COSs for patients with different severity burns and possibly for children and adults. 
The need for these bolt-on projects remains to be explored. 
International patient validation of COSB-i: One limitation of the above work, is that, although 
there was collaboration with more than 650 HCPs, only patients from the UK were included. 
We have had requests from countries including China (Hong Kong), Germany and Brazil to 
translate the COSB-i Delphi survey into the native languages of these countries. We will 





7.5.2 Secondary work: to address the methodological challenges 
with outcome reporting 
In parallel with the implementation of COSB-i, outcomes research will continue as a second 
priority. Outcomes research can be defined as the study of the end results of healthcare. It can 
also be described as the effect of treatments on endpoints important to patients and 
society(669-671). It is therefore crucial that this work takes patients’ preferences and values 
into account. The follow-on methodological work will, with the involvement of patients and 
other stakeholders, focus on describing the definitions of specific burn care-related outcomes 
and generic definitions of terms associated with outcomes and COS research. 
The objectives of this work are to: 
1. Determine definitions for core and non-core outcomes in burn care research.  
It is important that clarity is achieved, in terms of definitions for core and non-core outcomes 
in burn care. COSs do not restrict researchers to reporting of core outcomes alone, and 
researchers will continue to use non-core outcomes. It is important that the most commonly 
used non-core outcomes, have clarity of meaning, to allow comparison and collation of data. 
OMERACT have formalised this process, by describing an inner, middle and outer core set of 
outcomes. These are ranked in terms of importance from inner to outer(635). This still 
requires standard outcome definitions, and, ultimately, standard measures.  
A lexicon of definitions: for the commonly used outcomes in burn care, would be one solution 
to this issue. This would allow aggregation of data across trials for non-core outcomes. There 
is precedence for this in paediatric palliative care(672). The authors of this work define a 
lexicon as: “a shared vocabulary using a stock of terms that carry a particular meaning for 
those working within the field”. They developed, through multidisciplinary consensus 
processes, international agreement on definitions for 18 terms of importance 
(http://pediatricpalliative.com/publications ). 
In Chapter Four, results from an SR showed, that in studies reporting burn wound infection 




types and numbers of indicators used for the definition. This supports the need for a Core 
Indicator Set to standardise the reporting of BWI, across trials presenting data for this 
outcome. This work has been started through the UK-based ICon-B (Infection Consensus in 
Burn care research) group led by the author of this thesis. The protocol for this work has been 
published(328). The national work is completed with four chosen indicators. Further work 
will be undertaken through the collaborative burn research network developed through the 
work to develop the COSB-i. This will be to validate the findings of the UK work and agree any 
changes internationally. This would be the first important step, using BWI as an example, 
towards agreeing definitions of commonly-used outcomes in burn care research 
internationally. 
Agreeing a common language in clinical burn care: consensus on definitions of burn care 
outcomes, in terms of meaning and context, will create clinical impact as well as standardising 
research outcome reporting. It will allow clinicians to speak to each other using the same 
language and promote the development of guidelines, in which there is clarity about the 
chosen outcomes. For example, it will be easier to standardise the use of antibiotics in burn 
services, when there is clarity about what is meant by a burn wound infection. There will be 
the facility to compare different wound dressings, when it is clear what we mean by wound 
healing and when clinicians have a standardised measure to reflect this. Conversations with 
patients and carers will be clearer and, ultimately, more accurate comparisons will be possible 
between healthcare provision across services. 
 
2. Unique outcomes and ORH.  
In determining standard definitions for unique, healthcare area-specific outcomes, a clear 
understanding as to what makes one outcome different to the next, is needed. This was 
explored in Chapter Three. Work to establish this, needs to be continued internationally with 
collaboration across researchers with an interest in outcomes research, and through COMET. 
The impact will affect COS long-lists, the magnitude of ORH (as defined in Chapter Three), 
prioritising healthcare areas for COS requirement and formal searching for trials reporting 
specific outcomes. There is also a need to standardise other terms used in outcome research. 




tools, outcomes, outcome domains, outcome definitions and outcome measures. Despite the 
comprehensive work by COMET, there is still confusion regarding these terms in the 
literature(673). Work has been undertaken in terms of defining and classifying outcome 
domains through the efforts of Williamson and colleagues(115, 674). Less work has been 
undertaken in studying specific outcome definitions and differentiating between these and 
outcome measures. An example is wound healing (outcome or outcome domain), percentage 
wound healed in two weeks (outcome definition) and measurement of unhealed wound area 
using tracing and computer software (outcome measure). 
Clarifying what makes one outcome different to another will allow an understanding of ORH. 
Qualitative reporting of ORH across trials is reported in COS-development reviews. However, 
authors often put a number to this, implying that they can accurately report the scale of the 
variation. The magnitude of ORH hinges on agreeing the granularity required when defining 
an outcome. If COS developers can determine how many verbatim outcomes can be grouped 
under one term, they can then report ORH quantitatively, and compare these results with 
other COS developers. This would mean that researchers and research funders could prioritise 
healthcare areas for COS development. Future work will take this discussion further with COS 
researchers, COMET and other international interested parties. 
Through the specific and under-pinning methodological work described above, limiting 
research waste in burn care and other healthcare research will increase the synthesised 
evidence base, allowing more clinical decisions to be evidence-based.  
7.6 Recommendations 
Through the research in this thesis, the following recommendations for future work can be 
made: 
1. To operationalise and implement the COSB-i, through agreeing outcome definitions, 
measures and timepoint(s) of assessment for the seven chosen outcomes. 
a. Agree whether there is a need for a more detailed short and longer-term COS for 




2. Agree international definitions for commonly reported outcomes in burn care research (core 
and non-core), using burn wound infection as an example (lexicon of definitions). 
3. Agree a definition for a generic unique outcome, to allow the quantification of outcome 
variation across trials and to determine the healthcare areas, where the scale of ORH 





Chapter 8 Conclusions 
This thesis has explored the reasons that limit researchers’ ability to synthesise RCT data to 
support clinical decision-making in burn care. It has answered the thesis research question: 
It is possible to increase the provision of data from burn care RCTs, that can be 
synthesised into evidence to answer clinical questions.  
Four methodological challenges in aggregating outcome data from trials have been 
highlighted in this thesis. These include the variation in choice and definition of outcomes, 
the timing of outcome assessment and agreeing what makes one outcome different to another. 
One solution to these methodological challenges is the development of a COS.  
Development of the international COS in burn care research (COSB-i), has utilised shared 
decision-making across more than 750 HCPs and patients across 77 countries of varying 
income status. Involvement of patients and multidisciplinary HCP stakeholders, including 
clinicians, researchers, research funders, research commissioners and journal editors, is likely 
to optimise implementation and use of the COS in future RCTs. The first global COS for burn 
care research, reflects the priorities of patients and burn care professionals.  
The COSB-i project has led to agreement on seven core outcomes to be reported in all burn 
care trials internationally. These include death, serious complications, ability to do daily tasks, 
time to heal, neuropathic pain and itch, patient psychology and time to return to work, school 
or previous occupation. It is now necessary to determine definitions, measures and timepoints 
of assessment for each core outcome and to validate the COS with international patients. 
The conclusion of the work in this thesis, is that, knowledge of challenges in outcome choice 
and reporting in burn care research, support the development of COSB-i. It is hoped that the 
first COS for patients with burn injuries will, through standardised outcome reporting, 
improve evidence synthesis. This should increase the evidence base for burn care, resolve 
persisting uncertainty over clinical management and ultimately improve the recovery of more 
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A.1 First author papers published in peer-reviewed 
journals: 
• Young A, Brookes S, Rumsey N, Blazeby J. Agreement on what to measure in 
randomised controlled trials in burn care: study protocol for the development of a core 
outcome set. BMJ Open. 2017 Jun 1;7(6):e017267. 
• Young AE, Davies A, Bland S, Brookes S, Blazeby JM. Systematic review of clinical 
outcome reporting in randomised controlled trials of burn care. BMJ Open. 2019 Feb 
1;9(2):e025135. 
• Young AE, Brookes ST, Avery KN, Davies A, Metcalfe C, Blazeby JM. A systematic 
review of core outcome set development studies demonstrates difficulties in defining 
unique outcomes. Journal of clinical epidemiology. 2019 Nov 1;115:14-24. 
• Young A, Reeves BC, Cheng HY, Wasiak J, Muir D, Davies A, Blazeby J. Risk of bias and 
reporting completeness of randomised controlled trials in burn care: protocol for a 
systematic review. BMJ Open. 2019 Dec 1;9(12). Note: this paper is directly related to 
the work in this thesis but is not reported here and relates to an on-going project. 
A.2 Senior author paper published in a peer-review 
journal with work led by the thesis author: 
• Davies A, Teare L, Falder S, Coy K, Dumville JC, Collins D, Moore L, Dheansa B, 




the development of a core indicator set for reporting burn wound infection in trials: 
ICon-B study. BMJ Open. 2019 May 1;9(5):e026056. 
A.3 Paper In Press in a peer-reviewed journal: 
• A systematic review of intervention studies demonstrates the need to develop a 
minimum set of indicators to report the presence of burn wound infection. Accepted 
by Burns in March 2020. In press.  
A.4 Paper submitted to a peer-reviewed journal: 
• Amber Young, Fatima Yaqub, Chris Metcalfe, Sarvnaz Sepehripour, Jane Blazeby. 
Clinical trials in burns care primarily focus on short-term outcomes of uncertain 
longer-term patient benefit: a systematic review. Submitted to the Journal of Clinical 
Epidemiology December 2019. Not peer-reviewed. Returned with the suggestion to 





Appendix B Studies included in the 
systematic review in Chapter Two. 
Trial title First Author Year of 
publication 
1. Comparison of silver nylon wound dressing and silver sulfadiazine in partial burn 
wound therapy. (377) 
Abedini F 2012 
2. Healing of burn wounds by topical treatment: A randomized controlled comparison 
between silver sulfadiazine and nano-crystalline silver. (675) 
Adhya A 
2015 
3. An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-
dimer and Doppler ultrasound as screening tools. (676) 
Ahuja R 
2016 
4. An analysis of deep vein thrombosis in burn patients (part II): A randomized and 
controlled study of thrombo-prophylaxis with low molecular weight heparin. (677) 
Ahuja R 
2016 
5. A four arm, double blind, randomized and placebo-controlled study of pregabalin in 
the management of post-burn pruritus. (678) 
Ahuja R 
2012 
6. Propranolol attenuates haemorrhage and accelerates wound healing in severely 
burned adults. (679) 
Ali A 
2015 
7. Aerobic exercise training in modulation of aerobic physical fitness and balance of 
burned patients. (680) 
Ali Z 
2015 
8. Silk sericin ameliorates wound healing and its clinical efficacy in burn wounds. (380) Aramwit P 2013 
9. A Randomized Controlled Trial Comparing Endoscopic-Assisted Versus Open Neck 




10. A prospective, randomised study of a novel transforming methacrylate dressing 
compared with a silver-containing sodium carboxymethylcellulose dressing on 
partial-thickness skin graft donor sites in burn patients. (682) 
Assadian O 
2013 
11. Multimodal quantitative analysis of early pulsed-dye laser treatment of scars at a 
pediatric burn hospital. (683) 
Bailey J 
2012 
12. Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: 
a randomized, controlled, double-blind clinical trial. (684) 
Bechir M 
2013 
13. A prospective randomized trial comparing silver sulfadiazine cream with a water-
soluble poly-antimicrobial gel in partial-thickness burn wounds. (685) 
Black J  
2015 
14. Clinical effectiveness of dermal substitution in burns by topical negative pressure: a 
multi-center randomized controlled trial. (686) 
Bloeman M 
2012 
15. Effect of subcutaneous epinephrine/saline/local anesthetic versus saline-only 
injection on split-thickness skin graft donor site perfusion, healing, and pain. (687) 
Blome Eberwein S 
2013 
16. A randomized controlled study of silver-based burns dressing in a pediatric 
emergency department. (345) 
Brown M 
2016 




18. Play and heal: randomized controlled trial of DittoTM intervention efficacy on 
improving re-epithelialization in pediatric burns. (689) 
Brown N 
2013 
19. The implementation and evaluation of therapeutic touch in burn patients: an 
instructive experience of conducting a scientific study within a non-academic 
nursing setting.  
Busch M 
2012 
20. Prophylactic sequential bronchoscopy after inhalation injury: results from a three-
year prospective randomized trial. (690) 
Carr J 
2013 




22. A randomized controlled trial to compare the effects of liquid versus powdered 
recombinant human growth hormone in treating patients with severe burns. (691) 
Chen G 
2016 
23. The Effect of Continuous Sedation Therapy on Immunomodulation, Plasma Levels 
of Antioxidants, and Indicators of Tissue Repair in Post-Burn Sepsis Patients. (692) 
Chen Li 
2015 
24. Application of acellular dermal xenografts in full-thickness skin burns. (693) Chen X 2013 
25. Effectiveness of medical hypnosis for pain reduction and faster wound healing in 
pediatric acute burn injury: study protocol for a randomized controlled trial. (694) 
Chester S 
2016 
26. Safety of recombinant human granulocyte-macrophage colony-stimulating factor in 
healing pediatric severe burns. (695) 
Chi Y 
2015 




28. The effect of burn rehabilitation massage therapy on hypertrophic scar after burn: a 
randomized controlled trial. (697) 
Cho YS 
2014 
29. Effect of extracorporeal shock wave therapy on scar pain in burn patients: A 
prospective, randomized, single-blind, placebo-controlled study. (698) 
Cho YS 
2016 
30. Characterization of early thermal burns and the effects of hyperbaric oxygen 
treatment: a pilot study. (383) 
Chong SJ 
2013 
31. Effects of different duration exercise programs in children with severe burns. (508) Clayton RP 2016 
32. The effect of healing touch on sleep patterns of pediatric burn patients. (699) Cone L 2014 
33. Effect of N-acetylcysteine treatment on oxidative stress and inflammation after 
severe burn. (700) 
Csontos C 
2012 
34. The effects of intravenous glutamine supplementation in severely burned, multiple 
traumatized patients. (701) 
Cucerean-Badica 
2013 




36. Evaluation of the "Early" Use of Albumin in Children with Extensive Burns: A 
Randomized Controlled Trial 
Dittrich MH 
2016 
37. Interim pressure garment therapy (4-6 mmHg) and its effect on donor site healing in 
burn patients: study protocol for a randomised controlled trial. (702) 
Donovan M 
2016 
38. Effect of whole body vibration on leg muscle strength after healed burns: a 
randomized controlled trial. (703) 
Ebid AA 
2012 
39. Effect of isokinetic training on muscle strength, size and gait after healed pediatric 
burn: a randomized controlled study. (704) 
Ebid AA 
2014 




41. Effects of whole-body vibration exercise on bone mineral content and density in 
thermally injured children. (706) 
Edionwe J 
2016 
42. Efficacy of platelet rich plasma application in comparison to conventional dressing 
therapy in partial thickness burn wound. (707) 
Ehmer al Ibran 
2014 
43. Effect of probiotic administration in the therapy of pediatric thermal burn. (708) El-ghazely MH 2016 
44. Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury: 
a study of different doses. (709) 
Elsharnouby NM 
2014 




46. Impact of stress-induced diabetes on outcomes in severely burned children. (370) Finnerty CC 2014 
47. Outcome of Burns Treated With Autologous Cultured Proliferating Epidermal Cells: 
A Prospective Randomized Multi-center Intra-patient Comparative Trial. (711) 
Gardien KL 
2014 
48. Randomized controlled trial of three burns dressings for partial thickness burns in 
children. (712) 
Gee Kee EL 
2015 
49. Topical petrolatum gel alone versus topical silver sulfadiazine with standard gauze 
dressings for the treatment of superficial partial thickness burns in adults: a 
randomized controlled trial. (713) 
Genuino GAS 
2014 
50. HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo 
in burn patients with inhalation trauma: study protocol for a multi-center 
randomized controlled trial. (714) 
Glas GJ 
2014 
51. A multi-center study on the regenerative effects of erythropoietin in burn and 
scalding injuries: study protocol for a randomized controlled trial. (715) 
Gunter CI 
2013 
52. Early rehabilitative exercise training in the recovery from pediatric burn. (716) Hardee JP 2014 
53. Quality of pediatric second-degree burn wound scars following the application of 
basic fibroblast growth factor: results of a randomized, controlled pilot study. (717) 
Hayashida K 
2012 
54. Long-term propranolol use in severely burned pediatric patients: a randomized 






55. Reversal of growth arrest with the combined administration of oxandrolone and 
propranolol in severely burned children. (719) 
Herndon DN 
2016 
56. Cost-Effectiveness of Laser Doppler Imaging in Burn Care in The Netherlands: A 
Randomized Controlled Trial. (720) 
Hop MJ 
2016 




58. Low dose of glucocorticoid decreases the incidence of complications in severely 
burned patients by attenuating systemic inflammation. (722) 
Huang G 
2015 
59. An assessment of early Child Life Therapy pain and anxiety management: A 
prospective randomised controlled trial. (723) 
Hyland E 
2015 
60. Prospective, randomised controlled trial comparing VersajetTM hydrosurgery and 
conventional debridement of partial thickness paediatric burns. (724) 
Hyland EJ 
2015 
61. Construction of skin graft seams in burn patients: A prospective randomized double-
blinded study. (725) 
Isaac K 
2016 
62. Multi-axis shoulder abduction splint in acute burn rehabilitation: a randomized 
controlled pilot trial. (726) 
Jang KU 
2015 
63. Glucose control in severely burned patients using metformin: An interim safety and 
efficacy analysis of a phase II randomized controlled trial. (363) 
Jeschke MG 
2016 
64. The effect of ketoconazole on post-burn inflammation, hypermetabolism and 
clinical outcomes. (337) 
Jeschke MG 
2012 
65. The Effect of Distraction Technique on the Pain of Dressing Change among 3-6 
Year-old Children. (727) 
Kaheni S 
2016 
66. Prospective randomize-controlled comparison between silICone plus herbal extract 
gel versus Aloe Vera gel for burn scar prophylaxis. (728) 
Keorochana K 
2015 
67. Effects of Enteral Glutamine Supplementation on Reduction of Infection in Adult 
Patients with Severe Burns. (338) 
Kibor DK 
2014 
68. Effects of sustained release growth hormone treatment during the rehabilitation of 
adult severe burn survivors. (729) 
Kim J 
2016 
69. Virtual reality for acute pain reduction in adolescents undergoing burn wound care: 
a prospective randomized controlled trial. (730) 
Kipping B 
2012 
70. The effects of splinting on shoulder function in adult burns. (731) Kolmus AM 2012 
71. Prospective study on burns treated with Integra, a cellulose sponge and split 
thickness skin graft: comparative clinical and histological study--randomized 
controlled trial. (732) 
Lagus H 
2013 




73. Anti-inflammatory effect of taurine in burned patients. (734) Lak S 2015 
74. A randomized controlled pilot study comparing aqueous cream with a beeswax and 
herbal oil cream in the provision of relief from postburn pruritis. (735) 
Lewis PA 
2012 
75. Human acellular dermal matrix allograft: A randomized, controlled human trial for 
the long-term evaluation of patients with extensive burns. (736) 
Li X 
2015 
76. Selective digestive decontamination attenuates organ dysfunction in critically ill 
burn patients. (737) 
Lopez-Rodriguez L 
2015 
77. Results of a prospective randomized controlled trial of early ambulation for patients 
with lower extremity autografts. (738) 
Lorello DJ 
2014 
78. Moist occlusive dressing (Aquacel(Â®) Ag) versus moist open dressing (MEBO(Â®)) 
in the management of partial-thickness facial burns: a comparative study in Ain 
Shams University. (739) 
Mabrouk A 
2012 
79. Enhancement of burn wounds healing by platelet dressing. (740) Maghsoudi H 2013 




81. Silver-coated nylon dressing plus active DC microcurrent for healing of autogenous 
skin donor sites. (742) 
Malin EW 
2013 
82. The application of platelet-rich plasma in the treatment of deep dermal burns: A 
randomized, double-blind, intra-patient-controlled study. (743) 
Marck RE 
2016 
83. Clinical safety and efficacy of probiotic administration following burn injury. (391) Mayes T 2015 
84. Three donor site dressings in pediatric split-thickness skin grafts: study protocol for 
a randomised controlled trial. (744) 
McBride CA 
2015 
85. Evaluation of who oral rehydration solution (ORS) and salt tablets in resuscitating 







86. Efficacy and adverse events of early high-frequency oscillatory ventilation in adult 
burn patients with acute respiratory distress syndrome. (746) 
Mohamed SA 
2016 
87. Effect of amniotic membrane on graft take in extremity burns. (747) Mohammadi AA 2013 
88. Comparison of the application of allogeneic fibroblast and autologous mesh grafting 
with conventional method in the treatment of third-degree burns. (748) 
Moravvej H 
2016 




90. Clinical Efficacy Test of Polyester Containing Herbal Extract Dressings in Burn 
Wound Healing. (750) 
Muangman P 
2016 
91. Effect of oral olive oil on healing of 10-20% total body surface area burn wounds in 
hospitalized patients. (353) 
Najmi M 
2015 




93. Comparing outcomes of sheet grafting with 1:1 mesh grafting in patients with 
thermal burns: a randomized trial. (752) 
Nikkah D 
2014 
94. Comparison of hydrogel produced by radiation as applied at the research center 
(Yazd branch) with maxgel and routine dressing for second-degree burn repair in 
Yazd burn hospital. (753) 
Noorbala MT 
2016 
95. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a 
multi-center, randomized, controlled trial. (754) 
Oen IMMH 
2012 
96. Influences of purposeful activity versus rote exercise on improving pain and hand 
function in pediatric burn. (755) 
Omar MTA 
2012 
97. Botulinum toxin and burn induces contracture. (756) Omranifard M 2016 
98. Results of a pilot multi-center genotype-based randomized placebo-controlled trial 
of propranolol to reduce pain after major thermal burn injury. (757) 
Orrey DC 
2015 
99. A proper enteral nutrition support improves sequential organ failure score and 
decreases length of stay in hospital in burned patients. (758) 
Ostradrahimi A 
2016 
100. Topical silver sulfadiazine vs collagenase ointment for the treatment of partial 
thickness burns in children: a prospective randomized trial. (354) 
Ostlie DJ 
2012 
101. Prospective randomized phase II Trial of accelerated re-epithelialization of 




102. A randomized and controlled multi-center prospective study of the Chinese 
medicinal compound Fufang Xuelian Burn Ointment for the treatment of superficial 
and deep second-degree burn wounds. (760) 
Ouyang J 
2014 
103. Prospective comparison of packed red blood cell-to-fresh frozen plasma transfusion 
ratio of 4: 1 versus 1: 1 during acute massive burn excision. (761) 
Palmieri T 
2012 
104. A herbal cream consisting of Aloe Vera, Lavandulastoechas, and Pelargonium 
roseum as an alternative for silver sulfadiazine in burn management. (355) 
Panahi Y 
2012 
105. Interactive gaming consoles reduced pain during acute minor burn rehabilitation: A 
randomized, pilot trial. (762) 
Parker M 
2016 
106. A Pilot Prospective Randomized Control Trial Comparing Exercises Using 
Videogame Therapy to Standard Physical Therapy: 6 Months Follow-Up. (763) 
Parry I 
2015 
107. An open, prospective, randomized pilot investigation evaluating pain with the use of 
a soft silICone wound contact layer vs bridal veil and staples on split thickness skin 
grafts as a primary dressing. (764) 
Patton ML 
2013 




109. Effects of propranolol and exercise training in children with severe burns. (766) Porro LJ 2013 
110. Five-year outcomes after oxandrolone administration in severely burned children: a 
randomized clinical trial of safety and efficacy. (767) 
Porro LJ 
2012 
111. Clinical effectiveness, quality of life and cost-effectiveness of Flaminal versus 
Flamazine in the treatment of partial thickness burns: study protocol for a 
randomized controlled trial. (768) 
Rashaan ZM 
2016 
112. Five-Year Outcomes after Long-Term Oxandrolone Administration in Severely 
Burned Children: A Randomized Clinical Trial. (769) 
Reeves PT 
2016 
113. A novel rapid and selective enzymatic debridement agent for burn wound 
management: a multi-center RCT. (770) 
Rosenburg L 
2013 
114. Effects of cholecalciferol supplementation and optimized calcium intakes on vitamin 
D status, muscle strength and bone health: a one-year pilot randomized controlled 






115. Evaluation of Amniotic Membrane Effectiveness in Skin Graft Donor Site Dressing in 
Burn Patients. (772) 
Salehi SH 
2015 
116. A feasibility study assessing cortical plasticity in chronic neuropathic pain following 
burn injury. (773) 
Santos Portilla A 
2013 
117. Perioperative treatment algorithm for bleeding burn patients reduces allogeneic 
blood product requirements. (774) 
Schaden E 
2012 
118. A prospective clinical trial comparing Biobrane, Dressilk, and PolyMem dressings on 
partial-thickness skin graft donor sites. (775) 
Schulz A 
2016 
119. Effectiveness of Aloe Vera gel compared with 1% silver sulphadiazine cream as burn 
wound dressing in second degree burns. (266) 
Shahzad M 
2013 
120. The comparison between modified kligman formulation versus kligman formulation 
and intense pulsed light in the treatment of the post-burn hyperpigmentation. (776) 
Siadat A 
2016 
121. A comparative study of spray keratinocytes and autologous meshed split-thickness 
skin graft in the treatment of acute burn injuries. (777) 
Sood R 
2015 
122. Long-Term Administration of Oxandrolone Improves Lung Function in Pediatric 
Burned Patients. (778) 
Sousse LE 
2016 
123. An open, parallel, randomized, comparative, multicenter investigation evaluating 
the efficacy and tolerability of Mepilex Ag versus silver sulfadiazine in the treatment 
of deep partial-thickness burn injuries. (779) 
Tang H 
2015 
124. Non-ablative fractional laser provides long-term improvement of mature burn scars 
- A randomized controlled trial with histological assessment. (780) 
Taudorf EH 
2015 
125. Fluid therapy lidco controlled trial - Optimization of volume resuscitation of 
extensively burned patients through noninvasive continuous real-time 
hemodynamic monitoring LiDCO. (781) 
Tokarik M 
2013 




127. Laser Doppler imaging as a tool in the burn wound treatment protocol. (783) Venclauskiene A 2014 
128. Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: 
a randomized clinical trial. (784) 
Venet F 
2015 
129. A Comparative Study of Paediatric Thermal Burns Treated with Topical Heparin and 
Without Heparin. (785) 
Venkatachalapathy 
TS 2014 
130. Aquacel() Ag dressing versus ActicoatTM dressing in partial thickness burns: a 




131. Skin stretching for primary closure of acute burn wounds. (786) Verhaegen PDHM 2014 
132. Xbox KinectTM based rehabilitation as a feasible adjunct for minor upper limb 
burns rehabilitation: A pilot RCT. (787) 
Voon K 
2016 








135. A prospective randomised clinical pilot study to compare the effectiveness of 
Biobrane (R) synthetic wound dressing, with or without autologous cell suspension, 
to the local standard treatment regimen in paediatric scald injuries. (789) 
Wood F 
2012 
136. Effective symptomatic treatment for severe and intractable pruritus associated with 




137. Propranolol reduces cardiac index but does not adversely affect peripheral perfusion 
in severely burned children. (791) 
Wurzer P 
2016 
138. A new method of microskin autografting with a Vaseline-based moisture dressing on 
granulation tissue. (792) 
Xiao H 
2014 
139. Recombinant human granulocyte-macrophage colony-stimulating factor hydrogel 
promotes healing of deep partial thickness burn wounds. (406) 
Yan H 
2012 
140. A comparative study of the dressings silver sulfadiazine and Aquacel Ag in the 
management of superficial partial-thickness burns. (793) 
Yarboro D 
2013 
141. A clinical trial designed to evaluate the safety and effectiveness of a thermosensitive 
hydrogel-type cultured epidermal allograft for deep second-degree burns. (794) 
Yim H 
2014 
142. Study of the use of recombinant human granulocyte-macrophage colony-stimulating 
factor hydrogel externally to treat residual wounds of extensive deep partial-
thickness burn. (402) 
Yuan L 
2015 
143. Effect of Olea ointment and Acetate Mafenide on burn wounds - A randomized 
clinical trial. (795) 





144. Effects of puerarin on the inflammatory role of burn-related procedural pain 
mediated by P2X7 receptors. (796) 
Zhang J 
2013 
145. Effects of early enteral nutrition on the gastrointestinal motility and intestinal 
mucosal barrier of patients with burn-induced invasive fungal infection. (797) 
Zhang Y 
2016 
146. Maximizing the safety of glycerol preserved human amniotic membrane as a 
biological dressing. (798) 
Zidan SM 
2015 
147. Therapeutic Value of Blood Purification and Prognostic Utilities of Early Serum 
Procalcitonin, C Reactive Protein, and Brain Natriuretic Peptide Levels in Severely 







Appendix C Studies included in the 
systematic review in Chapter Three. 
Trial title First Author Year of 
publication 
148. Defining clinically important peri-operative blood loss and transfusion for the StEP collaborative: 
protocol for a scoping review(800) Bartoszko J 2017 
149. Reporting Clinical Outcomes of Breast Reconstruction: A Systematic Review(317) Potter S 2010 
150. Assessment of Cosmesis After Breast Reconstruction Surgery: a Systematic Review (801) Potter S 2011 
151. Development of a core outcome set for research and audit studies in reconstructive breast 
surgery(589) Potter S 2015 
152. Systematic review and critical appraisal of the impact of acellular dermal matrix use on the outcomes 
of implant-based breast reconstruction(802) Potter S 2015 
153. 2017 EULAR recommendations for a core data set to support observational research and clinical care in 
rheumatoid arthritis(803) Radner H 2018 
154. A core outcome set for adult cardiac surgery trials: A consensus study(804) Benstoem C 2017 
155. Evaluating Outcomes Used in Cardiothoracic Surgery Interventional Research: A Systematic Review of 
Reviews to Develop a Core Outcome Set(805) Benstoem C 2015 
156. A Core Outcome Set for Children With Feeding Tubes and Neurologic Impairment: A Systematic 
Review(806) Kapadia M 2016 
157. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review(807) Johnston B 2010 
158. A core outcome set for clinical trials in acute diarrhoea(808) Karas J 2015 
159. Choice of primary outcomes in randomised trials and SRs evaluating interventions for preterm birth 
prevention: a systematic review(809) Meher S 2014 
160. A Core Outcome Set for Evaluation of Interventions to Prevent Preterm Birth.(810) Van’t Hooft J 2016 
161. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized 
Prostate Cancer(811) Wilt T 2008 
162. A COS for localised prostate cancer effectiveness trials: protocol for a SR of the literature and 
stakeholder involvement through interviews and a delphi survey (812) Maclennan S 2015 
163. A COS for localised prostate cancer effectiveness trials(813) Maclennan S 2017 
164. Symptomatic and QoL outcomes after treatment for clinically localised prostate cancer; a SR(814) Whiting P 2016 
165. Effectiveness of prepregnancy care for women with pregestational diabetes mellitus: protocol for a 
systematic review of the literature and identification of a core outcomes set using a Delphi survey(815) Egan A 2015 
166. A core outcome set for studies evaluating the effectiveness of prepregnancy care for women with 
pregestational diabetes(816) Egan A 2017 
167. A Core Outcome Set for the Benefits and Adverse Events of Bariatric and Metabolic Surgery: The 
BARIACT Project.(603) Coulman K 2016 
168. Patient-reported outcomes in bariatric surgery: a systematic review of standards of reporting(817) Coulman K 2013 
169. Outcome reporting in bariatric surgery: an in-depth analysis to inform the development of a core 
outcome set, the BARIACT Study(230) Hopkins J 2015 
170. A core outcome set for clinical trials of interventions for young adults with type 1 diabetes: an 




171. SR of interventions to improve outcomes for young adults with type 1 diabetes(819) O’Hara M 2017 
172. A scoping review of outcomes related to orthodontic treatment measured in cleft lip and palate.(820) Tsichlaki A 2017 
173. A Systematic Review of Outcome Measures Employed in Aneurysmal Subarachnoid Hemorrhage 
(aSAH) Clinical Research(262) Andersen C 2018 
174. A systematic review of outcome measures used in clinical trials of treatment interventions following 
traumatic dental injuries(821) Sharif M 2015 
175. A systematic review of outcomes in postoperative pain studies in paediatric and adolescent patients: 
towards development of a core outcome set.(272) Ross A 2018 
176. A systematic review of outcomes reported in small bowel obstruction research.(822) Mellor K 2018 
177. Are dental researchers asking patient-important questions? A scoping review(421) Fleming P 2016 
178. Assessing outcomes of alcohol-related brain damage (ARBD): What should we be measuring?(823) Horton L 2015 
179. Cardioplegia in paediatric cardiac surgery: a systematic review of randomized controlled trials(824) Drury N 2018 
180. Choice of primary outcomes evaluating treatment for heavy menstrual bleeding: a systematic 
review(825) Herman M 2016 
181. Developing a core outcome set for chronic rhinosinusitis: a systematic review of outcomes utilised in 
the current literature(826) Soni-jaiswal A 2017 
182. CHronic Rhinosinusitis Outcome MEasures (CHROME) – developing a core outcome set for trials of 
interventions in chronic rhinosinusitis(827) Hopkins C 2018 
183. Clinical endpoints in trials of chemoradiation for patients with anal cancer.(828) Glynne-Jones R 2017 
184. Completeness of main outcomes across randomized trials in entire discipline: survey of chronic lung 
disease outcomes in preterm infants(549) Ioannidis J 2015 
185. Completeness of Outcomes Description Reported in Low Back Pain Rehabilitation Interventions: A 
Survey of 185 Randomized Trials(829) Gianola S 2016 
186. Complications associated with arthroscopic rotator cuff tear repair: definition of a core event set by 
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Appendix F    Patient interview consent form 
 
COSB  
Consent Form (Adult Participant) 
 
Study Title: COSB Core Outcomes for Burn Care Research.                        
 
 
Please read this consent/assent form carefully and put your initials in 
the boxes by the items to which you agree or give your consent. We 
are asking you to sign to show you understand what taking part in the 
study means and that you are happy to do so.  
 1. I confirm that I have read and understand version 1.0 of the information sheet dated 06/01/17 for this 
study. I have had the opportunity to consider the information, ask questions and have had these answered 
satisfactorily. I know who to contact if I have any further questions. 
 
2. I agree to take part in an interview with the research team about what recovery issues (outcomes) are 
important during recovery from a burn injury.  
 
3. I understand that I am taking part voluntarily and that I am free to withdraw from the study at any time, 
without giving any reason, and without my medical care or legal rights being affected. 
 
4. I agree that the interview can be audio-recorded.  
 
5. I understand that information from my medical notes will be recorded and processed by members of the 
research study team within the National Health Service and I am willing for them to do this. 
 




6. I understand that my information will be anonymised with a study number and kept strictly confidential 
and used only for the purposes of this study. My consent depends on the University Hospitals Bristol NHS 
Foundation Trust complying with its duties and obligations under the 1998 Data Protection Act.  
 
7. I understand that the information collected about me will be used to support other research in the future, 
and may be shared anonymously with other researchers. 
 
8. I agree to my General Practitioner being informed of my participation in the study. 
 
9. I understand that people who monitor research and make sure it is being done properly, may need to, see 
information about me to check the study. 
 
10. I agree to take part in this study. 
 
 
Full name: ___________________________________ Signature: _______________ Date:  







Appendix G Patient information for semi-
structured interviews. 
 






Patient Information Sheet  
Qualitative Interviews (Adult) 
 
Study Title: Core Outcomes for Burn Care Research. 
 
Agreeing how to measure recovery from a burn. 
 
We would like to ask if you would be happy to participate in this research study. 
 
This leaflet will explain why the study is being done and what will happen if you take part. 
 




What is the reason for this study? 
 
There are different ways to treat patients after a burn injury. Doctors need to test whether new treatments are 
better than older treatments.  To do this we need to measure how well patients recover with different care. People 
with burns have different experiences during their recovery. This could include issues such as the side effects of 
treatment including scarring, pain or itching or quality of life. We want to know which recovery issues or outcomes 
are most important to patients.  
 
Why have I been chosen? 
You have been chosen because you have had a burn injury. Your contact details were obtained via the medical team 
looking after you. 
 
Do I have to take part? 
No. It is up to you to decide whether to take part.  We will explain the study to you and go through this leaflet. If 
you decide to take part, you will be asked to sign a form and we recommend you keep this information sheet for 
reference. If you don’t want to take part, you don’t need to give a reason and your hospital care will stay the same. 
 
Can I change my mind? 
That’s fine. You can say no at any time. 
 




The research team will contact you to arrange an interview. This can take place at a time and location convenient 
to yourself. This could be in the hospital, University or at your home. The interview will last about one hour and no 
longer than 2 hours. You are free to stop the interview at any point. We will ask you about your recovery from the 
burn and what matters to you. This could include complications of treatment, what stops you doing what you enjoy 
or other issues affecting your daily quality of life. With your permission we will record the interview.  
If you undertake an interview at a time separate to a hospital appointment, you will be reimbursed for any travel 
costs. This will be undertaken on the basis of receipts provided to the study researchers. Petrol costs will be 
reimbursed at the rate 40p/ mile. 
 
What are the possible risks or disadvantages of taking part? 
There are very few risks of taking part in this study.  If you agree to take part in the study, the disadvantages 
include the possible anxiety caused by answering questions about what is important to you during your recovery 
from the burn. We can arrange support for you if this is the case. However, many patients find it helpful to talk 
about their recovery. You will have the opportunity to discuss any queries, anxieties or issues with a study 
researcher, for whom we will provide contact details. We will also inform your GP that you are taking part in this 
study.  
 
What are the possible benefits of taking part? 
The information we obtain from the study will help us to improve ways that doctors and health personnel measure 
the most important recovery issues or outcomes for patients when developing new treatments and deciding on the 
best care after burn injuries.  
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the research will be kept strictly confidential. Information will be 
collected, stored and analysed by the study researchers at the Hospital Trust and the University of Bristol. Any 
information collected about you will have your name and address removed so that you cannot be recognised from 
it. Access to this information will be restricted to members of the research team alone. You will never be identified 
in any publications. Audio tapes will be destroyed after 10 years in line with Data Protection Act regulations. 
 
What will happen to the results of this research study? 
The main results of the study will take 2-3 years to become available. We will send you a letter with what we have 
found out if you wish. We will also send regular updates to participants in a newsletter. We will publish results in 
scientific journals, as well as present reports at various local, national and international scientific meetings. You will 
not be identified in any report or publication.  
Who is organising and paying for this research?  
The research is being run by the University of Bristol and is funded by the National Institute for Health Research. 
The study is led by the Chief Investigator, Dr Amber Young, who is a Senior Research Fellow at the University of 
Bristol and Professor Jane Blazeby, who is a Professor of Surgery at the University of Bristol. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to 
protect your safety, rights, well-being and dignity. This study has been reviewed and given a favourable opinion by 
the xxxxxx Research Ethics Committee (reference number        ). Approval means that the Committee is satisfied 
that your rights will be respected, that any risks have been reduced to a minimum and balanced against possible 
benefits, and that you have been given sufficient information on which to make an informed decision to take part 
or not. 
 
Who do I contact if I want more information, have concerns or want to make a complaint?  
If you have any further questions concerning this study, please contact your consultant, nurse or the study contact 
below. If you remain unhappy about any aspects of the study, you can do so through the Patient Advice and Liaison 
Service (PALS). Details are on the NHS Choices website www.nhs.uk. 
 
 





Appendix H Interview Topic Guide 
COSB Interview Topic Guide – patient, parent and child participants. 
 
Introduction 
• Thank you for coming. My name is Amber Young and I’m a researcher at the University of 
Bristol.  
• I am working on the COSB project. I am undertaking a programme of research with the aim of 
achieving agreement about the most important areas of your recovery during recovery from a 
burn.  Researchers and clinicians will then use these to evaluate the impact of existing and new 
treatments. I want to agree these using knowledge from both patients and professionals 
• I would like to discuss with you what you thought were important areas of recovery to you 
during your (or your child’s) recovery from a burn. 
• There are no right or wrong answers or views, I just want to understand your thoughts on what 
was and is important during your recovery. I appreciate these issues can be difficult topics (for 
parents, children) and you can stop our discussion at any time. This should take no longer than 
an hour. 
• Do you have any questions at this point? 
• I will check that they are happy for me to record the interview and I will take verbal consent. 
Written consent will be taken beforehand. 
 
Questions: 
• Opening: Could you tell me a bit about you? 
o Prompt: do you work, do you have children etc 
 
• Could you tell me about how you/your child came to have the burn? 
 
• What was your experience of being treated in hospital?  
o Prompts: 
• Do you know how long you spent in hospital and what sort of treatment you 
received? 
• Did you need to go to intensive care? 
• Have you needed much medical care since you left hospital?  
 
• When you were burned, did you experience any worries about the effects of the burn at that 
time or for the future? If so, what were these? 
o Prompt:  
• Eg survival, scarring, pain? 
• Areas of your life that it was most important to ensure the burn didn’t affect eg 
function (eg related to work, school), the look of the burn (confidence, work, 
school, friends)? 
• Did the worries change over time? 
 
• What were the most important areas of your recovery to you after you got home? 
o Prompt: 




o Prompts could include work life; social life; family life; relationships 
(including intimacy) 
• Were you worried about the future? If so, in what way(s)? 
• Were there any issues that affected you that the doctors didn’t ask about at your 
out-patient appointments? 
• Were there issues that bothered you more than they seemed to bother the medical 
staff? 
• Were there issues that the doctors asked about that didn’t worry you? 
 
• Were  your family and friends worried about any effects of your burn at any time after the burn 
injury? If so, what were they worried about? 
o Prompt: (as above; work life; social life; family life; relationships (including intimate 
relationships)  
• What matters to you now while you are getting better?  
 
• If there are any areas of healthcare that could have been improved, what would that/they be? 
o Prompt: treatment of infection, management of pain, improving success of skin-
grafting? 
 
• Are there any other aspects of your recovery that you thought were important and we haven’t 
talked about? 
 
• To finish with, could we summarise what the most important areas of your recovery after the 
injury were to you? 
 
• Closing: Researcher thanks interviewee and asks if they would like a summary of the study 
results once complete 
 






Appendix I    Delphi Participant Information 
 
 
Study Title: Core Outcomes for Burn Care Research. 
Invitation to a questionnaire survey for adult patients or parents/carers. 
                    
You are being invited to take part in a research study. Before you decide, it is important for us to explain 
clearly why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others, if you wish. Thank you for reading this. 
 
What is the reason for this study?  
There are different ways to treat patients after a burn injury. Doctors need to test whether new 
treatments are better than older treatments. To do this we need to measure how well patients recover 
with different care. People with burns have different experiences during their recovery. This could 
include issues such as scarring, pain or itching or quality of life. We want to know which recovery issues 
or outcomes are most important to patients.  
 
Why have I been chosen? 
You have been chosen because you or your child have had a burn injury. Your contact details were 
obtained via the medical team looking after you or your child. 
 
What will happen if I take part? 
If you agree to take part, you will be sent two sets of questionnaires by email over the following months. 
We would like you to complete the questionnaires (they take about 15-30 minutes), which ask you to 
rate how important you think each outcome is to include in a minimum (core) outcome set ie how 
important each issue is to patients recovering from a burn. The questionnaire has been designed based 
on all the many different outcomes currently reported in the research literature. If there are any 
outcomes you think we may have missed, please add these in the space provided at the end of the 
questionnaire. 
Please return the questionnaire to us in the enclosed stamped addressed envelope. A second 
questionnaire will be sent in the next few months.  
If you are able to participate in this study we will also invite you to a meeting (with expenses covered) 
to select the final core outcome set.  
 
Do I have to take part? 
No. It is up to you to decide whether to take part. If you agree to participate please sign and return one 
copy of the enclosed Consent Form in the prepaid envelope (at no cost to yourself). Please sign and 
keep the other copy for your own records. On receiving this form, a member of the research team will 
send you the first questionnaire to complete. If you decide to take part you are still free to withdraw at 




will not affect the standard of care you or your child receive. If you do decide to take part we 
recommend you keep this information sheet for reference. 
 
What are the possible risks or disadvantages of taking part? 
There are very few risks of taking part in this study. If you agree to take part in the study, the 
disadvantages include the possible anxiety caused by answering questions about what is important to 
you during your recovery from the burn. We can arrange support for you if this is the case. However, 
many patients find it helpful to talk about their recovery. You will have the opportunity to discuss any 
queries, anxieties or issues with a study researcher, for whom we will provide contact details. We will 
also inform your GP that you are taking part in this study.  
 
What are the possible benefits of taking part? 
The information we obtain from the study will help us to improve ways that doctors measure the most 
important recovery issues or outcomes for patients when developing new treatments and deciding on 
the best care after burn injuries.  
 
Will my taking part in this study be kept confidential? 
All information that is collected from you during the research will be kept strictly confidential. 
Information will be collected, stored and analysed by the study researchers at the University of Bristol. 
Any information collected from or about you or your child will have your names and addresses removed 
so that neither of you can be recognised from it. Access to this information will be restricted to 
members of the research team alone. You will never be identified in any publications.  
 
What will happen to the results of this research study? 
The main results of the study will take 2-3 years to become available. We will send you a letter with 
what we have found out if you wish. We will also send regular updates to participants in a newsletter. 
We will publish results in scientific journals, as well as present reports at various local, national and 
international scientific meetings. You will not be identified in any report or publication.  
 
Who is organising and paying for this research?  
The research is being run by the University of Bristol and is funded by the National Institute for Health 
Research. The study is led by the Chief Investigator, Dr Amber Young, who is a Senior Research Fellow 
at the University of Bristol and Professor Jane Blazeby, who is a Professor of Surgery at the University. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your safety, rights, well-being and dignity. This study has been reviewed and 
given a favourable opinion by the xxxxxx Research Ethics Committee (reference number    ). Approval 
means that the Committee is satisfied that your rights will be respected, that any risks have been 
reduced to a minimum and balanced against possible benefits, and that you have been given sufficient 
information on which to make an informed decision to take part or not. 
 
Who do I contact if I want more information, have concerns or want to make a complaint?  
If you have any further questions concerning this study, please contact your consultant, nurse or the 
study contact below. If you remain unhappy about any aspects of the study, you can do so through the 
Patient Advice and Liaison Service (PALS). Details are on the NHS Choices website www.nhs.uk. 
 
 
Thank you so much for helping us with this research. 




Appendix J Delphi questionnaires. 
SECTION C: Before wound healing 
This Section asks you about what outcomes occurring before wound 
healing are important to measure in research trials.  
C1: Medical outcomes affecting a patient’s burn or body during the 
process of healing  
How important is it to measure the following outcomes in research 
about burns? 
C1.1 How well a patient with a burn 
is able to fight infection. 
 
For example: a burn can affect the 
body’s ability to fight infection. 
Medical tests like white cell count can 




Please mark a cross under the number that best represents 
your view about how important this outcome is. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.2 The amount of fluid coming 
from the burn wound (exudate). 
 
For example: whether and how much 
the burn leaks fluid. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





C1.3 The nature of the fluid coming 
from the burn wound. 
 
For example: what colour is the fluid 
coming from the wound, and has it 
changed? 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.4 The need for blood transfusions 
during treatment for a burn. 
 
For example: does a patient need to be 
given blood or blood products during 
their treatment. This sometimes 
happens if the burn is large or a patient 
needs an operation for a skin graft. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.5 The difficulty patients have with 
body temperature 
 
For example: A burn can affect the way 
the body handles temperature by 
increasing a patient’s sensitivity to heat 
or by being unable to sweat. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.6 How quickly a patient’s burn 
wounds heal. 
 
For example: how many days or weeks 
does it take for the burn to heal 
completely. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





C1.7 How quickly a patient’s burn 
wound heals after receiving a skin 
graft. 
 
A skin graft is when healthy skin is 
taken from another part of the body and 
placed over the burn wound to help it 
heal.  
For example: how well a burn that has 
needed a skin graft heals. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  




C1.8 How quickly the donor site heals 
in patients who have had a skin graft. 
 
Donor site: is the place from which 
healthy skin is taken for a skin graft – 
usually top of the thigh 
 
For example: how soon does the site 
where the skin graft has come from 
heal. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.9 Whether the donor site becomes 
infected. 
 
Donor site: is the place from which 
healthy skin is taken for a skin graft –– 
usually top of the thigh 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





For example: whether the area of the 
body that the skin is taken from for a 
skin graft becomes infected. 
C1.10 Whether a burn wound 
becomes infected. 
 
For example: Burn wounds may 
become infected because they have lost 
the outer layer of the skin. This will 
require treatment such as wound 
cleaning and/or antibiotics. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
 
C.1.11 Whether a patient has an 
infection elsewhere in the body, other 
than in the burn wound. 
 
For example: chest infection, urine 
infection. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.12 Whether a burn infection 
results in bloodstream infection 
(sepsis). 
 
For example: severe infection in the 
blood with risk to life. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.13 Whether patients experience 
mild complications relating to the 
burn or its treatment.  
 
Not at all 
important 
Important 









For example: a rash from the dressing 
requiring no treatment and not affecting 
a patient’s recovery. 
          
 
C1.14 Whether patients experience 
moderate complications relating to 
the burn or its treatment, which will 
get better with treatment but may 
affect a patient’s length of stay in 
hospital. 
 
For example: allergy to medication or 
bleeding under their skin graft. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
 
C1.15 Whether patients experience 
serious complications relating to the 
burn or its treatment which could 
result in death, or require 
considerable treatment and may 
considerably extend the hospital stay  
 
For example: Blood clots in the lungs 
or legs from lying in bed. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  








C1.16 Death due directly to the 
burn injury soon after a patient 
is injured. 
 
For example: death due to ‘burn 
shock’ or due to a burn wound 
infection or sepsis. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.17 Death of a patient from 
any cause soon after a patient is 
injured.  
 
For example: death from a heart 
attack. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C.1.18 The effect of the burn on 
how well the body uses energy. 
 
For example: the body may have a 
very high use of energy when 
trying to heal the wounds so that 
muscles become weak and there is 
weight loss. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
 
C1.19 The effect of the burn on a 
patient's heart and blood 
circulation function. 
 
Large burns can affect patients’ 
heart function.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  







For example: low blood pressure 
requiring intensive care and drugs 
which could be life-threatening or 
high blood pressure. 
C1.20 Effect of the burn on a 
patient's kidney function that 
does not require dialysis. 
 
Burns can affect the functioning of 
a patient’s kidneys. The kidneys 
filter waste products out of your 
blood. Dialysis is a machine that 
does the work a patient’s kidneys 
normally do. 
 
For example: minor effects of the 
burn on the working of a patient’s 
kidneys requiring drugs or more 
fluid. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
 
C1.21 Kidney failure caused by 
the burn that requires dialysis. 
 
For example: serious effect of the 
burn on the kidneys that mean a 
machine is needed that does the 
work of the kidneys (dialysis), 
which may or may not be 
permanent. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  






C1.22 The effect the burn has on 
a patient's liver function. 
 
For example: Rarely, a burn injury 
can affect a patient’s liver because 
of changes in the patient’s blood 
pressure or infection. This would 
be serious and affect a patient’s 
ability to clot their blood normally, 
increase their time in hospital and 
if very serious may be a risk to life. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
 
C1.23 Whether a patient with a 
burn has any difficulty with 
breathing or their lung 
function. 
 
For example: a small number of 
patients with burns have 
problems with their breathing or 
lungs due to inhaling smoke, or 
because the burn or fluid given to 
treat the burn can affect the 
lungs. This might mean that a 
patient needs to be helped to 
breathe with a ventilator or use 
oxygen.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





C1.24 The effect of a burn on 
the function of a patient's 
stomach or bowel. 
 
For example: diarrhoea, 
constipation, sickness, vomiting, 
nausea, inability to keep food 
down. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.25 Whether the burn causes 
several body organs to stop 
working well at the same time 
(multi-organ dysfunction). 
 
After a burn a patient can 
develop problems with several 
organs at once (called multi-
organ dysfunction), but with 
treatment the organs can recover.  
 
For example: poor kidney 
function and poor liver function 
at the same time that is likely to 
get better following treatment.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.26 Whether the burn causes 
several body organs to fail (not 
work at all) at the same time 
(multi-organ failure). 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





Rarely, a patient with a burn can 
develop organ failure in several 
organs at once (called multi-
organ failure).  
 
For example: kidney failure and 
liver failure at the same time, 
where it is unlikely to get better, 
or will need long-term care. 
C1.27 The amount of fluid given 
to a patient, either into a 
patient’s vein (through a 
‘drip’) or as a drink. 
 
When a patient loses skin due to 
a burn they will lose liquid 
through this area and if it is a 
large area, it may require 
replacement. 
 
For example: how much extra 
fluid through a drip does a patient 
need to have to ensure their 
organs work well. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.28 The length of time a 
patient stays in hospital after a 
burn injury. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





For example: the number of days 
or weeks after the injury that a 





C1.29 The length of time a patient 
stays in an intensive care unit after 
a burn injury. 
 
For example: number of days or 
weeks after the injury that a patient 
has to receive intensive care. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.30 The length of time a patient 
uses a breathing machine after a 
burn injury. 
 
For example: the amount of time a 
patient needs to be on a ‘ventilator’. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.31 Medical tests to find out how 
well the body is handling the stress 
of the burn injury (inflammatory 
markers).  
 
For example: blood or urine tests to 
find out how well the body is coping 
with the stress placed on the body 
after burn injury.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C1.32 Whether a patient can 
maintain their body weight. 
 
For example: burn injuries can affect 
a patient’s ability to eat normally and 
absorb their food. This can result in 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





weight loss, not being able to keep a 
normal weight. 
C1.33 The costs of burn treatment 
for the NHS. 
 
For example: how much the treatment 
for the burn costs the NHS/hospital 
through paying for staff, dressings and 
medications and equipment. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
 
C2: Other outcomes that relate to a patient’s experiences of having a 
burn injury during the process of healing 
How important is it to measure the following outcomes in research 
about burns? 
C2.1 The amount of dressing 
changes or cream applications 
needed to treat the burn. 
 
For example: How many times a 
patient needs to have their 
dressing changed, for how long 
and how frequently they have to 
apply creams. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.2 The number of 
outpatient appointments a 
patient needs to attend. 
 
Not at all 
important 
Important 









For example: How many times a 
patient needs to come to the 
hospital for follow-up 
appointments or dressing 
changes. 
          
 
C2.3 The number of surgical 
treatments/ operations a 
patient needs. 
 
For example: the number of 
times they need to have an 
operation or receive a treatment 
where they have a general 
anaesthetic (medicine to make 
you sleep during an operation).  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.4 The smell of the burn 
wound. 
 
For example: does the burn 
wound smell unpleasant? 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.5 How much medication a 
patient needs to treat a burn 
injury. 
 
For example: how many 
painkillers are needed or 
whether a patient needs 
medication for blood pressure? 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





C2.6 How well a patient sticks 
to their planned treatment. 
 
For example: do patients take 
medication, do they attend 
appointments and have blood 
tests as directed by their medical 
team? 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.7 The anxiety a patient 
experiences about their 
medical treatment. 
 
For example: worry about the 
pain of operations, dressing 
changes, blood tests. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.8 How comfortable wound 
dressings are for a patient. 
 
For example: do the dressings 
fall off, do they stop a patient 
moving normally, are they 
itchy? 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.9 The dignity of a patient 
during and after treatment. 
 
For example: does the patient 
feel respected, are they given 
privacy? 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





C2.10 Itch in the burn wound 




Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.11 Pain in the burn wound 
when treatment is not taking 
place. 
 
For example: pain all the time, 
pain at night. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.12 The amount of pain 
caused by medical treatments 
and tests for a patient with a 
burn. 
 
For example: pain when having 
dressing changes, blood tests.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.13 Pain in the donor site 
 
Donor site: is the place from 
which healthy skin is taken for a 
skin graft –– usually top of the 
thigh. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





For example: how sore is the 
area where the skin for a graft is 
taken from? 
C2.14 A patient's anxiety 
about the future. 
 
For example: worries about 
appearance, worries about 
working or school, worries 
about relationships. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.15 The effect being treated 
for a burn has on a patient or 
their family in terms of 
money. 
 
For example: lost salary for a 
patient or their carer, costs of 
travel to appointments and 
parking for a patient or their 
family, buying food at the 
hospital, costs of painkillers and 
prescriptions. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
C2.16 The effect of the burn 
and treatment on a patient's 
thirst. 
 
For example: feeling so thirsty 
that a drink of water does not 
make it better. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





C2.17 How much a patient 
understands the treatment 
they receive for a burn injury. 
 
For example: whether a patient 
understands the need for 
surgery, how long scar 
treatment will take. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  




SECTION D: After wound healing- when a patient’s wound has healed and 
they are at home  
This Section asks you about what outcomes are important after wound 
healing, when the wound is healed or has scarred. 
D1: Medical outcomes affecting a patient’s burn or body after the 
wound has healed  
How important is it to measure the following outcomes in research 
about burns? 
D1.1 The effect of a burn on the 
strength of a patient's bones after 
healing. 
 
For example: a burn injury can 
affect a patient’s bones. This might 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





include a change in bone density, 
brittle bones with an increased risk 
of broken bones (osteoporosis). 
D1.2 The costs of burn treatment 
for the NHS. 
 
For example: how much the 
treatment for the burn and scar 
costs the NHS/hospital through 
paying for staff, dressings and 
medications and equipment. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.3 Death of a patient from any 
cause.  
 
For example: death from a stroke 
or a heart attack after the burn has 
healed. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.4 The effect of the burn on 
how well the body uses energy. 
 
For example: a patient’s body may 
need to use a lot of energy during 
healing so that muscles become 
weak and there is weight loss. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.5 The effect of the burn on a 
patient's heart and blood 
circulation function. 
 
Not at all 
important 
Important 









For example: a burn injury can 
affect a patients’ heart functioning 
or circulation. A long-term effect 
after healing might include the 
need for blood pressure treatment. 
          
 
D1.6 Whether there are problems 
with the skin graft donor site 
after healing. 
 
Donor site: is the place from which 
healthy skin is taken for a skin graft 
–– usually top of the thigh. 
 
For example: pain, colour change 
of the donor site after it has healed. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.7 How much the burn affects 
a patient's ability to walk and get 
about normally. 
 
For example: being able to walk to 
the shops, go on foot outside of the 
house, move around at home.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.8 The effect of the burn scar 
on a patient’s movement 
(excluding walking). 
 
For example: inability to straighten 
arm, difficulty moving fingers 
normally. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





D1.9 The effect of the burn (and 
treatment) on a patient’s fitness. 
 
For example: ability to walk as far 
as normal, being able to do 
exercise. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.10 The effect the burn has on 
how well a patient's muscles 
work. 
 
For example: how well a patient 
can move their face, arms or legs 
normally. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.11 The effect of the burn on 
the strength of a patient's 
muscles. 
 
For example: poor muscle strength, 
difficulty with carrying children or 
shopping. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.12 Whether a patient can 
maintain their body weight after 
a burn injury after healing. 
 
For example: weight loss, not able 
to keep a normal weight. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  






D1.13 The effect a burn has 
on a child's growth. 
 
For example: A burn can 
rarely affect a child’s 
growth. This might mean not 
achieving potential height, 
slowing of growth. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.14 The difference in 
colour of a burn scar 
compared to normal skin. 
 
For example: whether a burn 
scar is very red or loss of 
colour in a scar. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 






Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D1.16 How much 
medication a patient needs 
to manage the burn scar 
and other symptoms after 
the injury. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





For example: whether a 
patient requires medication 
for a long time after the 
injury, how many painkillers 
are needed. 
 
D2: Outcomes that relate to a patient’s experiences of having a burn 
injury 
How important is it to measure the following outcomes in research 
about burns? 
D2.1 A patients' ability to 
carry out normal daily 
tasks. 
 
For example: dressing, 
washing, making food or 
drinks. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.2 How well a patient 
sticks to their planned 
treatment. 
 
For example: do patients 
take medication, do they 
attend appointments and 
have blood tests. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





D2.3 The anxiety patients 
experience about their 
medical treatment. 
 
For example: worry about 
the pain of operations needed 
for treating scars. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.4 Patients’ appearance 
after a burn injury. 
 
For example: appearance of 
scar, facial appearance, body 
image. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.5 The difficulty patients 
have with body 
temperature management 
after a burn. 
 
For example: sensitivity to 
heat, being unable to sweat. 
  
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.6 How much the burn 




For example: people looking, 
judgement by others, name-
calling. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  






D2.7 How much a patient 
understands the treatment 
they receive for a burn 
injury. 
 
For example: whether a 
patient understands the need 
for surgery, scar treatments.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.8 The amount of cream 
applications, or amount of 
time wearing pressure 
garments needed to treat 
the scar. 
 
For example: for how long 
and how frequently a patient 
has to apply creams or use 
pressure garments for their 
scars. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.9 The number of 
outpatient appointments a 
patient needs to attend. 
 
For example: How many 
times a patient needs to 
come to the hospital for 
follow-up appointments. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  





D2.10 The number of 
surgical treatments or 
operations a patient needs. 
 
For example: the number of 
times they need to have an 
operation or receive a 
treatment to help with 
scarring where they are put 
to sleep.  
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.11 How much 
treatment is required for a 
patient's burn scars. 
 
For example: how many 
times their scar may need 
surgery, whether and how 
long they need pressure 
garments, whether creams 
are needed. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.12 The dignity of a 
patient during scar 
treatment. 
 
For example: does the 
patient feel respected, are 
they given privacy? 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.13 The loss of a 
patient's hair due to the 
burn injury. 
Not at all 
important 
Important 











1 2 3 4 5 6 7 8 9  
          
 
D2.14 The amount of pain 





Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.15 The texture or feel of 
a burn scar. 
 
For example: whether a scar 
is rough, lumpy or tight. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.16 Whether the burn 
causes a patient to have 
problems with itch after 
healing. 
 
For example: some patients 
have itchy scars that can 
affect their ability to sleep, 
and take part in daily 
activities. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.17 A patient's anxiety 
about the future. 
 
Not at all 
important 
Important 









For example: worries about 
appearance, worries about 
working or school, worries 
about relationships. 
          
 
D2.18 The effect that being 
treated for a burn has on a 
patient or their family in 
terms of money 
 
For example: lost salary for a 
patient or their carer, costs of 
travel to appointments and 
parking for a patient or their 
family, buying food at the 
hospital, costs of painkillers 
and prescriptions. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.19 The effect of the 
burn on a patient's ability 
to think and remember 
clearly. 
 
For example: memory, 
concentration. 
 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.20 The effect a burn has 
on general well-being. 
 
For example: don't feel right, 
general illness. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  






D2.21 How much a burn 
affects the amount and 





Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.22 How the burn injury 




For example: effect of 
relationships with parents, 
brothers and sisters, 
boyfriend, girlfriend, partner, 
children, friends. 
Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
          
 
D2.23 How long a burn 
prevents a patient from 
returning to work or a 
child returning to school, 




Not at all 
important 
Important 





1 2 3 4 5 6 7 8 9  
















END OF QUESTIONNAIRE 
THANK YOU VERY MUCH FOR YOUR PARTICIPATION 




D2.24 Are there any other outcomes that you think are 





Appendix K Outcomes extracted from semi-
structured interviews. 
Outcomes reported in interviews from patients, carers and HCPs n=149 
Activities of daily living ICU treatment Return to work 
Analgesia Impact on family Relationships 
Anxiety Impact on friends Scar and aging 
Body image Impact on relationships Scar and gender 
Bullying Inconvenience Scar camouflage 
Burden of care Infection Scar colour 
Burn smell Itching Scar discomfort 
Children's worries Judgement by others Scar fragility 
Clothes Lack of empathy Scar height 
Communication Laser treatment Scar impact 
Complications of drugs Length of hospital stay Scar improvement 
Complications of medication Look of burn wound Scar management 
Concentration Look of scar Scar permanency 
Confidence Mask for scarring Scar problems 
Constipation Massage for scarring Scar sensation 
Contractures Memories Scar tightness 
Coping Memory of injury Scarring 
Cosmesis Mental health issues Sensation 
Cough Mobility Silicon 
creams for burn Mood Skin graft 
Creams for scarring Nasogastric feeding Skin graft impact 
Depression Need for surgery Skin graft loss 
Digestion Nexabrid pain Skin graft pain 
Dignity Non-surgical scar treatment Sleep quality 
Discharge planning Normality Sleep quality 
Distress Nutrition Stamina 
Donor site pain other people Steroid complications 
Dressing change pain Outpatient visits Suicide 
Dressings Outreach Sun issues 




Effect of growth pain general Surgery for scars 
Exercise issues Pain immediately after injury Survival 
Extension of burn Parent impact Swimming 
Exudate Patient information Temperature issues 
Face burn problems Patient knowledge of care The future anxiety 
Family roles Patient self-help groups Theatre trip 
Finance People looking Thirst 
Flashbacks Physiotherapy Time spent in hospital 
Friends Pressure garments for scarring Tiredness 
Functional impact general Progress Treatment by other people 
Gabapentin use Psychology Treatment for itch 
General anaesthesia PTSD Ventilator days 
Getting dressed Re-operation Washing 
Getting home Reconstruction Wearing shorts 
Guilt Recovery issues Worries re scarring 
hair loss Rehabilitation Worry re pain 
Hallucinations Relationships Wound breakdown 
Hand injury Return to home Wound infection 
Healing process Return to normal  






Appendix L COSB-i Consensus report  
 
COSB-international 
Core Outcomes for Burn Care Research 
 
Consensus Meeting  
 











28 participants attended the meeting, as well as 19 participants who joined the voting by telephone.  
Participant locations and job roles are illustrated in table 1. 
Table 1: Participant type, and country (n=47) 
Country of participant  N (%) 
UK 28 (59.6) 
Australia 6 (12.8) 
USA 4 (8.5) 
Belgium 1 (2.1) 
Indonesia 1 (2.1) 
Japan 1 (2.1) 
Netherlands 3 (6.4) 
Norway 1 (2.1) 
Sweden 1 (2.1) 
Not reported 1 (2.1) 
  
Participant group  
Health care professional incl. commissioners, researchers, charity sector staff 44(93.6) 
Patient/ parent of patient 3 (6.4) 
  
Participant group breakdown  
Researcher, academic or journal editor 11(23.4) 
Consultant plastic surgeon involved in burn care 5 (10.6) 
Registrar/junior doctor with at least 6 consecutive months’ burn care experience 2(4.3) 
Burn care research nurse or nurse 8(17.0) 
Psychologist/ counsellor working with patients with burns 1(2.1) 






2. Initial discussion about items for consensus voting 
 
30 items to be discussed and voted on were taken to the meeting. These are presented in 
tables 2 and 3.  
Items in Table 2 were those rated them as important (8-9) by both patients and professionals 
working with patients with burn injuries. Items presented in Table 3 were those where either 






Table 2: Outcomes rated as important (8-9) by at least 70% of both patients and professionals  
Outcome % rating 
 
 
Outcome % rating 
 
 Death due to burn injury 96.8 Scar pain 83.9 
Serious complications (e.g. 
 ) 
96.3 Time to heal a (grafted) wound 83.6 
Sepsis (bloodstream infection) 95.3 Breathing and lung function 79.5 
Multi-organ failure  92.9 Pain during procedures (dressing 
 
79.3 
Scar contractures 92.2 Kidney function 77.5 
Daily tasks 91.9 Appearance 75.3 
Wound infection 90.1 Pain in the burn wound  74.6 
Multi-organ dysfunction 89.9 Patient psychology 74.6 
Death from any cause 87.9 Growth (achieving expected height) 73.5 
Time to healing 85.8 Walking 72.8 
 
Table 3: Outcomes voted important (8-9) by at >70% of clinicians or patients 
Outcome % Patients rating outcome as 
important (8-9) 
% Clinicians rating outcome as 
important (8-9) 
Infection in donor site 81.6 66.1 
Understanding of treatment 
received 
80.9 57.3 
Well-being 76.1 67.1 
Donor site healing 73.5 64.0 
Anxiety 71.7 66.1 
Number of surgeries needed 70.2 60.9 
Anxiety about the future 70.2 65.8 




Time to return to work/school/ 
previous occupation 
67.4 74.3 
Length of time on ventilator 65.3 74.9 





1. Intensive care: There was discussion about length of stay on ICU and ventilator days. 
It was discussed that as most studies would not be conducted with an ICU patient 
population, these items relating to ICU would be unlikely to be core to burn care.  
2. Quality of life: it was raised that quality of life should be included in the voting set. 
Discussion indicated that this could be covered under patient psychology, and the 
specific measures of psychology would be further delineated during the measure 
development phase of the COS.  
3. Serious complications: Definition of serious complications should be expanded to 
include pulmonary embolism, sepsis, wound infection, deep vein thrombosis. This 
would be assessed in most trials as adverse events and specific events would be noted 
under this outcome. This would reduce items to be voted on. Serious complications 
could be used as the main heading, and within this outcome authors must report 3-4 
items. There was discussion about whether death should be considered under serious 
complications, however there was a decision that this outcome should be separated. 
Organ failure is also not included under this heading. 
4. Death: AY put forward that cause of death relating to burn or other causes could be 
merged under one item. It was agreed that this should be done.  
5. Multi-organ failure/dysfunction: it was discussed that these items are used 
interchangeably so combine to one field. It was further discussed that dysfunction of 
individual organs (e.g. kidney, heart and lungs, liver) could be combined under this 
heading if needed. 
6. Burn wound healing, healing of grafted wounds: It was agreeded that these items 
represented ‘healing of the burn wound’ and so could be combined.  
7. Scar pain and wound pain – Scar pain should be combined with itch to represent 
chronic neuropathic pain and itch. Discussed that these need to be kept separate from 
acute pain in the non-healed wound.  
8. Procedural and background pain – Combine have main heading of acute pain with 
sub categories.  
9. Walking: This could be covered under physical well-being or daily tasks  




• If adding sub-categories under a main heading it is important that outcomes 
already voted on in the Delphi survey and not selected to bring to the 
consensus meeting do not end up being added back into the core set by virtue 
of being added under another headline outcome. 
• If add too many sub-categories under main heading will become too difficult to 
deliver. 
ACTIONS resulting from discussion 
The following actions were taken after the above discussion: 
• Combine outcome death relating to burn, death from other causes 
• Combine multi organ failure and multiorgan dysfunction as often used 
interchangeably. Move kidney and lung function into organ dysfunction outcome. 
• Burn wound healing: should incorporate burn wound and grafted wound- healing of 
the wound is important. 
• Combine procedural and background pain under one heading- ‘Acute pain’.  
• Scar pain combined with itch- both to address long-term neuropathic pain, 
differentiated from acute pain. 
• Merge complications under one heading ‘complications’ to formally include PE, DVT, 
sepsis and wound infection 
The above decisions reduced the outcome list to be voted on to 11 items.  
• Death (combined 2) 
• Serious complications (to include sepsis, wound infection as above) 
• Multi-organ failure (combined with dysfunction, lung and kidney function) 
• Scar contractures 
• Daily tasks (to include walking) 
• Time to heal (combined healing of burn wound and healing of grafted wound) 
• Long-term pain (to include itch) 




Therefore, it was agreed that any outcomes that were voted as being important by either 
patients or professionals should be added to the voting (see table 3). Further discussion 
resulted in some of the items being merged under existing items from the above set.  




• Understanding of treatment received 
• Physical wellbeing to include walking 
• Number of surgeries needed 
• Length of stay in ICU – this was merged with Length of time on ventilator 
• Immune response to fighting infection 
• Time to return to work/school/previous occupation 
• Anxiety about future, anxiety – these were merged under ‘Psychology’. 
• Donor site healing- this was merged under ‘wound healing’  
 
3. International Consensus voting 
 
Voting slides were developed with changes of definitions of outcomes to reflect the decisions 
about item merging above. Seventeen outcomes were included in the first round of voting. 
Table 4 shows the final outcomes and their revised definitions, as well as the results of the 
round 1 vote.  
In the first round of voting up to 44 participants voted (range 39-44 votes per item). Please 
note that total voter numbers increased between rounds 1 and 2 due to additional voters 
joining the online voting.  
Table 4: Round 1 Outcomes, definitions presented and percentage voting to be included in COS 





Death Death of a patient from any cause soon 
after the patient is injured. Death due 
directly to the burn injury soon after the 
patient is injured.  
For example: death due to 'burn shock' or 
due to a burn wound infection or sepsis or 
death from a heart attack. 
41 36 (87.8) 
Organ failure/ 
dysfunction 
Whether the burn causes several of the 
patient's organs to fail/not work at all or 
stop working well (dysfunction).  




For example: kidney failure alongside liver 
failure, where it is unlikely to get better, or 
will need long-term care or poor kidney 
function and poor liver function at the same 
time that is likely to get better following 
treatment.  
Serious complications Includes: blood clot, sepsis, wound infection 
but not organ dysfunction/failure.  
39 36(92.3) 
Scar contractures The effect of the burn scar on a patient's 
ability to move joints (contractures).  
For example: inability to straighten arm, 
difficulty moving fingers normally, limited 
range of motion of joints.  
41 28 (68.3) 
Daily tasks A patient's ability to carry out normal daily 
tasks. This includes walking.  
For example: dressing, washing, making food 
or drinks. 
41 36 (87.8) 
Time to heal (incl. 
wound graft) 
How quickly a patient's burn wounds heal. 
This includes wounds after receiving a skin 
graft (A skin graft is when healthy skin is 
taken from another party of the body and 
placed over the burn wound to help it heal).  
For example: how many days or weeks does 
it take for the burn to heal completely or 
how well a burn that has needed a skin graft 
heals. 
41 29(70.7) 
Pain acute Pain in the burn wound. This includes 
background and procedural pain.  
For example: pain all the time, pain at night. 
39 23(59.0) 
Pain long-term The amount of pain caused by a burn scar. 
This includes itch. 
41 31 (75.6) 
Appearance Patients' appearance after a burn injury.  
For example: appearance of the scar, facial 
appearance, body image.  
44 27(61.5) 
Patient psychology The psycho-emotional effect a burn has on a 
patients. Distress and anxiety can often be 






For example: anxiety triggered by reminders 
of how the burn happened or low self-
esteem in case of a visible scar. 
Growth The effect a burn has on a child's growth.  
For example: not achieving potential height, 
slowing of growth. 
43 4(9.3) ≠ 
Understanding 
treatment 
How much a patient understands of the 
treatment.  
 
43 8(18.6) ≠ 
Physical wellbeing General Physical well-being 
 
42 20(47.6) ≠ 
Immune response Ability to fight infections 42 6(14.3) ≠ 
Number of surgeries Number of surgeries 43 16(37.2) ≠ 
Time to return to 
work/school/previous 
occupation 
Time to return to work/school/previous 
occupation 
43 34(79.1) 
Length of stay in ICU This includes length of time on a ventilator.  
 
44 19(43.2) ≠ 
≠indicates items not meeting the 50% cut off for inclusion in second voting round. 
 
Selection of items to carry through to round 2 vote 
Outcomes where at least 50% of the participants stated that they should be included in the COS 
were carried through to the second round. On this basis, 5 outcomes were removed prior to the 
second round vote (indicated using * in table 4).  
Table 5 illustrates the items that were voted upon in the second round of voting, the number of 
participants for each outcome and the % voting to include them in the COS. In round 2 45 people 
joined the voting (range 43-45 votes per item). 
Table 5: Round outcomes and voting results 
Outcome N 
voting 
N (%) voting to 




Death 43 34 (79.1)* 
Organ failure/ dysfunction 44 20 (45.5) 
Serious complications 45 41 (91.1)* 
Scar contractures 44 23 (52.3) 
Daily tasks 44 36 (82.0)* 
Time to heal (incl. wound graft) 44 27 (61.4)* 
Pain acute 45 21 (46.7) 
Pain long-term 45 30 (66.7)* 
Patient psychology 45 37 (82.2)* 
Physical wellbeing 45 15 (33.3) 
Time to return to work/school/previous 
occupation 
44 37( 84.1)* 
Appearance 44 24(54.6) 
*indicates final COS outcomes 
4. Final Core Outcome Set 
 
It was anticipated that between 5 and 7 items would be an appropriate number of outcomes to 
include in a COS. Following analysis seven outcomes were selected to be included in the burns core 
outcome set, using a cut-off of >60% of participants rating it as important to be included. 
1. Death: to include death from any cause and death from the burn 
2. Serious complications: to include Sepsis, wound infection, DVT, PE 
3. Daily tasks: to include walking 
4. Time to heal: to include wound healing, grated wound healing and donor site wounds 
5. Long-term pain and itch 
6. Patient psychology: to include anxiety and anxiety about the future 
7. Time to return to work/school/ previous occupation 
 
Further discussion 
There was further discussion about including organ failure/dysfunction to the COS under serious 




should not be included due to the cut-off % would be an outcome that people may wish to include in 
their reporting as it would be reported as a Serious Adverse Event (SAE) in research trials.  
Next steps 
• Disseminate meeting report to all collaborators and attendees for comment 
• Finalise the meeting report 
• Write main COS paper – co-authors will be agreed 
• Agree a dissemination plan 
Agree next steps to look at outcome measures and when outcomes should be measured (outcome 
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